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Chapter 1
1  Introduction
The development of a fertilized egg to an adult organism involves a 
complexity of growth and differentiation processes which are controlled by 
a.o. polypeptide growth factors and their cellular receptors. One of the best 
studied growth factor signaling system is the ErbB network, which is involved 
in the development of most organs in the multicellular organism.  The family 
consists of four ErbB receptors and eleven epidermal growth factor (EGF)-
like ligands, which are differentially expressed throughout the body with 
expression levels that strongly depend on the stage of development (1). 
Aberrant expression of ErbB receptors and their ligands can cause cancer. 
Gene amplifi cation of the ErbB1 and ErbB2 genes is frequently observed 
in breast cancers and correlates with chemotherapy resistance and poor 
patient prognosis (2-4). The ErbB receptors are therefore main targets for 
the development of anti-cancer drugs and currently several tyrosine kinase 
inhibitors and anti-ErbB antibodies have received FDA approval for therapeutic 
application. 
Crystal structures of both ligand-bound and unoccupied ErbB 
receptors have greatly increased our knowledge about the process whereby 
ligand binding induces receptor dimerization (5-9). In combination with 
mutation and domain-exchange studies, such crystal structure analyses have 
identifi ed the amino acids which are directly involved in high affi nity ErbB-
ligand interaction. However, the molecular basis for receptor selectivity and 
mitogenic activity of the ErbB ligands is less well understood. This thesis 
focusses mainly on amino acids in ligand molecules that prevent unintended 
ErbB binding, and thereby determine the receptor specifi city of EGF-like 
growth factors. Knowledge of the basis of high affi nity binding, specifi city and 
mitogenic activity are very valuable in the design of therapeutic ErbB ligands 
with designed properties, both agonistic and antagonistic. 
2 ErbB receptors and their ligands
The family of ErbB ligands consists of polypeptide growth factors that 
all share an EGF-like domain, which is essential and suffi cient for binding to 
and activation of ErbB receptors. This domain is characterized by a conserved 
spacing of six cysteines that make up three disulphide bridges. As a result EGF-
like growth factors are composed of an N-terminal linear region, an  A-loop 
(1st–3rd cysteine),  B-loop (2nd- 4th cysteine), a hinge region (4th–5th cysteine), a 
C-loop (5th–6th cysteine), and a C-terminal linear  (Figure 1). Mammals contain 
11 genes for EGF-like growth factors, some of which give rise to multiple 
isoforms. The average length of the EGF-like domain is about 50 amino acids. 
Figure 2 shows the amino acid sequence of the EGF-like domain of human 
ErbB ligands, as well as of related viral and Drosophila proteins. The ligands 
bind the four ErbB receptors in a highly selective manner, such that EGF, 
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transforming growth factor alpha (TGFA), amphiregulin (AREG) and epigen 
(EPGN) form a subfamily that binds selectively to ErbB1, while the subfamily 
consisting of betacellulin (BTC), epiregulin (EREG) and heparin-binding EGF 
(HBEGF) binds not only ErbB1, but also ErbB4. Finally the neuregulins form a 
subfamily of which NRG1 and NRG2 bind both ErbB3 and ErbB4, while NRG3 
and NRG4 are specifi c for ErbB4. ErbB2 does not bind ligand by itself, but is 
the preferred heterodimerization partner for all liganded ErbBs. 
In their mature form, the ligands EGF and TGFA consist only of an 
EGF-like domain, whereas the ligands HB-EGF, AREG and BTC have in addition 
a hydrophilic Arg-Lys rich region N-terminally of the EGF-like domain, which 
allows them to bind to heparan-sulphate groups present in the extracellular 
matrix. As a result of alternative splicing and multiple promoter use, the 
NRG1 and NRG2 genes give rise to many distinct isoforms. As a consequence, 
at least 15 different isoforms are transcribed from the NRG1 gene (reviewed 
in (10)). The α and β isoforms of NRG1 and NRG2 differ in the EGF-domain 
sequence C-terminally of the fi fth cysteine (see Figure 2). The so-called Type 
I, II and III isoforms differ in their N-terminal sequence, whereby Type II has 
an enlarged N-terminal region and Type III lacks an Ig-like domain but has 
an additional transmembrane domain. Some of these isoforms are initially 
synthesized as a transmembrane protein whereas others are secreted. The 
Ig-like domains, present in some of the NRG isoforms, interact with heparin-
sulphate proteoglycans to maintain high NRG concentrations at sites where 
Figure 1. The EGF domain. These ribbon structures of EGF and TGFA represent 
crystal structures. The unstructured N-terminal linear region of EGF is not depicted. 
The various domains are indicated. Figure taken from Ogiso et al. (7). 
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sustained ErbB receptor activation is required, for example in the neuro-
muscular junction (11). 
 The four ErbB receptors consist of an extracellular domain, a single 
transmembrane domain and an intracellular domain. The extracellular domain 
of the ErbB receptors can be subdivided in four subdomains; two ligand 
binding subdomains (L1 and L2) and two cysteine-rich subdomains (S1 and 
S2) (Figure 3). In some literature these extracellular subdomains are also 
numbered I to IV. The intracellular domain contains the tyrosine kinase region 
as well as the docking sites for signaling molecules and adaptor proteins. 
ErbB2 is an orphan receptor that is unable to bind ligand, while ErbB3 has 
impaired tyrosine kinase activity. 
3 Evolution of ErbB receptors and their ligands 
 During evolution ErbB receptors have remained conserved among 
many species and have been evolved from a single progenitor receptor 
(12).  In invertebrates, such as Caenorhabditis elegans and Drosophila 
melanogaster, only a single receptor type has been identifi ed. In mammals 
there are four family members, ErbB1 (EGFR), ErbB2 (neu), ErbB3 and 
ErbB4. Two receptors, resembling ErbB1 and ErbB4 homologues, have been 
Figure 2. Sequence alignment of EGF-like ligands. All sequences are human 
except for the Drosophila growth factors Spitz, Keren, Gurken, Vein and Argos, and 
the viral growth factors vaccinia virus growth factor (VGF), Shope fi broma virus 
growth factor (SFGF) and myxoma virus growth factor (MGF). Residue numbers are 
according to EGF, of which the conserved cysteines are indicated. 
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identifi ed in the ascidian Ciona intestinalis. Parallel to the evolution of the 
receptors their ligands have evolved: whereas the C. elegans ErbB receptor 
has only one ligand, Lin-3, the Drosophila EGF receptor (DER) has four ligands 
Spitz, Keren, Vein, and Gurken. The mammalian ErbB-ligand system is much 
more complex: the four receptors are bound by a set of eleven ligands. 
Comparison of vertebrate ErbB receptors suggests that a gene duplication 
event generated two ancestral receptors, an ErbB3/ErbB4 precursor and an 
ErbB1/ErbB2 precursor. Phylogenetic analysis suggests that the mammalian 
ligands initially segregated into ErbB1-specifi c and ErbB3/ErbB4-specifi c 
ligands (12, 13). Indeed, EGF and TGFA interact with high affi nity exclusively 
to ErbB1, while the neuregulins bind only ErbB3 and ErbB4. However, some 
of the ErbB ligands show dual specifi city, including betacellulin (BTC), heparin 
binding EGF-like growth factor (HB-EGF) and epiregulin (EREG), which 
interact with both ErbB1 and ErbB4. Phylogenetic analysis shows that TGFA 
and BTC, as well as AREG and HB-EGF and also EREG and epigen (EPGN) have 
shared ancestors. It therefore appears that after the second gene duplication 
event each of the ligand pairs developed into an ErbB1-specifi c ligand and a 
ligand that can interact with both ErbB1 and ErbB4. Apparently, ligands and 
receptors have coevolved while putting evolutionary pressure on each other. 
Since no ligands have been identifi ed that directly interact with ErbB2 and 
because ErbB2 is always in an active conformation, it is reasonable to assume 
that ErbB2 has evolved as a dimerization partner for other the ErbB receptors. 
The possibility to form heterodimers with the kinase-inactive ErbB3 receptor 
could have put evolutionary pressure on ErbB2 for maintenance of kinase 
activity and allowed ErbB3 to gain multiple PI3-kinase binding sites (12). 
Figure 3. Schematic representation of the mammalian ErbB family of 
receptor tyrosine kinases and the Drosophila epidermal growth factor 
receptor. The extracellular domains of the receptors consist of two leucine-rich 
ligand binding domains (L1 and L2, represented by balls) and two cysteine-rich 
dimerization domains (S1 and S2). In ErbB2 the major dimerization interface, S1, 
is continuously exposed for dimerization. The Drosophila epidermal growth factor 
receptor (DER) has an elongated S2 domain.
16
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4 Ligand-mediated receptor dimerization
Recent studies on the crystal structure of ErbB1 in complex with EGF 
and TGFA, as well as the crystal structures of ErbB2 and unliganded ErbB3 
and ErbB4, have provided a breakthrough in our understanding of ligand-
mediated receptor activation. The L1 and L2 domain are directly involved in 
ligand binding (7, 14), while the S1 and S2 domain are involved in receptor 
dimerization. As shown in Figure 4A, ligand binding results in the formation of 
a 2:2 ErbB1-ligand complex (7, 14). 
 The residues in EGF that directly interact with its receptor are located 
in three sites (Figure 4B). Site 1 contains the B-loop, the hinge region (C31, 
N32 and C33) and the N-terminal linear region, which all interact with the L1 
domain of ErbB1 (Figure 4C).  Site 2 contains R41 which forms an essential 
salt bridge with D355 in the L2 domain of the receptor (Figure 4D), while site 
3 contains the C-terminal linear region which interacts with the L2 domain 
(Figure 4E). More details are provided in the legend of Figure 4.  
Receptor dimerization occurs mostly through interactions between 
the S1 domain (Figure 5A, B and C), which forms the major dimerization 
interface. A dimerization arm, formed by a 20 amino acid β-hairpin, protrudes 
from the S1 domain of both receptors. The tip of the arm forms a hand-like 
structure that interacts with the arm of the other receptor. Mutation studies 
indicate that the S2 domain may provide a minor dimerization interface, 
but no crystallographic data are available to confi rm this. However, the 
S2 domain plays a central role to keep the receptor in an auto-inhibited 
(tethered) conformation in the absence of ligand. Such a  conformation has 
Figure 4. Crystal structure of ErbB1 in complex with EGF. A. Ribbon 
representation of the extracellular domain of the EGF-bound ErbB1 dimer. B. Three 
interaction sites by which the ligand binds its receptor. C. Close-up of the interaction 
site 1, consisting of the B-loop, the hinge region and the N-terminal linear region. 
The main interacting residues are I23 (L23 in TGFA) and L26 of EGF which can bind 
to the hydrophobic pocket in L1 formed by L14, L69 and L98. TGFA has a Glu (E26) 
instead of a Leu on position 26, which forms a salt bridge with R124 of ErbB1. 
K28 forms a salt bridge with E90 in the receptor while C31, N32 and C33 together 
interact with Q16, L17 and G18 in the receptor by forming a parallel β-sheet. In 
addition N32 forms a hydrogen bound with Q16 of the receptor. D. Close-up of the 
interaction site 2, in which R41  forms a salt bridge with D355 in the L2 domain 
of the receptor. This salt bridge is enforced by Y13 (F13 in TGFA) and L15 (F15 in 
TGFA) of the ligand, which interact with F357 and V350 in ErbB1, respectively. Due 
to this hydrophobic environment R41 is pointed out into the proper orientation 
to facilitate salt bridging with D355. E. Close-up of the interaction site 3, which 
includes the C-terminal linear region. The key residue in this interaction is L47, 
which binds into a hydrophobic pocket formed by L382, A415, V417, F412 and I438 
of ErbB1. In addition, Q43 and R45 in EGF form hydrogen bonds with Q384 in the 
receptor, while E43 and H44 in TGFA form hydrogen bonds with Q384 and Q408 in 
ErbB1. Figure taken from Ogiso et al. (7).
18
Chapter 1
been visualized in the crystal structure of unliganded ErbB3 (8) and ErbB4 
(9), whereas as similar structure was observed for EGF-bound ErbB1 at low 
pH conditions whereby the receptor cannot dimerize (6). Remarkably, the 
same β-hairpin loop that is involved in receptor dimerization also forms the 
tether by folding back to the S1 domain. Key residues in this interaction are 
described in the legend of Figure 5. Mutation of Y246 in the S1 domain ErbB1, 
one of the key residues involved in both maintenance of the auto-inhibited 
conformation and receptor dimerization, had hardly any effect on EGF 
binding, but abolished EGF-induced receptor dimerization, phosphorylation 
and MAPK activation. On  the other hand, mutations in the S2 domain which 
also disrupted the intramolecular tether did not affect EGF-induced receptor 
activation (15).
Binding of activating ligands to the ErbB receptor is accompanied by 
a dramatic rearrangement of its extracellular domain. Upon ligand binding 
S1 will dissociate from S2,  and the subsequent rotation will bring the ligand 
binding domains L1 and L2 close  together, such that a single ligand molecule 
can bridge the two domains, while in addition bringing the dimerization 
interface in the exposed conformation. 
Reports about the homodimerization of ErbB2 and ErbB3 are 
contradictory. Although homodimers of ErbB2 has been described in ErbB2 
overexpressing breast cancer cells (16), ErbB2 and ErbB3 do not generally 
form homodimers. Chimeric ErbB receptors comprising of an extracellular 
ErbB3 domain and a intracellular ErbB1 (ErbB3/ErbB1) failed to form 
signaling dimers upon stimulation with NRG, while in presence of ErbB2 
signaling ErbB3/ErbB1-ErbB2 heterodimers were formed (17). These fi ndings 
demonstrate that the ErbB3 extracellular domains are not able to interact with 
each other. ErbB2 is prevented from homodimerization by charge repulsion 
since its dimerization interface is highly negatively charged (5). Furthermore, 
Citri et al. (18) proposed a model in which HSP90 interacts with the ErbB2 
kinase domain, thereby keeping putative ErbB2 homodimers in an inactive 
state, while ligand-induced heterodimerization disrupts the interaction 
between HSP90 and ErbB2.  
Besides S1 and S2, also the transmembrane and juxtamembrane 
domain appear to be involved in receptor dimerization. The transmembrane 
domains of the ErbB receptors contain two dimerization motives, a N-
terminal and a C-terminal motif, corresponding to an active and an inactive 
state, respectively. Based on computational analysis of the transmembrane 
domains, ErbB2 dimerization would be mediated by the C-terminal motif, 
resulting in an inactive ErbB2 homodimer. From this inactive state the ErbB2 
homodimer might rotate into the active state, mediated by the N-terminal 
motif. Moreover, Moriki et al. (19) analysed receptor dimerization by inserting 
cysteine residues at strategic positions in the putative α-helix axis of the 
extracellular juxtamembrane region. Depending on the position of the inserted 
cysteine the mutant receptors spontaneously formed disulphide bridges. 
These results suggest that ligand binding to the fl exible extracellular domains 
19
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of the receptor dimer induce rotation or twist of fi rst the juxtamembrane 
regions, and subsequently of the transmembrane domains, which may be 
necessary for the kinase domain to become appropriately positioned for 
phosphorylation of substrate molecules. These molecular switch models for 
ErbB2 dimerization explain the oncogenic properties of the ErbB2 mutant in 
which V664 is mutated to a Glu. V664 is part of the C-terminal motif and when 
this residue is mutated to a Glu, the polar side chain of E664 will be exposed 
to a hydrophobic lipid environment, which is energetically unfavourable. As 
a result, inactive ErbB2 homodimers mediated by the C-terminal motif will 
not be formed when V664 is mutated to E664. However, the level of ErbB2 
homodimerization mediated by the N-terminal motif will be increased because 
of hydrogen bond formation (20), resulting in autophosphorylation of the 
receptors. On the other hand, a single nucleotide polymorphism in ErbB2 
resulting in the V655I mutation is associated with reduced risk for mammary 
carcinomas (21). The molecular shift model proposes that substitution of Val 
by the bulkier Ile residue at this position will destabilize the formation of 
active ErbB2 dimers that are mediated by the N-terminal dimerization motif. 
Thus the transmembrane region controls dimer formation and rare mutations 
in this region might explain the occurrence of active ErbB2 homodimers. 
4.1 The asymmetrical model of ErbB transphosphorylation
 In addition to the extracellular domain, crystal structures have been 
determined of the intracellular region of ErbB1. The crystal structure of the 
Figure 5. The cysteine-rich domains S1 and S2 are involved in dimerization 
and in the formation of the auto-inhibited conformation. A. The major 
dimerization interface of an ErbB1 homodimer. B. and C. Close-up of the binding 
region of the major dimerization interface from two different sites of view. A 
dimerization arm, formed by a 20 amino acid β-hairpin, protrudes from the S1 
domain of both receptors. The tip of the arm forms a hand-like structure that 
interacts with the arm of the other receptor. Key residues in this interaction are 
Y246, P248 and Y251 in the hand-like structure which interact with F230, F263, 
A265, Y275 and R285 in the arm of the other receptor. Outside the dimerization 
arm two regions are involved in the S1-S1 interaction: D279 interacts with H280 
in the other receptor while Q193, Q194 and C195 interact with P204 and S205 in 
the other receptor (7, 14). D. ErbB1 in the auto-inhibited conformation. E. Close-
up of the S1-S2 interaction in ErbB1. Key residues in this interaction are D563, 
H566 and K585 (D562, H565 and K583 in ErbB3) interacting with Y246 and Y251 
(Y246, F251 and Q252 in ErbB3) of the S1 domain. F. Surface representation of the 
extracellular domain of auto-inhibited ErbB3. EGF and sites in ErbB3 homologous 
to the sites in ErbB1 to which EGF binds are depicted in red. The distance between 
the two putative ligand binding sites in ErbB3 is about 60Å, indicating that a domain 
rearrangement is likely to occur upon ligand binding. G. Transition between the 
auto-inhibited conformation and the ligand-bound ErbB1 dimer. EGF binding is 
proposed to induce a 130o rotation of the receptor resulting in the exposure of the 
dimerization arm to allow dimerization. Figure taken from Ferguson et al. (6).
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kinase domain of ErbB1 in complex with 4-anilinoquinazoline, an ErbB1-
specifi c tyrosine kinase inhibitor (TKI), suggests that the kinase domain is 
always in an active conformation (22). The kinase domains of ErbB receptors 
differ from all other known receptor tyrosine kinases in that their activation 
loop (K836-848) adopts a conformation in the unphosphorylated state which 
is similar to that of other kinases in the phosphorylated state (22). Although 
these studies were performed with unliganded ErbB1, mutation of  Y845 in 
ErbB1 into Phe does not block EGF-induced ErbB1 signaling (23), suggesting 
that activation of the ErbB1 kinase is independent of its phosphorylation 
state. 
In another study, Zhang et al. (24) demonstrated that the intracellular 
domains of an ErbB1 homodimer can show an inactive symmetric or an 
active asymmetric orientation. In the symmetric inactive conformation the 
tyrosine kinases directly interact with each other back-to-back and thereby 
keep their kinase domains in an auto-inhibited orientation (Figure 6B). In 
the asymmetric active conformation one tyrosine kinase phosphorylates the 
C-terminal tail of the other receptor (Figure 6E and F). The authors assume 
that transphosphorylation of both ErbB1 receptors in a homodimer requires 
a dynamic switch in orientation of two receptor kinase domains (Figure 6E 
and F). In a heterodimer, however, ErbB2 and ErbB3 will prefer an orientation 
(Figure 6E) in which the C-terminal tail of ErbB3 is phosphorylated by the 
kinase of ErbB2. Evolutionary analysis showed that the amino acid sequences 
of ErbB1, ErbB2 and ErbB4 at the interface of the kinase that interact with 
the C-terminal tail of its partner receptor are highly conserved among 
vertebrates, while for ErbB3 many variations were found (25). This suggests 
that because of its inactive kinase there might be no evolutionary pressure in 
ErbB3 on the maintenance of residues facilitating an interaction of the kinase 
domain with the C-terminal domain of its partner receptor. It remains unclear, 
however, how ErbB2 is phosphorylated in an ErbB2-ErbB3 heterodimer by the 
kinase-defective ErbB3.
In addition to the extracellular domain and the transmembrane region 
also regions in the intracellular domain are involved in dimer formation. 
A sequence of three amino acid residues (LVI) at the C-terminal end of 
the impaired ErbB3 kinase region has been reported to be essential for 
transactivation by ErbB2 (26). The corresponding region in ErbB2 (VVI) was 
found to be necessary for ligand-independent homodimerization (27). In a 
crystal structure of the ErbB1 kinase domain the LVI sequence is in close 
contact with the C-loop of the kinase domain (22). In this interaction L955 is 
completely buried and therefore not available for interaction with the partner 
receptor or adaptor molecules. A more plausible explanation would be that the 
tripeptide segment mediates a rotation in the intracellular region that affects 
the availability of the C-terminal tail as a substrate for transphosphorylation. 
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Figure 6. Asymmetric interaction of the intracellular domains in the active 
ErbB1 homodimer.  A and D illustrate unoccupied ErbB1 receptors. E and F 
illustrate the ligand-activated ErbB1 dimer. A shows two ErbB monomers. B shows 
the low affi nity form of the ErbB1 homodimer in which the kinase domains are in 
such orientation that they do not interact with the C-terminal intracellular domain 
of its partner receptor. C and D show high affi nity forms of ErbB1 in which the 
intracellular domains are asymmetrically orientated. E and F show ligand induced 
ErbB1 homodimer in which the intracellular domains are asymmetrically orientated. 
In the asymmetrical orientations of the ErbB1 homodimers the C-terminal 
intracellular domain of the one receptor is bound and activated by the kinase 
domain of the other receptor. Figure is taken from Landau and Ben-Tal (25). 
23
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5 High and low affi nity ErbB1 binding sites
 Scatchard analysis of [125I]-EGF binding to ErbB1 overexpressing 
cells has provided evidence that EGF can bind its receptor with at least two 
different affi nities. Approximately 5% of the ErbB1 molecules bind EGF with 
high affi nity (Kd 10-100 pM) whereas the majority of receptors (~ 95%) bind 
EGF with a much lower affi nity (Kd 2-5 nM). Although this phenomenon has 
been known for decades (28), its interpretation is still a matter of debate. 
The observation that the anti-ErbB1 antibody 2E9 binds only low affi nity 
receptors, indicates that low and high affi nity receptors are physical entities. 
Based on the crystal structure of the EGF/ErbB1 complex, it has been 
proposed that the monomeric tethered confi guration corresponds to the 
majority of low affi nity receptors, whereas un unliganded extended dimeric 
confi guration corresponds to the minority of the high-affi nity class of ErbB1. 
However, mutagenic disruption of the autoinhibitory tether did not give rise 
to a single receptor population that binds ligand with high affi nity, and also 
did disruption of receptor dimerization not yield a receptor that binds EGF 
with only a single low affi nity (29). Thus, these results demonstrate that the 
extended confi guration of ErbB1 does not account for the high affi nity EGF 
binding sites. Mathematical analysis by Klein et al. (30) could only explain the 
existence of high and low affi nity binding sites by postulating an additional 
component to the dimeric ErbB1/EGF complex.
  For measuring the inter-EGF distance and the vertical distance of 
EGF to the plasma membrane in the EGF/ErbB1 complex, use has been made 
of Fluorescence resonance energy transfer (FRET) analysis in combination 
with ensemble fl uorescence lifetime imaging microscopy (FLIM). Using these 
techniques Webb et al. (31) found that high affi nity ErbB1 ectodomains are 
orientated fl at on the membrane, whereas low affi nity ectodomains are 
oriented vertically to the plasma membrane. These studies were performed 
in the presence or absence of 2E9 antibodies by which selectively low affi nity 
receptors were blocked. Moreover, they observed that the extracellular 
domains (ECDs) of low affi nity ErbB1 dimers are orientated side-by-side, 
whereas ECDs of high affi nity ErbB1 dimers are orientated head-to-head. 
Macdonald and Pike (32) explain the occurrence of high and low affi nity 
binding sites of ErbB1 by negative cooperativity on cells that express such 
high levels of ErbB1 that the receptors spontaneously aggregate. The essence 
of their model is that the affi nity of two occupied monomers for each other 
is, by an order of magnitude, lower than the affi nity of an occupied monomer 
for an unoccupied monomer, implying that at high EGF concentrations, 
EGF should induce disassembly of receptor dimers. In conclusion, studies 
describing the nature of low and high affi nity ErbB1 receptors are explained in 
very complex models. The explanation for the nature of high and low affi nity 
ErbB1 receptors of Webb et al. (31) and Macdonald and Pike (32) have in 
common that the orientation of high affi nity ErbB1 dimers on cells expressing 
high levels of ErbB1 is different from the orientation of ErbB1 monomers.  
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6 Mutational analysis of ligand-receptor interaction
 
 The relative contribution of individual ligand residues and combinations 
of residues on ligand–receptor interaction have been studied extensively by 
site-directed mutagenesis, alanine-scanning mutagenesis, domain-exchange 
and phage display strategies. Groenen et al. (33) and Campion et al. (34) 
have reviewed the effect of point mutations in EGF and TGFA on their ErbB1 
binding affi nity. These studies showed that, in addition to the structurally 
important cysteines and glycines, in particular Y13/F13, L15/F15, H16, R41 
and L47 are essential for high affi nity receptor. Figure 2 shows the amino acid 
sequences of the EGF-like ligands. A phage display study in which positions 
13, 15 and 16 in EGF were randomized, confi rmed the importance of Y13, L15 
and H16 for ErbB1 binding (35). Multiple single amino acid mutation studies 
demonstrated that R41 and L47 are essential for high affi nity ErbB1 binding 
(33). 
The importance of Y13 and the B-loop residues M21, Y22 and A30 for 
high affi nity binding of EGF to ErbB1 was examined by reintroduction of these 
amino acids into the 13th EGF-like repeat of the Drosophila Notch protein, 
which has an EGF-like structure but does not bind ErbB1. Notch proteins 
in which combinations of these four amino acids were introduced, showed 
ErbB1 binding affi nity similar to wild type EGF (36). Remarkably, most of 
the amino acids that were found to be essential for high affi nity binding are 
involved in binding to the L2 domain of the receptor, whereas there appears 
more freedom in mutating the amino acids involved in L1 domain binding 
without loss of high affi nity binding. The length of the B-loop of EGF can be 
shortened without loss of binding affi nity, as been demonstrated by an EGF-
mutant in which the B-loop is shortened to 8 amino acids (37). Also EGF with 
an extended B-loop of 12 amino acids following incorporation of residues 
from the Drosophila protein Argos, retained binding affi nity for ErbB1 (38), 
although some loss of affi nity was observed, most likely due to the absence 
of L26 at the correct position in the B-loop (33).  
 In case of NRG1β, a full alanine scanning and phage display affi nity 
optimisation has been carried out. Alanine scanning mutagenesis showed that 
H2L3 in the N-terminal linear region, the complete A-loop, R31 in the B-loop, 
the hinge residue K45, the complete C-loop, and Q46, Y48 and M50 in the 
C-terminal linear region are important for high affi nity ErbB3 binding (39). 
For high affi nity ErbB4 binding the residues S1, F13, V15, N16, G42, R44, 
Q46, S52 and F53 appeared essential, indicating that the requirements for 
binding of NRG1β to ErbB3 and ErbB4 partly overlap, but are not identical. 
Phage display mutagenesis of the complete NRG1β EGF-like domain showed 
strong conservation of L3, V4, V15, N16, G17, G18, E17, V23, Q46, Y48 
and V49 (40). In particular mutations in the B-loop and the M50I mutation 
increased the affi nity for ErbB3, indicating that the wild-type sequence of 
NRG1β is suboptimal for ErbB3 binding. Combination of these mutations in 
the B-loop and the M50I mutation resulted in a neuregulin variant, designated 
25
General Introduction
NRG-optimized (NRGopt), which showed a 3-fold increased affi nity for ErbB3. 
These studies also showed that the so-called omega loop (L26, S27, N28), 
three additional residues at the tip of the B-loop, is not essential for receptor 
binding of NRG1β. Shortening of its B-loop from 13 to 10 residues, as similarly 
present in EGF and TGFA, did not impair binding to ErbB3 and ErbB4 (41).  
NRG1 and NRG2 have multiple C-terminal linear regions as a result 
of alternative splicing. Single amino acid exchange between residues of the 
C-terminal linear region of the isoforms NRG2α and NRG2β showed that 
exchange of K45 from NRG2α for F45 from NRG2β resulted in enhanced 
affi nity of NRG2α and reduced affi nity of NRG2β for ErbB4. These studies 
demonstrate that minor changes in the amino acid sequences of ErbB ligands 
can cause strong alterations in the ErbB binding affi nity.
7 Mutational analysis of ErbB specifi city
 
 Domain-exchange studies between ligand molecules have been 
instrumental to study the ErbB specifi city of EGF-like growth factors. Studies 
in which intercysteine domains were exchanged between EGF and NRG1β 
showed that introduction of the N-terminal linear region of NRG1β into EGF 
results in a chimera, designated biregulin, that binds with high affi nity to not 
only ErbB1 but also to ErbB3 (41). We have shown that introduction of the 
N-terminal linear region of TGFA into EGF (chimera T1E) is also suffi cient 
to broaden its receptor specifi city to ErbB3 and ErbB4. Subsequent studies 
showed that introduction of the sequence H2/F3 from TGFA is suffi cient 
to make EGF an ErbB3 and ErbB4 binding ligand. Phage display analysis 
revealed that EGF with an N-terminal linear region containing the sequence 
W2/V3/R4 shows similar high binding affi nity as EGF for ErbB1, and as NRG1β 
for binding to ErbB3 and ErbB4. A different observation was made when a 
single intercysteine region of EGF was introduced into NRG1β. This left the 
affi nity for ErbB3 and ErbB4 intact, but did not result in detectable affi nity for 
ErbB1 (41). In contrast, introduction of a single intercysteine region of NRG1β 
into EGF or TGFA strongly reduced the affi nity for ErbB1, without a detectable 
gain in affi nity for ErbB3 and ErbB4 (41). These results show that relatively 
small changes in ligand molecules can alter their receptor specifi city. 
Domain-exchange studies between the extracellular regions of ErbB 
receptors showed that EGF is able to induce phosphorylation of a chimeric 
receptor in which either the L1 or the L2 domain of ErbB1 was substituted 
by the corresponding domain of ErbB4, but not when both domains were 
exchanged. In addition, NRG1β was able to induce receptor phosphorylation 
of a chimeric receptor in which the L1 domain of ErbB1 was exchanged for the 
L1 domain of ErbB4. Exchange of the L2 domain of ErbB4 by the L2 domain 
of ErbB1 abolished NRG1β-induced phosphorylation, which indicates that 
particularly sequences in the L1 domain of ErbB1 prevent binding of NRG1β 
to this receptor (42).
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8 ErbB ligand processing
 ErbB ligands are produced as transmembrane precursors which are 
subsequently  released as soluble ligands after cleavage by cell surface 
proteases (10, 43). The ADAM (a disintegrin and metalloprotease) family 
members ADAM9, ADAM10, ADAM12 and ADAM17 (a.k.a. TACE) and MMP 
(matrix metalloprotease) proteases are largely responsible for shedding of 
membrane-bound ErbB ligands (44). The production of soluble ErbB ligands 
through ectodomain shedding can occur in response to the activation of G-
protein coupled receptors (GPCR) (45). Stimulation of GPCR leads to the 
activation of metalloproteases that induce cleavage and release of ligand, 
which subsequently activate ErbB receptors on its cell surface, thus leading 
to the rapid ErbB phosphorylation (46). While in vitro membrane-anchored 
proTGFA and proHB-EGF are biologically active and can interact with the 
ErbB receptors on adjacent cells, ectodomain shedding of the ligands 
appears essential for ErbB activation in vivo. ADAM10 is the main sheddase 
for EGF and BTC. In ADAM17-defi cient cells no shedding of TGFA, HB-EGF 
and AREG is observed (47-49), and consequently ADAM17 knockout mice 
die prenatally with a phenotype that resembles that of HB-EGF and ErbB1 
knockouts. Although there is redundancy among the ADAM family members, 
ADAM9, ADAM10 and ADAM12, which are also known to be involved in HB-
EGF shedding, cannot restore the effect of ADAM17 depletion which controls 
shedding of HB-EGF during heart development (50).
 Similar to TGFA and HB-EGF, NRG is cleaved by ADAM17. In case 
of the Ig-NRGs (Type I and II) this results in release from the plasma 
membrane. In case of the cysteine-rich domain (CRD)-NRGs (Type III) 
the ligand remains bound to the membrane, since they have an additional 
transmembrane domain. The CRD-NRGs are biologically active as well as the 
transmembrane Ig-NRG precursor (51). CRD-NRG knock-out mice die shortly 
after birth because they cannot breath due to the absence on functional 
neuromuscular synapses (52). Furthermore, the number of skeletal muscle 
cells and Schwann cells are severely reduced in CRD-NRG knock-out mice 
compared to wild-type mice. Ig-NRG knock-out mice, with normal levels of 
CRD-NRG, show a normal development of  Schwann cell precursors, but die 
at E10.5 due to defects in cardiac, cranial sensory and sympathetic neuron 
development similar to pan-NRG knock-out mice (53). In contrast, CRD-NRG 
knock-out mice have a normal development of the heart (52).  
 Overexpression of ADAMs and MMPs, on the other hand, results in 
extensive ErbB ligand shedding, which can lead to pathological conditions 
such as myocardial hypertrophy (54) and cancer (55, 56). Therefore, ADAMs 
and MMPs are interesting drug targets for the treatment of cardiac disease 
and cancer. 
27
General Introduction
9 ErbB-induced signaling pathways
 The combination of four receptors and multiple ligands allows for a high 
degree of signal diversifi cation, with multiple regulatory levels controlling the 
cellular outcome. The biological responses will depend on the identity of the 
ligand, the nature of the receptor dimer formed, and the identity, magnitude 
and duration of the induced intracellular signals. Upon ligand-induced 
receptor homo- and hetero-dimerization the tyrosine kinase domains of both 
receptors are activated which transphosphorylate tyrosine residues in the C-
terminal region of their intracellular domain (57, 58). These phosphorylated 
tyrosines form binding sites for SH2 and PTB domain containing signaling 
and adaptor molecules (reviewed in (59)). The 5-8 amino acids surrounding 
the phosphorylated tyrosine determine the specifi city for binding of SH2 and 
PTB containing proteins. Each ErbB receptor contains a unique set of tyrosine 
residues which bind a distinct subset of signaling molecules (60) (Figure 7).  
 The three main signal transduction pathways activated by the ErbB 
family members are the RAS/mitogen-activated protein kinase (RAS-MAPK) 
signaling cascade, the phosphatidylinositol 3’-kinase/protein kinase B (PI3K-
PKB/Akt) pathway and the  phospholipase C-gamma/protein kinase C (PLCγ-
PKC) pathway (reviewed in (61)). The RAS-MAPK cascade is initiated by the 
Figure 7. ErbB-induced signaling pathways. The four main signal transduction 
cascades activated upon ErbB activation are the RAS-MAPK, PI3K-Akt, PLCγ-
PKC, and the STAT pathways. Collectively, these pathways culminate in cellular 
proliferation, migration, and survival. Figure taken from Marmor et al. (61).
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binding of Grb2 to phosphorylated tyrosines, either directly via its SH2 domain 
or indirectly through PTB domain-mediated binding of the adaptor molecule 
Shc. Grb2 recruits Sos, which uploads Ras with GTP. Ras activates the serine/
threonine kinase Raf, which results subsequently in the phosphorylation and 
activation of MEK1/2 (MAPKK) and Erk1/2 (MAPK). Erk1/2 phosphorylates 
multiple cytoplasmic and cytoskeletal proteins including MAPK-activated 
protein kinases and the ribosomal p70-S6 kinase. After translocation to the 
nucleus MAPK activates the transcription factors Sp1, E2F, Elk-1 and AP1. Sp1 
and AP1 are responsible for the upregulation of cyclin D1, which activates 
the cyclin-dependent kinases CDK4 and CDK6, and thereby promotes cells to 
progress into the S-phase.
   ErbB-induced activation of the PI3K-PKB/Akt pathway starts by the 
SH2-mediated recruitment of the p85 protein (reviewed in (62)), which is 
the regulatory subunit of the p110 catalytic subunit of PI3K. This kinase is 
able to phosphorylate membrane-bound PIP2 to PIP3. PIP3 subsequently 
recruits PKB/Akt through its PH domain to the plasma membrane, where it 
is subsequently activated by phosphorylation through PDK1 and an as yet 
unknown kinase. Activated Akt promotes cell survival by phosphorylation 
of the pro-apoptotic molecule Bad, which as a result is no longer able  to 
dimerize with Bcl-2 and Bcl-X. Akt also promotes cell cycle progression by 
downregulation of the cyclin-dependent kinase inhibitor P27KIP1. Furthermore, 
Akt negatively regulates the activity of Raf and GSK-3 kinase as well as of the 
cell cycle regulatory transcription factor FKHR, while it promotes initiation of 
protein translation through mTOR and the ribosomal p70-S6 kinase.  
 PLCγ is recruited to the ErbB receptor either directly by binding through 
its SH2 domain or indirectly through binding with its PH domain to PIP2 (61, 
62). Activation of PLCγ by the ErbB kinase of by other cellular kinases results 
in the hydrolysis of PIP2, thus generating the second messengers DAG and 
IP3. Binding of IP3 to the IP3 receptors on the endoplasmic reticulum leads to 
Ca2+ infl ux from the endoplasmic reticulum (ER) to the cytoplasm. Increased 
cytoplasmic Ca2+ levels lead to the activation of calcium/calmodulin-dependent 
protein kinases and phosphatases. Together with DAG high cytoplasmic Ca2+ 
concentrations will result in activation of protein kinase C (PKC), a serine/
threonine kinase that among others can activate Raf and downstream 
pathways.  
 Another pathway that can be activated by ErbB receptors is c-Src. 
This oncogen product is able to phosphorylate additional tyrosine residues 
in ErbB1, as well as in cytoskeletal and endocytic proteins, and in addition is 
able to activate the oncogenic transcription factor c-Myc (63). Furthermore, 
ErbB1 is able to directly activate the nuclear transcription factors STAT1, 
STAT3 and STAT5 (64). Upon tyrosine phosphorylation the cytoplasmic STAT 
proteins dimerize, translocate to the nucleus and activate transcription of 
genes, which are critical for proliferation. 
A more recently identifi ed adaptor protein that binds tyrosine 
phosphorylated ErbB1 is Gab1.  Together with the tyrosine phosphatase Shp2 
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it forms an ErbB1 specifi c interaction between the RAS/MAPK cascade and the 
PI3K/Akt pathway (65).  In contrast to ErbB3, ErbB1 cannot directly associate 
with the p85 subunit of PI3K. ErbB1-mediated PI3K activation involves the 
adaptor proteins Grb2 and Gab1 (66). While Grb2 directly associates with 
ErbB1, Gab1 binds ErbB1 indirectly via Grb2, after which it is able to bind the 
p85 subunit of PI3K. The ErbB1-activated adaptor protein Shp2 controls the 
ErbB1-mediated PI3K activation by dephosphorylating the p85 binding sites 
on Gab1, thereby terminating the Gab1-PI3K positive feedback loop. 
Despite sharing some pathways, each ErbB receptor interacts with a 
different set of signaling molecules. The RAS-MAPK pathway and the PI3K-Akt 
pathway are activated by all four ErbB receptors, but not to the same extent. 
The potency and kinetics of the PI3K-Akt pathway, however, is quite different. 
Since ErbB3 has six docking sites for p85, the ErbB2-ErbB3 heterodimer is a 
very strong activator of the PI3K-Akt pathway. ErbB4 can also directly interact 
with p85, but only through one docking site, while ErbB1 depends on Gab1 
for activation the PI3K-Akt pathway. ErbB3 is the only ErbB receptor that 
does not interact with Cbl, while ErbB1, ErbB2 and ErbB4 have functional Cbl 
binding sites (67). Furthermore, ErbB3 does not have sites for binding to the 
adaptor protein Grb2, but can interact with the adaptor proteins Shc and Grb7 
(63).
As a result of alternative splicing there are four ErbB4 isoforms, 
which differ in their signaling pathways. The JM-a isoform can be cleaved by 
TACE and γ-secretase at the extracellular juxtamembrane region, resulting 
in the formation of a soluble extracellular fragment and a transmembrane 
fragment. Upon further cleavage this leads to the formation of an intracellular 
fragment (ErbB4 s80) that can translocate to the nucleus where it binds 
nuclear proteins including transcription factors. In contrast, the JM-b isoform 
cannot be cleaved in his way and gives rise to a full length transmembrane 
receptor. For both the JM-a and JM-b isoform there are two further subforms, 
Cyt-1 and Cyt-2, which differ in their intracellular domain. In contrast to 
Cyt-1, the Cyt-2 subforms lack the PI3K binding motif and are therefore 
unable to activate the PI3K/Akt pathway. The JM-b mediated form of signal 
transduction, relying on activation of tyrosine kinase activity, is referred to as 
canonical ErbB4 signaling, whereas the JM-a mediated form, relying on direct 
binding of nuclear proteins, is referred to as non-canonical ErbB4 signaling. 
It has been established that non-canonical ErbB4 signaling regulates the 
activity of at least the STAT5A, Eto2, Mdm2 and YAP nuclear proteins. It has 
been established that NRG1β and BTC are able to induce different second 
messengers upon binding to ErbB4 receptors. Whether this implies that 
ligands may preferentially induce canonical or non-canonical  ErbB4 signaling, 
is currently unknown (10). 
 There is increasing evidence that upon activation also other ErbB 
receptors can be translocated to the nucleus where they are directly involved 
in transcriptional activation (68-70). However, the signifi cance of ErbB nuclear 
translocation in signal transduction is still a subject of debate. Nuclear ErbB1 
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has been shown to recognize an AT-rich response sequence (ATRS) in the 
promoter of the cyclin D1 and iNOS gene (68, 69). Nuclear ErbB2 appears 
associated with the cyclo-oxygenase (COX-2) promoter where it interacts 
with so called HER-2-associated DNA sequences (HAS) (71). The presence 
of ErbB3 has been reported in the nucleus of mammary epithelial cells, but a 
functional role for a nuclear ErbB3 has not been attributed yet (70).
9.1 Negative regulation of ErbB signaling
 Upon ligand binding activated ErbB1 is rapidly removed from the cell 
surface by internalization through clathrin-coated pits (reviewed in (72)). The 
phosphorylated receptor recruits the adaptor protein c-Cbl, a ubiquitin ligase 
which is responsible for ubiquitination of the receptor (73). Subsequently, 
the endocytic adaptor molecule Eps15 recruits the ubiquitinated receptor to 
the clathrin-coated pits by targeting AP-2 to the plasma membrane (74, 75). 
AP-2 complexes on the membrane then drive the assembly of clathrin-coated 
vesicles by creating a coated pit. The release of the clathrin-coated vesicle 
(early endosome) from the plasma membrane involves the GTPase dynamin 
(reviewed in (76)). Fusion of the early endosome with other internal vesicles 
forms the sorting endosome from which unoccupied receptors can recycle back 
to the plasma membrane (reviewed in (77)). Receptors that are still bound 
by their ligand remain in the endosome, which matures to a late endosome 
(multi-vesicular body or MVB). During endosomal maturation the pH of the 
lumen decreases due to the action of the vacuolar H+ATPases. Before entering 
the multi-vesicular bodies ligand-bound ErbB receptors are still capable of 
signaling (78). Once in the MVB the cytoplasmic tail is sequestred from the 
cytoplasm which prevents its interaction with cytoplasmic signaling molecules 
(79). After fusion with pre-existing lysosomes, both the receptor and the 
ligand are fi nally degraded by the lysosomal proteases (80). Upon activation 
of ErbB1 by EGF the EGF-ErbB1 complex is internalized via clatherin-coated 
vesicles and continues to signal in the endosomes until both are degraded in 
the lysosomes. TGFA on the other hand also induces receptor internalization 
but dissociates from the receptor due to the low pH in the endosomes, 
resulting in receptor recycling to the cell surface where it can be reactivated.
 UBPY accelerates ErbB1 degradation by deubiquitinating the receptor 
on endosomes (81, 82). Also Sprouty has been identifi ed as a protein 
that affects ErbB1 ubiquitination. Originally, Sprouty has been identifi ed 
as an inhibitor of Drosophila EGF receptor signaling (83). Its mammalian 
homologues have been shown to inhibit ErbB1 signaling and to prevent MAPK 
phosphorylation (reviewed in (83)). Activation of ErbB1 induces enhanced 
transcription of the Sprouty-2 gene and phosphorylation of the Sprouty 
protein. Phosphorylated Sprouty binds c-Cbl, which on the one hand prevents 
ErbB1 ubiquitination, but on the other hand targets Sprouty for lysosomal 
degradation (84). Recent publications show that Sprouty-2 associates with 
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the multi-adaptor protein CIN85 and couples Cbl to CIN85 in order to inhibit 
ErbB1 ubiquitination (85). CIN85 probably functions as a scaffold molecule 
that binds to numerous endocytic accessory proteins and thereby controls 
traffi cking of ErbB1 along endocytic and recycling pathways. 
 Caveolae are specialized forms of lipid rafts that are marked by the 
presence of the protein Caveolin-1 (86). With the exception of ErbB3, the 
ErbB family members are preferentially located in caveolae, while upon ligand 
binding ErbB1, ErbB2 and ErbB4 migrate out of the caveolae to the bulk of 
the plasma membrane. The Caveolin-1 gene has been described as a tumor 
suppressor gene since down regulation of Caveolin1 is suffi cient for MAPK 
activation and cell transformation (87). The extracellular juxtamembrane 
region of  ErbB1 contains a sequence that targets the receptor to the 
caveolae/rafts (88). Interaction of ErbBs with Caveolin-1 results in inhibition 
of their tyrosine kinase activity (89). Since caveolae are enriched in signaling 
molecules like RAS and Src, and Caveolin 1 inhibits receptor tyrosine kinase 
activity, caveolae might regulate the activity of early ErbB signaling in these 
preassembled complexes. 
 Decorin, a small leucine-rich proteoglycan, has been described as a 
negative regulator of ErbB1 signaling. Decorin causes a slow but sustained 
internalization of unliganded ErbB1 via caveolae-mediated endocytosis (90). 
These so-called caveosomes are non-clathrin coated vesicles that similar 
to clathrin-coated endosomes fuse with the late endosome, resulting in 
lysosomal degradation of the receptor. Unlike unliganded receptors in the 
early endosome, the receptors in the caveosomes cannot recycle to the 
plasma membrane. Decorin directly interacts with the L2 domain of ErbB1 
(91), and since the decorin binding site partially overlaps with the ligand 
binding site, this protein may decrease the available number of ligand binding 
sites on the cell surface. In addition to clathrin-mediated and caveolin-
mediated endocytosis, clathrin- and caveosome-independent endocytosis of 
ubiquitinated ErbB1 has been reported to occur in the lipid rafts. This process 
of so-called raft-endocytosis occurs particularly at high ligand concentrations 
(92).
 Ectodomain shedding of ErbBs by secretase enzymes and TACE 
may negatively regulate ErbB signaling. The resulting soluble extracellular 
domains of ErbB3 and ErbB4 have been shown to act as scavengers of NRGs, 
and thereby prevent their binding to the full length membrane-bound ErbB3 
and ErbB4 (93). The recombinant extracellular domain (ECD) of ErbB1 
(amino acid 30-501) also acts as a scavenger of ErbB1 ligands, but there is 
no evidence that  ECD of ErbB1 occurs naturally (94). A soluble extracellular 
domain of ErbB2 has been identifi ed, which is not formed by proteolytic 
cleavage, however, but instead  results from  alternative splicing of the ErbB2 
transcript (95). This splicing product, known as Herstatin, consists of the 
extracellular domain of ErbB2 linked to a C-terminal proline-rich domain. 
Herstatin prevents the formation of active heterodimers by binding with 
its L1 domain to liganded ErbB receptors or unliganded ErbB receptors in 
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the extended conformation  (96). Ectodomain shedding of ErbB2, however, 
results in the formation of a constitutively active p95 fragment, as observed 
in breast cancer cells. Prevention of ErbB2 ectodomain shedding by Herceptin 
is therefore one of the mechanisms by which this monoclonal antibody is 
successful in the treatment of breast cancer. 
 An additional negative feedback loop in ErbB signaling is provided 
by the products of the three LRIG genes.  The  best characterized member, 
LIG-1, is upregulated upon ligand-induced ErbB activation (97). Targeted 
disruption of the LIG-1 gene causes psoriasis-like epidermal hyperplasias 
(98). Since ErbB1 is involved in skin development, the LIG-1-null phenotype 
might be linked to ErbB1 signaling. LIG-1 directly interacts with all four 
members of the ErbB family. The extracellular domain of the LIG-1 proteins 
consists of fi fteen leucine-rich regions (LRR) and three immunoglobulin-like 
(Ig) domains, which both are suffi cient for ErbB1 binding (99). LIG-1 binds 
ErbB1 and stimulates ubiquitination of both LIG-1 itself and of ErbB1 by 
recruiting Cbl, thereby reducing the half-life of the receptor. Although LIG-1 
expression is upregulated by ErbB activation, the LIG-1-targeted receptors 
require receptor activation, with the consequence that LIG-1 reduces the 
number of ligand binding sites on the cell surface. The LRIG genes have been 
reported as homologues of the Drosophila EGF receptor antagonist Kekkon 
which also contains LRR and Ig domains. However, the working mechanism of 
Kekkon is different, since this protein interferes on the level of ligand binding 
and receptor dimerization (100). 
9.2 Juxtacrine signaling by ErbB ligands
 Membrane-ancored precursors of TGFA, AREG, HB-EGF and NRG1 
are able to bind and activate ErbB receptors in a juxtacrine fashion. In 
contrast to the soluble ligands forms, these non-diffusible ligands can only 
transmit their signals to neighbouring cells, which ensures signaling in a 
proper temporal and spatial context. Juxtacrine activation of ErbB1 by AREG 
has been shown to play a role in trophoblast growth in the placenta (101). 
Membrane-bound ligands may have additional functions besides activating 
ErbB receptors on neighbouring cells. The transmembrane form of TGFA 
interacts with CD9 (102), a tetraspanning transmembrane molecule that 
binds various integrines (103), which suggests that the transmembrane 
form of TGFA may in addition be involved in cell adhesion. This hypothesis is 
strengthened by the observation that ErbB1, together with E-cadherin and 
α- and β-catenin, is localized at the zona adherens in polarized cells (104). 
Increased CD9 expression inhibits TGFA release by metalloprotease activity 
(102) and inhibits motility and metastasis in carcinoma cell lines (105, 106), 
while decreased CD9 expression is correlated with poor prognosis in breast 
cancer. CD9 co-precipitates with AREG and HB-EGF in keratinocytes resulting 
in increased juxtacrine ErbB activation (107). 
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 Transmembrane isoforms of NRG1 have been reported to mediate 
bidirectional signaling in neurons (108). In the model of back signaling 
NRG1 is proteolytically cleaved upon ErbB receptor binding. Consequently 
the intracellular domain is released and is translocated to the nucleus where 
it represses expression of several regulators of apoptosis. In addition the 
intracellular region of NRG1 interacts with LIMK1 (109), a cytoplasmic protein 
kinase implicated in development of visuospatial cognition. LIMK1 shuttles 
between the nucleus and the cytoplasm and is involved in transcription 
regulation, but the signifi cance of LIMK1 in NRG1 back signaling remains to 
be demonstrated (110).  
10 ErbB function in development and differentiation
 The expression of the four ErbB receptors and the eleven ligands differs 
spatially and temporally during development. Table I gives an overview of the 
site of expression and known in vivo function of all ErbB ligands. Knock-out 
mice have shown crucial roles of the ErbB family members and their ligands 
in development of the cardiovascular system, nervous system, epithelium 
and mammary gland. Table II gives an overview of the results of these knock-
out studies. The specifi c developmental role of the various NRG isoforms is 
described in a separate section.
10.1 Cardiovascular system 
 The importance of ErbB2, ErbB3, ErbB4 and their ligand NRG1 in the 
development of the cardiovascular system has been demonstrated by the use 
of knock-out mice lacking these genes. Mice lacking ErbB2, ErbB4 or NRG1 die 
at embryonic day 10 due to aborted development of myocardial trabeculae 
in the heart ventricle (111-113). As a result this mutant has a heart with 
irregular beat, an enlarged common ventricle and a reduced blood fl ow. Mice 
lacking ErbB3 survive until embryonic day 13 and exhibit cardiac cushion 
abnormalities leading to blood refl ux through defective valves (114). HB-EGF 
knock-out mice and mice lacking ErbB1 and TACE (ADAM17) have defective 
valvogenesis. This suggests that cardiac valvogenesis is dependent on ErbB1 
activation by TACE-derived soluble HB-EGF.
10.2 Nervous system
 NRG1 and its receptors are very important for neuronal development. 
NRG1 is produced by neurons and regulates glial cell proliferation, axon 
myelination, neuronal migration, axon guidance and synapse formation. 
During early brain development NRG1, together with ErbB4, provides 
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patterning information for the proper migration of neural crest cells. For 
the formation of the projection of the thalamus to the cortex the axons are 
guided by GABAergic interneurons that express type III NRG1β (115). The 
thalamo-cortical axon conveys the sensory and motor input to the cerebral 
cortex. The appropriate direction of ErbB4-expressing thalamo-cortical axon 
migration, from the ganglionic eminence towards the developing cortex, is 
navigated by a gradient of soluble Type I and Type II NRG1β which serve 
as a chemoattractant (116). In vivo, loss of NRG1/ErbB4 signaling causes 
an alteration in the migration of cortical interneurons and a reduction in 
the number of GABAergic interneurons in the postnatal cortex (117). NRG1 
regulates synaptic plasticity by activation ErbB4 on the presynaptic GABAergic 
interneurons, thereby enhancing activation-dependent GABA release (118). 
A role for ErbB1 in neurogenesis is indicated by the observation that mice 
lacking ErbB1 develop strain-dependent progressive neurodegeneration 
(119). 
10.3 Neuregulin and ErbB4 involvement in schizophrenia
 Schizophrenia is a disabling neurophysiological disorder that affects 
0.5%-1% of the world’s population and is characterized by abnormalities 
in the perception of reality. Genetic linkage studies in multiple populations 
from six different countries have identifi ed more than 80 single nucleotide 
polymorphisms (SNPs) in the human NRG1 gene (118) and 18 in the human 
ErbB4 gene (120, 121). Most of these SNPs are localized in the 5’ region of the 
NRG1β gene and there is increasing evidence that these SNPs may regulate 
NRG1 expression (121-123).  Brain samples of schizophrenia patients show 
increased levels of Type I NRG1β (122). The upregulated expression of the 
CYT1 isoform of ErbB4 in schizophrenia patients suggests an important role 
of the PI3K-Akt pathway. Moreover, risk factors for schizophrenia, such as 
corticosteroids and cannabis, suppress the activity of the PI3K-Akt pathway 
(124). The combination of increased levels of NRG and ErbB4 transcripts in 
brain samples of schizophrenia patients attribute to the so-called “Gain-of-
function and hypoglutamatergic function in schizophrenia hypothesis (118) 
This implies that increased ErbB4 signaling stimulates GABA transmission, 
which reduces the fi ring rate of glutamate-dependent neurons. Hypofunction 
of the glutamatergic-pathways has been found in the brains of patients with 
schizophrenia (125).     
 
10.4 Epithelial development 
 ErbB1 knock-out mice differ in their phenotype, depending on their 
genetic background. Such mice either die at either mid-gastrulation (SV129 
strain), at birth (C57BL/6 strain) or on postnatal day 20 (CD1, C3H and MF1 
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strains). Mice lacking ErbB1 exhibit strain-dependent phenotypes ranging 
from placental to postnatal skin and lung defects. Poorly differentiated 
lungs are also observed in HB-EGF defi cient mice (50). TGFA plays a role 
in determining skin architecture and hair development, as indicated by the 
observation that TGFA (-/-) mice show a misalignment of the hair follicles, 
known as waviness of the coat. Although these mice are healthy and fertile, 
some older mice suffer from corneal infl ammations as well as from lens and 
retinal defects (126, 127).
10.5 Mammary gland
 The development of the mammary gland is very complex. AREG, BTC, 
HB-EGF, EPR, EGF, NRG1 and TGFA each have a unique temporal expression 
pattern during mammary development, maturation and involution (128). 
In addition there is a dynamic expression of all four ErbB receptors during 
postnatal development. During ductal morphogenesis ErbB1 and ErbB2 
colocalize, but they are localized differently in the mature gland. ErbB1 and 
ErbB2 are preferentially expressed in both lactating ducts and aveoli, while 
ErbB3 and ErbB4 expression is restricted to the aveoli. During pregnancy 
and lactation ErbB3 and ErbB4 expression is upregulated, but after involution 
ErbB4 is absent in the mammary gland (129). A switch from ErbB3 to ErbB4 
expression has been observed in the developing mammary gland, suggesting 
that the two receptors play different roles in mammary morphogenesis. 
ErbB1 and ErbB2 are highly expressed at puberty, suggesting a role of 
these receptors in proliferation at this stage of development, while both are 
expressed to a minor extent in late-stage pregnancy and lactation (130). 
To establish the role of ErbB4 in the development of the mammary gland, 
ErbB4 knock-out mice have been developed that re-express ErbB4 under the 
regulatory control of the cardiac α-myosin heavy chain promoter (131). These 
cardiac-rescued ErbB4 knock-out mice are viable, but their mammary lobular 
alveoli fail to differentiate correctly and lactation is defective.
10.6 Developmental role of NRG isoforms 
 A mentioned earlier at least 15 different NRG1 isoforms are produced 
from the NRG1 gene as a result of alternative splicing and alternative 
promoter use (reviewed in (10)). The biological signifi cance of some of the 
NRG1 isoforms has been studied using knockout mice. Mice that form NRG1 
type III, but lack  type I and type II,  die at E10.5 because of defects in cardiac 
development and show defects in cranial sensory neuron and sympathetic 
development, similar to mice in which the NRG1 gene has been completely 
knocked out (132). Interestingly, these mice have normal Schwann cell 
production (53), indicating that Type III NRG1 is involved in formation of such 
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cells. Type III knock-out mice do not show heart defects, indicating that type 
III NRG1 is not involved in heart development (52). However, these type III 
knock-out mice die immediately after birth, because they have no functional 
neuromuscular synapses and cannot breath. They also show a reduction 
in the number of spinal motor, sensory neurons and Schwann cells. Mice 
that cannot form the NRG1α isoform do not have abnormalities in heart or 
neuron development, but in stead show defects in breast development (133), 
indicating that NRG1α is essential for the development of heart and neuron 
tissues and NRG1β for breast development. 
11 ErbB receptors and cancer
11.1 Overexpression of ErbB1 and ErbB2 in tumors
 Overexpression of ErbB1 as a result of gene amplifi cation or increased 
transcription has been reported in lung, pancreas and breast tumors (134) 
and is associated with poor prognosis. Moreover, 80% of the head and neck 
tumors show overexpression of ErbB1 (135). ErbB2 overexpression has 
been reported for breast, lung, pancreas, colon and ovarian cancer and 
also correlates with poor patient survival (4, 136). ErbB3 is overexpressed 
in Non-Small Cell Lung Carcinoma (NSCLC), Head and Neck Squamous 
Cell Carcinoma (HNSCC) and primary breast carcinomas, which negatively 
correlates with tumor survival upon treatment with ErbB1 or ErbB2 directed 
drugs (137, 138). In addition, many tumors are able to produce ErbB ligands 
themselves,  resulting is autocrine receptor activation  and constitutively high 
autophosphorylation levels (139-141). 
In vitro, overexpression of ErbB1 in NIH3T3 cells results in a transformed 
phenotype in the presence of ligand (142). In contrast, overexpression of 
ErbB2 alone induces only small colonies of NIH3T3 cells in soft agar, indicating 
that ErbB2 alone is unable to induce anchorage independent cell growth, an in 
vitro characteristic of cellular transformation. ErbB2-induced transformation 
of these cells depends on heterodimerization with ErbB3, which is triggered 
by endogenously produced neuregulin (143). In a variety of human breast 
tumor cells, transcriptional downregulation of ErbB3 expression has been 
shown to impair proliferation, indicating that ErbB2 overexpression alone is 
not suffi cient to drive breast tumor cell outgrowth.
Furthermore, in breast tumors (144) and in gliomas (145) ErbB1 
gene amplifi cation is often accompanied with structural rearrangements of 
the gene. The most frequently occurring ErbB1 variant in glioblastomas is 
the constitutively active EGFRvIII. This variant has a deletion of exons 2-7, 
resulting in a lack of the L1 domain and part of the S1 major dimerization 
interface. It has been speculated that the lack of the S1 domain abolishes 
the formation of the auto-inhibited tethered conformation (6), resulting in 
constitutive activation of this ErbB1 variant (146). Since EGFRvIII lacks the 
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major dimerization interface it is unable to dimerize (147). This observation 
demonstrates that dimerisation is not essential for activation of the kinase 
domain. In a subgroup of patients with NSCLC activating mutations have been 
found in the ErbB1 tyrosine kinase domain. Interestingly, these patients have 
a higher probability of responding to ErbB1 tyrosine kinase inhibitors than 
patients with wild-type ErbB1 (148-150). Although mutations in the kinase 
domain of ErbB2 have been found in NSCLC patients (151) overexpression 
appears the principal mechanism by which ErbB2 mediates breast cancer.  
11.2 Role of ErbB3 in tumor progression
 
While many publications focus on overexpression of ErbB1 and 
ErbB2 in tumors, much less is known in about the role of ErbB3 and ErbB4 
in tumorigenesis. The low frequency of ErbB3 and ErbB4 overexpression in 
carcinomas agrees with the observation that ErbB3 alone is insuffi cient for 
NRG1-mediated transformation of NIH3T3 cells (143). Autocrine activation of 
the ErbB2-ErbB3 heterodimer by NRG1α has been observed in NSLCSs and 
could be blocked by antibodies that prevent ligand binding to ErbB3 (152). 
ErbB2-ErbB3 heterodimers contain multiple binding sites for the p85 subunit 
of PI3K, and as a consequence activation of these receptors induces a strong 
anti-apoptotic signal for e.g. breast tumors.
11.3 Role of ErbB4 in tumor progression
Reports on the role of ErbB4 in tumorigenesis are controversial. ErbB4 
has weak tumor suppressor activity in breast cancer, while the presence of 
ErbB4 in lung cancer has been associated with increased proliferation. A 
possible explanation for the controversial role of ErbB4 tumor progression 
might result from the different isoforms of this receptor. In both normal and 
malignant breast tissue, both CYT-isotypes are expressed at equal levels, 
whereas in breast cancer cells only the cleavable JM-a isoforms are present 
(153). Overexpression of the JM-a CYT2 isoform enhances proliferation of 
breast cancer cells while overexpression of the corresponding JM-b isoform 
does not (154). Interestingly,  expression of the JM-a isoform  is much higher 
in estrogen receptor positive cells than in estrogen receptor negative cells 
(153). Increasing evidence suggests that the intracellular fragment of ErbB4 
may be a direct coactivator of the estrogen receptor (155).  
12 ErbB targeting in anti-cancer therapy
 Overexpression of ErbB1 and ErbB2 has been associated with a poor 
clinical outcome in patients suffering from epithelial cancers. Therefore ErbB1 
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and ErbB2 are important targets for cancer therapy. Several antibodies 
directed against the extracellular domain of ErbB receptors as well as 
inhibitors that target the kinase domain of the receptors (TKIs) are approved 
for clinical use or in advanced clinical trials. Treatment of tumor cells with 
ErbB inactivating antibodies or TKIs rapidly downregulates PI3K-Akt, MAPK, 
Src and STAT signaling and, as a consequence, blocks the proliferation of 
tumor cell lines and xenografts in nude mice (156-158).
Herceptin/trastuzumab is one of the best characterized antibodies 
for anti-cancer treatment and is currently used in the clinic for treatment of 
a.o. estrogen-insensitive breast cancer. Herceptin is the humanized form of 
the mouse monoclonal 4D5. In vitro, Herceptin downregulates cell surface 
ErbB2 by inducing receptor endocytosis and degradation (159) and inhibits 
cell cycle progression by inducing the formation of p27Kip1/Cdk2 complexes 
(160-162). Furthermore Herceptin inhibits the basal and activated ErbB2 
ectodomain cleavage in breast cancer cells, thereby preventing the formation 
of a constitutively active p95 fragment (163). Crystallographic data showed 
that Herceptin binds to the juxtamembrane region of ErbB2 thereby blocking 
the cleavage site (164) (Figure 8). In vivo, Herceptin acts in addition by 
inducing antibody-dependent cell-mediated cytotoxicity (ADCC) against 
ErbB2 overexpressing tumor cells (162). Furthermore, Herceptin down-
regulates the production of vascular endothelial growth factor production by 
tumor cells both in vitro and in vivo (165). In a study in which the effi ciency of 
Herceptin on ErbB2 overexpressing breast cancer cells was determined, 26% 
of the patients showed reduction of tumor size. Of all patients 6% showed a 
total disappearance of radiographically apparent tumor, and 20% responded 
partially. In 28% of all patients that responded to Herceptin no reoccurrence 
of the tumor was observed within the fi rst 12 months (166).
Although Herceptin treatment has been shown to be successfull there 
are some side effects. Cardiotoxicity has been reported to occur particularly 
when Herceptin is administered in combination with antineoplastic agents such 
as anthracyclines. ErbB2 has been demonstrated to be essential for prevention 
of dilated cardiomyopathy (167). Herceptin enhances tumor necrosis factor-
mediated apoptosis in breast and ovarian cancer cell lines that overexpress 
ErbB2 (168), and is known to induce ADCC against ErbB2 overexpressing 
tumors, but ADCC against heart tissue has not been reported. 
Another ErbB2-targeted monoclonal antibody, pertuzumab (Omnitarg, 
2C4; Genentech), is currently being tested in Phase I clinical trials in cancer 
patients with different types of solid tumors. In contrast to trastuzumab, 
pertuzumab sterically blocks ErbB2 dimerization with other ErbB receptors 
and blocks ligand-activated signaling from ErbB1/ErbB2 and ErbB2/ErbB3 
heterodimers (169). This characteristic might explain why pertuzumab inhibits 
the growth of tumors that express low levels of ErbB2, while trastuzumab 
does not (169). 
Cetuximab is a chimeric antibody directed against ErbB1. It is FDA 
approved for treatment of colorectal cancer and is now in clinical trails for 
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treatment of patients with pancreatic cancer and HNSCC and NSCLC (170). 
Cetuximab interacts exclusively with domain III of ErbB1 on a site that partly 
overlaps with the ligand binding region. Furthermore it sterically prevents 
the receptor from adopting the extended conformation which is required for 
dimerization (171). 
Tyrosine kinase inhibitors (TKIs) are small organic molecules, that 
compete with ATP for binding to the receptor kinase. Anilinoquinazoline 
derivates are both selective and effective inhibitors of the ErbB1 tyrosine 
kinase. Many of these inhibitors are being tested for the treatment of cancer 
including Tarceva and Iressa, which are currently approved for the treatment 
of NSCLC. 
Figure 8. Ligand activation of ErbB1 and antibody targeting of ErbB1 and 
ErbB2. The  ectodomains  of  ErbB1 and ErbB2  are shown  in  surface  representation. 
The extracellular domains are numbered I to IV (L1, S1, L2 and S2 respectively). 
The dimerization arm in domain II is indicated by a dashed circle in A, B and C. 
The antibodies are indicated in D, E and F. The receptor ectodomains have been 
orientated such that the position of domain IV is common. The membrane bilayer 
is represented by the cylindrical structures. A: Structure of the unbound ErbB1 
ectodomain (autoinhibited, tethered state). B: Structure of the 1:1 EGF:ErbB1 
ectodomain complex  (dimerization-competent state).  C: Structure of the 2:2 EGF:
ErbB1 ectodomain complex (dimerized, activated state). D: Structure of cetuximab 
bound to domain III (L2) of the ErbB1 ectodomain. E: Structure of Herceptin bound 
to domain IV (S2) of the ErbB2 ectodomain. F: Structure of pertuzumab bound to 
domain II (S1) of the ErbB2 ectodomain. Figure taken from Hubbard et al. (203).
                     Cetuximab              Herceptin           Pertuzumab
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13 Tumor resistance to ErbB1 and ErbB2 directed drugs
Not all patients whose tumor overexpress ErbB1 or ErbB2 respond to 
Herceptin or Iressa. ErbB2 is highly phosphorylated in ErbB2 overexpressing 
breast cancer cells and the PI3K/Akt pathway is constitutively active even in 
absence of ligand. Because ErbB3 has a defective kinase domain, its role in 
tumorigenesis has long been underestimated. ErbB3 has multiple p85/p110α 
(subunit of PI3K) binding sites and forms the link between ErbB2 and the 
PI3K/Akt pathway, and may therefore play an important role in the resistance 
to Herceptin and Iressa. Knockdown of ErbB3 by siRNA in the human breast 
cancer SKBR3 cell line restored its sensitivity to the ErbB1-specifi c tyrosine 
kinase inhibitor Iressa (172). Herceptin causes dissociation of the ligand-
independent constitutive ErbB2-ErbB3 heterodimer, thereby preventing the 
activation of the PI3K-Akt pathway (173). NRG1, however, prevents Herceptin 
from disrupting the ErbB2-ErbB3 heterodimer. Knockdown of NRG1 expression 
by siRNA blocked ErbB3 activation and subsequent PI3K-Akt activation, and 
sensitized MCF-7 cells to the topoisomerase II inhibitor doxorubicin (174, 
175). Furthermore, Herceptin appeared unable to prevent Akt activation in 
cancer cells with activating mutations in PI3K or low expression levels of 
PTEN (176), suggesting that mutant PI3K and low PTEN are markers for poor 
patient response to Herceptin. Chemical inhibitors of PI3K, such as GDC-
0941, act synergistically with Herceptin in inhibition of Akt activity (173). 
GDC-0941 also inhibits Akt activity in Herceptin-resistant tumor cells. PI3K 
inhibitors are in clinical trials and may hopefully prevent ErbB3-mediated 
resistance to Herceptin.  
14 Role of the Drosophila epidermal growth factor receptor in 
development
 The Drosophila epidermal growth factor receptor (DER) signaling 
complex consists of only a single receptor and four activating ligands: Spitz, 
Keren, Gurken and Vein. The EGF receptor system in fl ies is unique because 
in addition to these activating ligands also a secreted antagonist has been 
identifi ed, named Argos. DER is expressed in almost every tissue in the fl y 
and is a key regulator in its development by directing cell fate choices, cell 
division, cell survival and cell migration (reviewed (177)). In most cases 
DER is activated by ligands produced in adjacent cells, but DER can also be 
activated by a concentration gradient of DER ligand, in which the level of DER 
activation determines the cell fate choices (178-180). Unlike their mammalian 
homologues the DER activating ligands Spitz, Keren and Gurken are produced 
as large inactive transmembrane precursors (83, 181-183). The activation 
of these ligands is tightly regulated by the cleavage of the membrane-bound 
precursor and is known as a key step in DER activation. Ligand processing 
is controlled by the type II transmembrane protein Star and the seven-
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transmembrane domain protease Rhomboid (184, 185). Star transports the 
ligand precursor from the endoplasmatic reticulum to the Golgi compartment 
(186) and Rhomboid is responsible for cleavage of the ligand precursor (184, 
185). Secretion of DER ligands and subsequent DER activation is modulated 
by the compartmentalization of the three different Rhomboid members Rho1, 
Rho2 and Rho3 (187). Rho1 is broadly expressed and is concentrated in 
large patches near the apical membrane of the cell (188). Rho-2 and Rho-
3 are expressed in the germ line and in the developing eye, respectively. 
In addition to cleavage of the ligand precursor, Rhomboid also cleaves Star 
(189). Cleavage of Star restricts the amount of DER ligand that is traffi cked. 
Rho2 and Rho3 cleave the DER ligand precursor and Star already in the ER, 
making it impossible for Star to transport Spitz to the late compartments of 
the secretory pathway at the apical membrane. This property attenuates DER 
activation, primarily by reducing the amount of Star that can direct the ligand 
precursor to the late compartment, where cleavage of Spitz and subsequent 
secretion take place (187). Since the pattern of Rhomboid activation coincides 
with that of DER-induced MAPK-activation (190), regulation of Rhomboid 
expression appears the most important step in DER activation. The dynamic 
control of Rhomboid expression is very complex. The maternal morphogen 
Dorsal acts in concert with basic helix-loop-helix proteins, including Twist, to 
induce Rhomboid expression in both lateral and ventral regions. Expression 
is blocked in ventral regions (the presumptive mesoderm) by Snail, which 
is also a direct target of Dorsal (191). In addition activated DER induces 
Rhomboid expression (178), resulting in a positive feedback loop that gives 
rise to enhanced DER activation. 
 Vein is a large secreted ligand that does not need further processing. 
Spitz is involved in the development of almost all tissues. The role of Keren 
in development remains speculative. The only experimental evidence is that 
Spitz and Keren act redundantly in the development of the eye (192). Vein 
is involved in muscle development patterning of the ventral ectoderm and 
proximal-distal patterning in leg development. Vein is also a transcriptional 
target of DER, and since Vein is only a weak activating ligand it is most likely 
involved in the maintenance of a low activation level of DER at sites where 
no Spitz processing occurs. Activation of DER by Gurken is restricted to the 
ovary. Argos, is also a large secreted protein which is highly induced upon 
DER activation and  provides a negative feedback loop in DER signaling (193). 
Argos is essential for the formation of several body axes, eye development, 
brain development and for the induction of bract cells in the developing leg. 
In addition to induction of Argos,  three other negative feed back loops are 
involved in the attenuation of DER signaling, which are mediated by Kekkon, 
Sprouty and DCbl. Kekkon is a transmembrane protein that interferes with 
ligand binding and receptor dimerization (100). Sprouty inhibits the RAS/MAPK 
pathway, by direct interaction with Drk (Drosophila homologue of mammalian 
Grb2) and Gap1 (194), while DCbl induces ubiquitination of activated DER, 
resulting in endocytosis and degradation of the receptor (195). Unlike Argos, 
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Sprouty is also active in mammalian cells, while LRIG1 is the mammalian 
homologue of Kekkon1. 
14.1 The antagonistic mechanism of Argos
 For many years it has been thought that Argos acts as an antagonist 
of DER signaling by direct binding to the receptor and thereby preventing the 
binding of an activating ligand. Similarly to the agonistic ligands, Argos has 
an EGF-like domain which is essential and suffi cient for its biological function, 
suggesting that Argos may directly interact with DER (196). Moreover, BIAcore 
measurements indeed showed that Argos binds with high affi nity (17-41 nM) 
to DER (197). However, in 2004 Klein et al. (198) reported that Argos inhibits 
epidermal growth factor receptor signaling by sequestering the ligands, 
and recently the crystal structure of Argos in complex with Spitz has been 
published (199). This crystal structure demonstrated that Argos does not fold 
according to an EGF-like domain, which makes it unlikely that Argos competes 
with Spitz for interaction with DER. Instead Argos has a three-fi nger toxin fold 
(200) which clamps Spitz by covering 35% of the Spitz surface with a Kd of 
7.7 nM (199).  Based on the amino acid sequence no mammalian homologues 
of Argos have ever been identifi ed.
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THESIS OUTLINE
 The ErbB signaling network is a complex system of four ErbB 
receptors, which are each activated by a different subset of in total eleven 
ligands. Depending on their ErbB binding specifi city,  EGF-like growth factors 
can be divided into three subfamilies: EGF, TGFA, AREG and EPGN form a 
subfamily that binds exclusively to ErbB1, while the subfamily consisting 
of BTC, EREG and HBEGF binds not only ErbB1, but also ErbB4. Finally the 
neuregulins form a subfamily of which NRG1 and NRG2 bind both ErbB3 and 
ErbB4, while NRG3 and NRG4 appear specifi c for ErbB4 (39). ErbB2 does 
not bind ligand by itself, but is the preferred heterodimerization partner for 
all liganded ErbBs and is particularly important for ErbB3 signaling which 
has a defective tyrosine kinase domain. Within each subfamily the various 
ligands can bind their receptor with different affi nities: EGF, TGFA and AREG 
bind ErbB1 with high affi nity while EPGN is a low affi nity ErbB1 ligand. BTC 
and HBEGF are high affi nity ErbB4 binders, while EREG binds ErbB4 with 
low affi nity. Finally the β isoforms of NRG1 and NRG2 bind ErbB3 and ErbB4 
homodimers with relative high affi nities, while the α isoforms has low binding 
affi nity for ErbB3 and ErbB4 which is stabilized upon heterodimerization with 
ErbB2 in order to interact with moderate affi nities. The aim of the present 
study is to understand the molecular basis for ErbB specifi city and affi nity of 
EGF-like growth factors.  In this context we posed the following questions: 
1. What is the molecular basis of the ligand-receptor binding affi nity?
2. What is the molecular basis of receptor specifi city of ErbB ligands? 
3. What mechanism determines hetero- versus homodimerization?
4. What is the relation between binding affi nity and the mitogenic 
potential of a ligand?
 Chapter 2 describes a phage display approach to investigate the 
sequential requirements for ErbB3 binding and subsequent ErbB2-ErbB3 
heterodimer formation by ligands. In that study we used the EGF-TGFA 
chimera T1E as a template molecule because it binds with low affi nity to 
ErbB3 homodimers and with high affi nity to ErbB2-ErbB3 heterodimers. T1E 
variants with a modifi ed C-terminus were selected in order to discriminate 
their ability to form ErbB3 homodimers from the formation of ErbB2-ErbB3 
heterodimers. We observed that the ligands have no specifi c selectivity and 
the ErbB-3 affi nity of a ligand determines whether it forms preferentially 
ErbB3 homodimers or ErbB-2/ErbB-3 heterodimers.
 In chapter 3 we postulate the concept that receptor affi nity is 
controlled by ligand residues that are directly involved in receptor binding 
(positive constraints), while receptor selectivity is mainly controlled by 
evolutionary conserved residues that are not essential for high affi nity 
binding, but prevent the undesired binding to other ErbB receptors (negative 
constraints). Using phage display we optimized positive constraints in the C-
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terminal region of T1E for high affi nity binding to ErbB1, ErbB3 and ErbB4, 
while negative constraints for ErbB3 and ErbB4 were released. Homology 
models of ErbB3 and ErbB4 identifi ed R45 in EGF as a negative constraint 
preventing interaction with ErbB3 and ErbB4. Panerbin, a T1E selectant that 
binds with high affi nity to all three receptors, proved to be an excellent tool 
for determining the relative amount of ErbB receptors on breast tumor cells.
 Chapter 4 describes an EGF mutant with high binding affi nity for 
ErbB3. This EGF mutant, designated WVR/EGF/IADIQ consist of a N-terminal 
and a C-terminal linear region which are optimized for ErbB3 binding. 
VWR/EGF/IADIQ still binds to ErbB1 and is able to activate ErbB2-ErbB3 
heterodimers but not ErbB1-ErbB3 heterodimers while NRG can. VWR/EGF/
IADIQ is the fi rst reported ligand which has a higher affi nity for ErbB3 than 
for ErbB4.
 In chapter 5 we demonstrate that positive constraints found in a T1E 
background are able to increase the binding affi nity of natural ligands for their 
receptors, indicating that evolution has not selected ligands for their highest 
binding affi nity. Furthermore we show that an increase of ErbB binding affi nity 
does not necessary result in enhanced mitogenic activity. These observations 
are discussed in terms of sequential requirements for optimization of ErbB 
affi nity, selectivity and mitogenic potential during evolution.  
 Chapter 6 describes the use of a radio-labeled high affi nity NRG1β 
mutant, NRG/YYDLL, for determination of ErbB3 levels by receptor binding 
analysis. Furthermore, we show by differential competition with unlabeled 
NRG/YYDLL and BTC that the number of ErbB3 and ErbB4 receptors can be 
quantifi ed separately on cultured human breast cancer cells.
 Chapter 7 discusses why NRG1β does not interact with ErbB1. Based 
on homology models of NRG1β with ErbB3 or ErbB4, we identifi ed the amino 
acids in NRG1β that are directly involved in ErbB3 or ErbB4 interaction. These 
models did not provide any indication for a putative steric clash or a charge 
repulsion that could prevent NRG1β from binding ErbB1. Using domain 
exchange studies we observed that the NRG1β A1-loop and C-loop sequences 
are involved in preventing ErbB1 binding.  
 Chapter 8 describes an attempt to humanize the DER agonist Spitz 
using a domain exchange approach with EGF. The binding characteristics 
of the EGF-Spitz chimeras tested on ErbB1 and DER provided information 
about the sequence requirements for high affi nity binding to both receptors. 
However, the question why Spitz does not bind ErbB1 and why EGF does not 
bind DER remains unanswered.
 In chapter 9 the above data are discussed in terms of models for: 1) 
the acquirement of receptor specifi city of ErbB ligands during the evolution; 
2) the relationship between ErbB affi nity and mitogenic activity; and 3) the 
role of negative constraints in receptor specifi city of ErbB ligands.
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Chapter 2
ABSTRACT
 
 EGF-like growth factors activate their ErbB receptors by promoting 
receptor-mediated homodimerisation, or alternatively by the formation of 
heterodimers with the orphan ErbB2 through an as yet unknown mechanism. 
To investigate the selectivity in dimer formation by ligands, we have applied 
the phage display approach to obtain ligands with modifi ed C-terminal 
residues that discriminate between ErbB2 and ErbB3 as dimerisation partner. 
We used the EGF/TGFα chimera T1E as template molecule, since it binds to 
ErbB3 homodimers with low, and ErbB2/ErbB3 heterodimers with high affi nity. 
Many phage variants were selected with enhanced binding affi nity for ErbB3 
homodimers, indicating that C-terminal residues contribute to the interaction 
with ErbB3. These variants were also potent ligands for ErbB2/ErbB3 
heterodimers, in spite of negative selection for such heterodimers. In contrast, 
phage variants positively selected for binding to ErbB2/ErbB3 heterodimers, 
but negatively for binding to ErbB3 homodimers, can be considered as 
“second best” ErbB3 binders, which require ErbB2 heterodimerisation for 
stable complex formation. Our fi ndings imply that EGF-like ligands bind ErbB3 
through a multi-domain interaction, involving at least both linear endings 
of the ligand. Apparently the ErbB3 affi nity of a ligand determines whether 
it can form only ErbB2/ErbB3 complexes or also ErbB3 homodimers. As no 
separate binding domain for ErbB2 could be identifi ed, our data support a 
model in which ErbB heterodimerisation occurs through a receptor-mediated 
mechanism, and not through bivalent ligands. 
INTRODUCTION 
 The recent determination of the crystal structure of the extracellular 
domain of ErbB-1 in complex with its ligands epidermal growth factor (EGF) or 
transforming growth factor α (TGFα) has provided evidence for the formation 
of homodimeric ErbB1 complexes through a receptor-mediated dimerisation 
mechanism (1,2). Ligand binding to both domains I and III of the extracellular 
domain of the receptor involves the transition of ErbB1 from a ‘closed’ to an 
‘open’ state, which then permits dimerisation with another liganded ErbB1 
through interaction of domain II residues within these receptors. Most likely 
this mechanism can serve as a paradigm for homodimerisaton of other liganded 
ErbB receptors, such as ErbB3 and ErbB4. However, it is well established that 
EGF-like growth factors preferentially signal through heterodimers of their 
cognate receptor with the orphan ErbB2. The mechanism by which EGF-like 
growth factors bind their receptors in heterodimeric receptor complexes 
remains an open question. 
 Dimerisation of ligand-bound receptor tyrosine kinases is a 
mechanism that is thought to activate the intrinsic kinase domain, 
followed by transphosphorylation and subsequent docking of cellular signal 
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transducing proteins. As a consequence, ligand binding serves as a potential 
site for regulation of cell proliferation in diseases where ErbB receptors are 
overexpressed, as has been observed for ErbB-1 and ErbB2 in multiple human 
cancers (3). ErbB2 has no known ligand, but by decelerating the ligand 
dissociation rate it serves as a preferred dimerisation partner for all other ErbB 
members (4-6). Heterodimer formation with ErbB2 is especially important in 
the case of the ErbB3, which together with ErbB4 forms the natural receptor 
for the different neuregulins (NRGs). ErbB3 contains a defective kinase and 
hence ErbB3 homo-dimers are biologically inactive (7,8). The ErbB2/ErbB3 
heterodimer, however, is the most prominent and strongest transforming 
signaling complex activated by NRG1 (9-12) and provides an attractive model 
system to study the mechanism of ligand-induced ErbB heterodimerisation.
 EGF-like growth factors share a structurally conserved EGF motif, 
characterised by three disulphide-bonded loops (the A-, B- and C-loop), 
in addition to a linear N-terminal and C-terminal region. Structural and 
mutational analyses have shown that residues in the A-loop, C-loop and 
C-terminal linear region of EGF and TGFα primarily bind to domain III of 
ErbB1, followed by an interaction of residues in their B-loop with domain I 
of the receptor (1,2,13-16). By contrast, NRG-1β has been shown to bind 
with high affi nity to a proteolytic fragment of ErbB3 containing only domain I 
(17). Moreover, NRG binding to ErbB1/ErbB4 chimeras requires the presence 
of domain I of the latter receptor, suggesting that ligand binding to NRG 
receptors primarily involves interaction with domain I of the receptor (18). 
Alanine scanning of NRG-1β revealed that hydrophobic and charged residues 
in the linear N-terminal region and the B-loop, that form a surface patch on 
one site of the triple β-sheet, are the major determinants in ErbB3 binding 
(19,20). On the other hand, also residues in the C-terminal region of NRG 
may play a role in receptor binding, since the natural α- and β- isoforms 
of NRG1 and NRG2, which only vary in sequences C-terminal of the fi fth 
cysteine, strongly differ in their ability to bind and activate distinct ErbB 
combinations (21-24). Exchange studies between NRG1α and NRG1β have 
shown that particularly the linear C-terminal region determines the binding 
properties and mitogenic potential of these isoforms (25). Therefore it has 
been proposed that NRGs may have a bivalent character and interact with 
both ErbB3 and ErbB2 through separate binding sites (26).
 To evaluate the contribution of residues in the linear C-terminal 
region of EGF-like ligands for selective dimer formation, we applied the 
phage display technique to select ligands that discriminate between ErbB-2 
and ErbB-3 as dimerisation partner in ErbB3 complexes. In earlier work we 
and others showed that EGF chimeras in which the linear N-terminus was 
replaced by either NRG (biregulin) or TGFα (T1E) residues gained high binding 
affi nity to ErbB2/ErbB3 heterodimers, while they bound only weakly to ErbB3 
alone (27,28). Unlike NRG1β, both T1E and biregulin seem dependent on 
subsequent binding of ErbB2 to stabilise their low affi nity interaction with 
ErbB3. In a previous study we could attribute the weak ErbB3 interaction 
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of the chimera T1E in part to the presence of sub-optimal sequences in the 
linear N-terminus. Based on a phage display approach we enhanced the 
binding affi nity for ErbB-3 relative to T1E by substitution of only two residues 
in EGF (D2W and S3V/R)(29). In the present study we have used the same 
approach to subject fi ve residues in the linear C-terminal region of T1E for 
randomisation and selection for altered receptor selectivity and affi nity. The 
targeted residues in T1E correspond to the positions in the NRG isoforms that 
have been implicated in the differential activation of ErbB dimers. Here we 
show that T1E can be strongly optimised for binding to ErbB3 by the current 
phage display approach, indicating that residues in the linear C-terminal tail 
contribute to the ability of ligands to bind ErbB-3 homodimers. Moreover, 
in spite of negative selection protocols we consistently observed a direct 
relation between the ability of T1E variants to bind ErbB3 and their ability to 
induce ErbB2/ErbB3 heterodimers. Since no sequences selective for ErbB2 
heterodimerisation could be identifi ed, our fi ndings support a model in which 
ErbB heterodimerisation is driven by receptor-mediated and not by ligand-
mediated interactions. 
   
RESULTS
The linear C-terminal region of T1E infl uences the ErbB2/ErbB3 binding 
effi ciency
 Previous work showed that the chimeric EGF-like ligands biregulin 
and T1E bind only weakly to ErbB3, due to sub-optimal sequences in the N-
terminal linear region (26,29). The observed high affi nity binding of T1E and 
biregulin for cells expressing both ErbB2 and ErbB3 thus appears to depend 
critically on additional stabilisation of the complex by ErbB2. The strong 
dependence on ErbB2 as dimerisation partner makes this type of molecules 
a good model system for identifying residues that mediate the selective 
recruitment of ErbB2 versus ErbB3 as dimerisation partner. 
 In this study we have examined whether sequences in the C-terminal 
linear region of T1E play a direct role in the formation of ErbB3 homodimeric 
and ErbB2/ErbB3 heterodimeric complexes, as suggested by a comparison of 
the different NRG isoforms. Thereto we initially exchanged the C-terminal linear 
tail of T1E, composed of EGF sequences, for the corresponding sequences of 
TGFα (Glu44-Ala50), NRG1β (Gln45-Ala51) and an optimised NRG1β mutant. 
This latter mutant has been obtained from a previous phage display study 
on NRG1β by selection for high affi nity binding to ErbB3 ectodomains, and 
contains the mutations N47H and M50I compared to the wild-type NRG1β EGF 
domain (30). The TGFα C-terminus was included because it shows the highest 
sequence similarity with optimised NRG1β, and because previous studies 
have indicated that introduction of TGFα C-terminal residues into NRG-1α 
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strongly enhances binding affi nity for ErbB2/ErbB3 heterodimers on SK-BR-
3 cells (35). The nomenclature used for the T1E mutants follows previously 
used conventions, in which T1E6N is a chimera containing TGFα sequences 
up to the fi rst cysteine, followed by EGF sequences up to the sixth cysteine 
and NRG-1β residues in the C-terminal tail (Figure 1A). All T1E mutants 
were expressed as recombinant peptides in Escherichia coli, fi nally purifi ed 
by reverse-phase HPLC and verifi ed for the appropriate molecular weight by 
MALDI-TOF analysis. 
 The biological activity of the various T1E mutants was assessed by 
competitive binding analysis on stable transfectants of 32D cells that express 
defi ned ErbB combinations (12). Figure 1B shows clear differences in the 
ability of the T1E mutants tested to displace radiolabelled T1E from 32D cells 
coexpressing ErbB2 and ErbB3 (D23 cells). The IC50 of both T1E6N and T1E6T 
(50-60 ng/ml) was increased compared to T1E itself (6.7 ng/ml), whereas 
T1E6Nopt bound D23 cells with enhanced affi nity (3 ng/ml) comparable 
Figure 1: Exchange of the linear C-terminal region in the EGF/TGFα chimera T1E 
affects the binding to specifi c ErbB combinations. (A) Amino acid sequences of the 
T1E variants used in this study, aligned with human EGF and the EGF-domain of 
human NRG1β. Numbering of the conserved cysteines in bold face is according to 
T1E. (B) Displacement of [125I] T1E binding on 32D cells coexpressing ErbB2 and 
ErbB3 (D23 cells). (C) Displacement of [125I] NRG1β binding on 32D cells expressing 
ErbB3 (D3 cells). Cells were incubated for 2 hrs at 4°C with radiolabelled ligand (2 
ng/ml) in presence of serial dilutions of unlabelled NRG1β (closed squares), T1E 
(open circles), T1E6T (closed circles), T1E6N (open squares), or T1E6Nopt (open 
diamonds). Unbound ligand was removed by sedimentation of the cells through a 
serum cushion, after which cell-bound radioactivity was determined. Results express 
the mean ± sem of three independent experiments performed in duplicate.
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to wild type NRG-1β (2 ng/ml). Similar differences were observed in the 
ability of these T1E mutants to stimulate proliferation of D23 cells and the 
neuregulin-responsive MCF-7 human breast cancer cells, indicating that their 
relative binding affi nity corresponded to the ability to activate ErbB-2/ErbB-3 
complexes (data not shown). Thus, changes in the C-terminal sequences of 
T1E strongly affect its ability to interact with ErbB-2/ErbB-3 heterodimers. 
Despite the fact that NRG-1β is the natural activator for ErbB-2/ErbB-3 
heterodimers in vivo, its C-terminal sequences do not appear benefi cial for 
the interaction with ErbB-2/ErbB-3 in a T1E environment. In this respect the 
EGF residues present in T1E appear more effective in stabilising ErbB-2/ErbB-
3 complexes than the corresponding NRG-1β and TGF-α sequences.
 To further evaluate the role of the linear C-terminus in binding to 
ErbB-3, the binding affi nity of the T1E mutants was assessed by [125I] NRG-
1β displacement on 32D cells solely expressing ErbB-3 receptors (D3 cells). 
In agreement with crosslinking analyses, we assume that NRG-1β is able to 
induce homodimeric ErbB-3 complexes in D3 cells (12,26). Figure 1C shows 
that all T1E mutants have an affi nity for ErbB-3 alone that is at least 50-
fold lower than that of NRG-1β. Compared to T1E, T1E6Nopt shows increased 
binding affi nity, while T1E6N and T1E6T have almost similar binding affi nity. 
Thus, replacement of the C-terminal tail of T1E for NRG-1β sequences did 
not signifi cantly improve the weak binding of T1E to the ErbB-3 receptor. By 
contrast, introduction of the C-terminal tail of the optimised NRG-1β variant 
increased the relative binding affi nity of T1E for both homo-and heterodimeric 
ErbB-3 complexes, indicating these residues improve the recruitment of ErbB-
2 and ErbB-3 independent of the context of the NRG molecule. Together these 
fi ndings demonstrate that residues in the C-terminal region of T1E indeed 
contribute to the ligand preferences for distinct receptor complexes. 
Design of the T1E46-50 phage library and selection strategy
 
 To assess the precise contribution of individual residues in T1E to 
the recruitment of ErbB2 or ErbB3 into dimeric complexes, we randomly 
mutated fi ve positions in the linear C-terminus of T1E that correspond to the 
positions in the NRG isoforms implicated in differential ErbB binding using a 
phage display approach. By a combination of positive and negative selection 
strategies and specifi c elution methods, we subsequently selected variants 
that discriminated between binding to ErbB3 homodimers and to ErbB2/
ErbB3 heterodimers. To this end we used homodimeric ErbB3-IgG fusion 
proteins in addition to MDA-MB-453 cells, human breast carcinoma cells with 
overexpression of ErbB2 and ErbB3, which we have previously employed 
for affi nity optimisation of EGF variants to ErbB2/ErbB3 heterodimers (29). 
Figure 1A shows the sequence of the phage library of T1E variants. The 
Gln45 residue adjacent to Cys44 is conserved between EGF and NRG1β, 
and therefore the adjacent fi ve residues (Tyr46-Lys50) were targeted for 
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mutation. Because the randomised area is localised in close proximity to the 
fusion point with the pIII minor coat protein, a fl exible linker was introduced 
into the fUSE5 phage vector to minimise possible steric effects. The resulting 
phages each display 2-5 copies of the fusion proteins (32). The completeness 
of the T1E46-50 phage library was estimated from the number of independent 
transformants yielding 1.45 ×107, thereby covering fi ve times the theoretical 
diversity of 3.1 ×106 possible different amino acid combinations. Sequence 
analysis of an aliquot of the library revealed no deviation from the theoretical 
amino acid distribution.
Sequences of T1E46-50 clones isolated for preferential ErbB3 homodimer 
formation 
 Phage T1E variants that preferentially bind to ErbB3 homodimers 
but not ErbB2/ErbB3 heterodimers were isolated using alternating selection 
rounds on homodimeric ErbB3-IgG fusion proteins and whole MDA-MB-
453 cells. During the selection on cells the ErbB2 dependent phage clones 
were depleted from the cell surface by competitive elution with anti-ErbB2 
antibodies that are known to impair ligand binding (34). Subsequently the 
remaining phage clones bound to ErbB-3 receptors on the cell surface were 
harvested by acid elution. The alternation between exposure to soluble and 
cell-bound ErbB3 receptors reduced non-specifi c background binding of 
phages and excluded a possible selection advantage offered by the preformed 
dimeric ErbB3-IgG compared to the monomeric cell-expressed receptors.
 Individual phage clones were randomly picked after four selection 
rounds and subsequently analysed for binding to ErbB3 ectodomains in 
phage ELISA. Table 1 gives a survey of the sequences of 16 T1E46-50 clones 
selected for preferential binding to ErbB3 homodimers (ErbB3 selectants) 
with their corresponding binding properties. Binding ability of the clones to 
ErbB2/ErbB3 heterodimers was determined in ELISAs on intact cells (D23 
versus parental 32D cells) and on heterodimeric ErbB2/3-IgG fusions. Since 
these heterodimeric IgG fusion proteins were generated by cotransfection of 
the expression vectors encoding the respective receptors, experiments were 
carried out on a mixture of ErbB2/3-IgG heterodimers and ErbB2-IgG and 
ErbB3-IgG homodimers. As positive control EGF/W2V3 phage was used, a 
previously characterised EGF variant with high affi nity for ErbB3 homodimers 
and ErbB2/ErbB3 heterodimers (29). Wild-type T1E phage and EGF phage 
were used as additional controls. Table 1 indicates that all ErbB3 selectants 
displayed strong binding to ErbB3-IgG, with concomitant strong binding 
capacity to both ErbB2/3-IgG ectodomains and D23 cells. Thus, despite the 
negative selection for ErbB2 dimers, the T1E clones selected by this approach 
had not lost their ability to bind to ErbB2/ErbB3 heterodimers. In other words, 
the ErbB3 selectants are unable to discriminate between ErbB2 and ErbB3 as 
dimerisation partner. 
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 The most striking result in the sequences obtained was the abundant 
selection of Asp48 in 81% of the ErbB3 selectants, which is the corresponding 
residue in both EGF and TGFα. Substitutes found on positions 46, 47 and 49 
tended to be similar in character, being predominantly large and hydrophobic, 
although at position 46 a preference for Ile was observed (75%). At position 
47 residues Tyr and Phe were found in more than half of the ErbB3 selectants, 
indicating that aromatic side-chains seem to be favoured. The most frequently 
selected T1E46-50 clone, designated 3.1, contained IFDWA sequences (5/16 
times). The overall consensus sequence for T1E46-50 ErbB3 selectants, based 
on the frequency of occurrence of a certain (type of) amino acid detected at 
the respective position in ≥ 50% of all individual clones analysed, was I46-
aromatic47-D48-apolar49-X50 in which X represents any residue.
Sequences of T1E46-50 clones isolated for selective ErbB2/ErbB3 heterodimer 
formation
 In an inverse strategy, phage T1E variants were isolated that 
selectively bound to ErbB2/ErbB3 heterodimers but failed to bind to ErbB3 
homodimers. Thereto negative selection on homodimeric ErbB3-IgG fusion 
proteins was performed prior to the selection on MDA-MB-453 cells. Ligands 
that ultimately depended on ErbB2 for high affi nity binding were eluted from 
the cell surface by treatment with ErbB2 antibodies. Control cell pannings 
confi rmed the specifi c elution of wild-type T1E phages by this method (data 
not shown). After four rounds of selection, single clones were sequenced and 
analysed for binding properties in ELISAs in a similar way as described above 
for the ErbB3 selectants (Table 2). All T1E clones selected for preferential 
ErbB2/ErbB3 binding (ErbB-23 selectants) were found to bind strongly to 
both D23 cells and ErbB23-IgG ectodomains, confi rming that selection had 
been achieved. When the ErbB2/3 selectants were analysed for their ability 
to bind to ErbB3 homodimers, half of the clones lacked detectable binding 
for ErbB3-IgG, similar to phage T1E (group 1), while the remaining were still 
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able to bind with gradual affi nity to ErbB3 homodimers (group 2). Thus, only 
a fraction of the ErbB2/3 selectants was able to discriminate against ErbB3 as 
dimerisation partner in the ErbB3 complex. 
 When comparing the sequences of the two distinct groups of ErbB2/3 
selectants, both differences and similarities became apparent (Table 2). The 
consensus sequence of group 1 ErbB2/3 selectants could be assigned as Y46-
L47-X48-apolar49-D50, while the consensus sequence of group 2 strongly 
resembled that of the ErbB3 selectants in Table I. The diminished ability to 
bind to ErbB3 homodimers of the group 1 clones correlated with a shift of 
the acidic Asp from position 48 (72% group 2) to position 50 (52% group 1). 
Predominantly large hydrophobic residues were found at positions 46, 47 and 
49 in all ErbB2/3 selectants, similarly as observed for the ErbB3 selectants, 
although the exact nature of the side-chains differed. Taken together, the 
overall consensus sequence of ErbB2/3 selectants displays remarkable 
overlap with the consensus sequence for ErbB3 selectants. 
Selected T1E46-50  variants display gradual differences in ErbB3 binding 
 To gain further insight into the relative contribution of specifi c amino 
acids to the ability of ligands to bind ErbB3, we subjected a number of 
selected T1E46-50 phage variants to extended analysis using dose-response 
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experiments. Based on the similarity and divergence from the consensus 
sequences, individual T1E selectants that harbour acidic Asp residues (at 
position 48, 50, or at both positions) combined with distinct hydrophobic 
residues were chosen and produced as large-scale cultures. Phage T1E 
served as a positive control for ErbB2/ErbB3 binding, phage EGF/WV as a 
Figure 2: Binding characteristics of individual phage T1E46-50 variants selected for 
preferential ErbB3 homodimer binding (ErbB3 selectants) or preferential ErbB2/
ErbB3 heterodimer binding (ErbB2/3 selectants). (A, B) Phage ELISA on ErbB2/3-
IgG fusion proteins. (C, D) Phage ELISA on homodimeric ErbB3-IgG fusion proteins. 
Binding of ErbB3 selectants is depicted in panel (A, C), ErbB2/3 selectants in panel 
(B, D). Phage clones used were T1E46-50 variants IFDWA (grey squares), IADIQ (grey 
triangles), YYDID (grey diamonds), YLEID (closed circles), YLDIS (closed squares), 
YLQMN (closed triangles), YLTLD (crosses), YLALH (open diamonds), and YLSTD 
(open squares), while phage T1E (open circles), phage EGF/W2V3 (open triangles), 
and phage EGF (plusses) were used as positive and negative controls, respectively. 
Results are presented as mean of two experiments performed in duplicate.
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positive control for ErbB3 homodimer binding, while phage EGF was used as 
a negative control. 
 While no absolute binding affi nities could be determined by the used 
multivalent phage display system, the relative affi nities could readily be 
compared between the distinct clones. All clones, invariably whether they 
were isolated as ErbB3 selectants (Figure 2A) or as ErbB2/3 selectants 
(Figure 2B), were found to bind with similar strong affi nity to heterodimeric 
ErbB2/3-IgG complexes. The binding of wild-type T1E to the ErbB2/3-IgGs 
was relatively low in comparison to all other T1E variants and EGF/WV. This 
may be attributed to the fl exible linker region which is present in the T1E46-50 
phages but absent in the wild-type T1E phage. Conversely, the binding affi nity 
of the various T1E46-50 clones to ErbB3-IgGs showed strong variation between 
the clones, and in general the ErbB3 selectants (Figure 2C) were superior to 
the ErbB2/3 selectants (Figure 2D). Interestingly, the ErbB3 selectants with 
C-terminal sequences IFDWA, IADIQ and YYDID showed signifi cantly higher 
affi nity for ErbB3 than the positive control EGF/WV (Figure 2C), indicating 
that C-terminal sequences strongly contribute to enhanced ErbB3 affi nity. 
When comparing the ErbB-23 selectants, a more or less gradual decrease in 
ErbB3 binding affi nity was observed in the order: YYDID > YLEID = YLQMN = 
EGF/WV > YLDIS > YLTLD > T1E > YLSTD and YLALH >> EGF (Figure 2D). 
Thus, acidic residues seem to contribute directly to the ErbB3 binding affi nity 
when located at position 48, and to a lesser extent when present at position 
50. Moreover, acidic residues present at both positions seem benefi cial for 
ErbB-3 binding, while also the combination of Q48/N50 was shown to be 
effi cient. Apparently the depletion of the strongest ErbB3 binding clones from 
the pool of ErbB2/ErbB3 selectants has resulted in the isolation of the “second 
best” ErbB-3 binding clones. 
 In addition, the abilities of the distinct T1E variants to activate ErbB2/
ErbB3 heterodimers were assessed by measuring the IL-3 independent 
proliferation of D23 cells in an MTT assay. Figure 3 shows that all T1E variants 
are equipotent to phage EGF/WV and superior to phage T1E itself in inducing 
proliferative responses in D23 cells, indicating that functional ErbB2/ErbB3 
heterodimers are formed  in response to all selectants. Thus, the ErbB23 
selectants only ineffectively bind to ErbB3 homodimers, similar to T1E, but 
are still strong inducers of ErbB2/ErbB3 heterodimers. The ErbB3 selectants 
effectively bind to ErbB3 homodimers and ErbB2/ErbB3 heterodimers, similar 
to EGF/WV, but this increased ErbB3 affi nity does not result in enhanced 
mitogenic potency for cells expressing ErbB2 and ErbB3. Therefore it appears 
that a low threshold ErbB3 binding is already suffi cient for the effi cient 
formation of ErbB2/ErbB3 heterodimers. 
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DISCUSSION
 EGF-like ligands differ in their ability to recruit a dimerisation partner 
for their cognate receptor, resulting in differential potency and mitogenic 
responses. This suggests that ligands contain specifi c residues that mediate 
interaction with distinct ErbB complexes, including heterodimers with the 
orphan ErbB2. To investigate the selectivity in dimer formation by EGF-
related ligands, we have applied the phage display approach to obtain 
ligands with modifi ed C-terminal residues that have (i) altered selectivity 
and (ii) enhanced binding affi nity. Our fi ndings indicate that EGF-like growth 
factors contain multiple, independent binding domains for ErbB3, one of 
which is located in the C-terminal tail. However, no separate binding domain 
for ErbB2 could be identifi ed in this region. Instead, ligand-induced ErbB2/
ErbB3 heterodimerisation appears to occur as a consequence of a low affi nity 
interaction with ErbB3 and subsequent stabilisation by ErbB2. 
 To address the issue of dimer selectivity, distinct combinations of 
positive and negative selection strategies were applied to isolate ligands that 
were able to discriminate between ErbB2 and ErbB3 in complex formation with 
Figure 3: Ability of individual phage clones to induce proliferation of 32D cells 
expressing ErbB2 and ErbB3 (D23 cells). Cells were incubated for 24 hours in IL-3 
free medium containing serial dilutions of fi lter-sterilised T1E46-50 phages selected 
for ErbB3 homodimer binding (A) or ErbB2/ErbB3 heterodimer binding (B): IFDWA 
(grey squares), IADIQ (grey triangles), YYDID (grey diamonds), YLEID (closed 
circles), YLDIS (closed squares), YLQMN (closed triangles), YLTLD (crosses), YLALH 
(open diamonds), YLSTD (open squares), or phage T1E (open circles), phage EGF/
W2V3 (open triangles), and phage EGF (plusses). Viable cells were determined 
using the calorimetric MTT assay. Results are given as fold induction over non-
stimulated cells of duplicate measurements. 
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ErbB3. Two of our present observations argue against the hypothesis that the 
selectivity in recruitment of the dimerisation partner is mediated by sequences 
in the linear C-terminal tail of ligands. First, none of the ErbB3 selectants had 
impaired ability to form ErbB2/ErbB3 heterodimers, in spite of the negative 
selection for T1E variants that depended on ErbB2 dimerisation for binding. 
The most likely explanation is that the linear C-terminal region is not directly 
involved in the recruitment of ErbB2 as dimerisation partner, either because 
ligands do not harbour a separate ErbB2 binding site, or because such a site 
is located in a different region of the ligand. Hence, our data do not favour a 
model in which the linear C-terminal tail harbours a secondary binding site for 
ErbB2, as previously proposed in ligand bivalence models (26,36).
 Secondly, the incomplete discrimination against ErbB3 homodimer 
formation observed for the ErbB2/3 selectants might indicate that ligands 
require only a low level of ErbB3 binding affi nity to allow the effi cient formation 
of ErbB2/ErbB3 heterodimers. These ligands can thus be considered as the 
‘second best’ ErbB3 binders. Moreover, the observation that ligand variants 
positively selected for ErbB3 binding, but negatively for ErbB2/ErbB3 binding, 
are still potent activators of heterodimers also strongly indicates that binding 
to ErbB3 is suffi cient for heterodimer formation. It thus appears that the 
relative binding affi nity to ErbB3 is indicative for the binding behaviour of 
ligands to dimeric complexes, such that low affi nity binders only interact with 
ErbB2/ErbB3 heterodimers, while high affi nity binders can additionally form 
ErbB3 homodimers. 
 Our present observations argue for a separate ErbB3 binding site 
located in the linear C-terminal tail of EGF-like ligands. Previous mutagenesis 
studies have assigned several non-continuous hydrophobic and charged 
residues in the triple β-sheet formed by the linear N-terminal region and 
the B-loop region of NRG1 as the major determinants for ErbB3 binding 
(19,20,27). It can however not be excluded that additional residues in the 
ligand may contribute to receptor interaction. For instance, residues in the 
β-turn in the A-loop of NRG1 were also susceptible to Ala mutation, although 
this might be attributed to structural disturbance as well (20). The crucial 
importance of N-terminal residues was further emphasised by two phage 
display studies, revealing the strong requirement for aromaticity (His or Trp) 
combined with aliphatic or basic side chains for ErbB3 interaction (29,30). 
Here we show that optimised sequences in the C-terminal linear region also 
directly contribute to the ability of T1E ligands to interact with ErbB3, and that 
they can compensate for the presence of suboptimal residues in the linear N-
terminus of T1E. Notably, the T1E46-50 variants selected for prefential binding 
to ErbB3 homodimers displayed even stronger binding to ErbB3-IgG than the 
EGF/W2V3 mutant (Figure 2C). Thus, while residues in the N-terminus and 
B-loop appear to confer specifi city to ErbB3 binding, residues in the linear C-
terminal tail may further enhance receptor affi nity, in line with the differential 
ErbB-3 binding abilities of the distinct NRG1 isoforms. This suggests that both 
linear regions of the ligand participate independently in receptor binding, 
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such that ligand binding to ErbB3 occurs through a multi-domain receptor 
interaction. 
 The C-terminal sequence requirements for ErbB3 binding can be 
deduced from a comparison of the consensus sequences of the selected 
high and low affi nity ErbB3 binding variants. Large hydrophobic residues 
are preferred at positions 46, 47 and 49 in all selected T1E46-50 variants, 
while methionine was alternatively allowed at position 49. In particular Ile46 
contributes to enhanced ErbB-3 binding affi nity. In addition, the presence of 
an acidic residue facilitates specifi c binding to ErbB3, preferentially located 
at position 48 (for strong ErbB3 binding), or alternatively at position 50 (for 
weak ErbB3 binding). Since a combination of the polar residues Gln48 and 
Asn50 proved also suffi cient (Figure 2D), we propose that these two side-
chains are involved in hydrogen bonding. Interestingly, in the structure of 
receptor-bound TGFα several C-terminal residues interact with both domains 
I and III, among which the corresponding Asp47 in TGFα (1). It has been 
suggested that these residues determine the fi nal position of the two 
ligand-binding domains in the complex, and thereby infl uence the stability 
of the dimer. It is tempting to speculate that in the T1E selectants Asp48 
may serve a similar function when binding to ErbB3. Furthermore, all T1E 
variants selected for ErbB3 binding had maintained their ability to bind to 
ErbB-1 expressed on 32D cells and ErbB-1-IgG ectodomains, indicating that 
the requirements in the C-terminal tail for ErbB1 and ErbB3 interaction may 
partly overlap (unpublished observations). This observation is remarkable 
since the majority of selected clones lacked a Leu or Ile at position 49 in T1E 
(Leu47 in EGF), which is strictly conserved among ErbB1 ligands and known 
to be highly sensitive to site-directed mutagenesis (13,14). 
 Comparing the consensus sequence of the ErbB3 selectants with that 
of the natural ErbB3 ligands, one can conclude that the EGF linear C-terminal 
region comprising Tyr46-Asp48-Leu49 contributes positively to the interaction 
with ErbB3. The fi nding that T1E effectively forms ErbB2/ErbB3 heterodimers 
but not ErbB3 homodimers can thus not be attributed to inappropriate C-
terminal sequences, as previously thought. Rather, it refl ects the presence 
of suboptimal residues in both its N-terminal and C-terminal region (29). 
The observation that introduction of the NRG1β C-terminus into T1E did not 
increase the ErbB3 binding affi nity can be explained by the presence of only 
two out of four required determinants, Tyr47 and Met49, with Met being a 
less-favoured residue. In agreement, mutation of these two residues into 
alanine was found to reduce the ErbB-3 binding affi nity of NRG1β (20). 
Apparently, natural ligands are not necessarily optimised for high affi nity 
to their receptors, which is also indicated by the increase in ErbB3 binding 
affi nity of optimised NRG1β variants (30). Their affi nity enhancement was 
mostly attributed to the Met to Ile substitution in the C-terminal tail, as 
also shown by the T1E6Nopt mutant in our study. Interestingly, despite the 
abundant occurrence of Asp residues in the T1E variants optimised for ErbB3 
binding, acidic residues were not observed in optimised NRG1β variants, 
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which may be attributed to differences in the structural environment of T1E 
and NRG1β (30). We have recently solved the three-dimensional structure of 
T1E, but since that of the NRG1β isoform is unknown, a direct comparison is 
impossible.
 Our results imply that specifi c residues in the C-terminal tail of EGF-
related ligands are involved in direct interaction with ErbB3 but not ErbB2. This 
makes it unlikely that the formation of heterodimeric ErbB complexes is driven 
through bivalent binding of ligands to two different ErbB molecules. Instead, 
our fi ndings support a receptor-mediated dimerisation mechanism, in which 
ligand binding to ErbB3 determines the formation of both ErbB3 homodimers 
and ErbB2/ErbB3 heterodimers (Figure 4). In a variant of this model, it has 
been proposed that ligands only induce ErbB3 homodimers, which may 
subsequently stabilise two ErbB2 molecules into a tetrameric complex (37-40). 
Based on the analogy of the crystal structures of ErbB1 and ErbB3, it is most 
likely that homodimeric ErbB3 complexes are formed through a conformation-
induced mechanism with a 2:2 stoichiometry (1,2,41). In this scenario the 
ligand would bind domain I of ErbB3 through the linear N-terminal and B-loop 
regions, while its C-terminal residues would interact with receptor domain 
III. In the conformation-induced model, selectivity between the formation 
Figure 4: Models for ligand-induced ErbB2/ErbB3 heterodimerisation, including 
ligand-mediated (left panel) and receptor-mediated (middle and right panel) 
mechanisms. The ErbB3 receptor is shown in white and ErbB2 in grey. The 
orientation of the linear N-and C-terminal regions of the ligand is indicated by N and 
C, respectively. The middle panel depicts the ErbB2/ErbB3 heterodimeric complex 
induced by a ligand with low ErbB3 affi nity, and the ErbB3 homodimeric complex 
induced by a ligand with high ErbB3 affi nity. For details see text.
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of inactive ErbB3 homodimers and active ErbB2/ErbB3 heterodimers will be 
achieved through the intrinsic property of a ligand to bind ErbB3 (Figure 4). 
Ligands with high affi nity for domain I and/or III of ErbB3, including NRG1β 
and some of the ErbB3 variants selected here, have a high potency to bring 
ErbB3 into the “open” dimerisation state and will thus induce both ErbB3 
homodimers and ErbB2/ErbB3 heterodimers. Ligands with relatively low 
affi nity for ErbB3 due to suboptimal interaction with domain I or III, such 
as T1E and NRG1α, have only a low potency to induce ErbB3 into the “open” 
state and only in the case the liganded ErbB3 is complexed by ErbB2 a stable 
complex is formed. This model presumes that the dimerisation site of ErbB2 
is maintained constitutively in the “open” confi guration, as an explanation for 
the preferential heterodimerisation with ErbB2. From an evolutionary point of 
view this would be a sensible mechanism to enhance the formation of active 
ErbB2/ErbB3 complexes and to avoid biologically inactive ErbB3 homodimers. 
In this respect NRG1β would be the optimal natural ligand if ErbB2 is present 
in excess over ErbB3, while the low affi nity NRG1α isoform would be more 
effective under conditions that ErbB3 is present in excess over ErbB2 (21,24). 
A switch in isoform production thus offers the cell a subtle method of control 
over cellular functions. 
EXPERIMENTAL PROCEDURES
Construction of T1E mutants
 The construction of T1E has been described previously (28). Residues 
in the linear C-terminal region following the sixth cysteine in pEZZ/Fx/T1E 
were replaced by the corresponding residues of TGFα and NRG1β by means 
of splice overlap extension polymerase chain reaction. The initial PCR 
fragments containing the complementary overhang sequences were made 
using pEZZ/Fx/T1E, pEZZ/Fx/TGFα and the NRG1β gene in pNRG8-g3 (a gift 
from Genentech Inc., San Francisco, CA) as templates. The fragment for the 
C-terminal region of the optimised NRG1β (referred to as NRG-58 (30)) was 
constructed using oligonucleotide primers containing mutations encoding 
Asn-His and Met-Ile substitutions. Mutant gene products were subsequently 
introduced in the pEZZ vector using the Bam-HI/Sal-I sites and verifi ed by 
automated cycle sequencing. Production, purifi cation and characterisation of 
recombinant T1E mutants was essentially performed as previously described 
(28).
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Cell lines
 Interleukin-3 dependent murine (m) 32D haematopoietic progenitor 
cells transfected with distinct human ErbB-encoding viral vectors or plasmids 
were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated 
fetal calf serum (FCS, GibcoBRL Life Technologies, Paisley, UK), 0.25 ng/ml 
mIL-3 (Promega, Madison, WI), and kept under continuous selection using 0.6 
mg/ml G418 (Calbiochem, La Jolla, CA) or 0.4 mg/ml hygromycin B (Sigma, 
St Louis, MO)(12). The human mammary carcinoma cell line MDA-MB-453 
was cultured in a 1:1 mixture of Dulbecco’s modifi ed Eagle’s medium and 
Ham’s F12 medium supplemented with 10% FCS. Human embryonic kidney 
293 cells were cultured in Dulbecco’s modifi ed Eagle’s medium (Gibco BRL) 
supplemented with 10% FCS.
Ligand Displacement Experiments
 Recombinant human NRG1β176-246 (R&D Systems, Minneapolis, MN) 
and T1E were radioiodinated using the Iodogen method (Pierce) according 
to the manufacturer’s protocol for indirect labelling, resulting in a specifi c 
activity of 40-80 μCi/μg protein. Ligand displacement analyses on 32D cells 
were performed as described (28).
Construction of the phage T1E46-50 library
 A phage library of T1E randomised by mutation to NNS codons 
(N=G/T/A/C, S=G/C) at positions Tyr46, Arg47, Asp48, Leu49 to Lys50 (T1E 
numbering) was constructed by a PCR-based approach using fUSE5/T1E 
as template (29,31). The randomised region in the peptide growth factor 
was directly followed by the Sfi -I restriction site, thereby omitting the EGF 
residues Trp51 to Arg55. Since the randomised sequence was located in close 
proximity of the pIII fusion point, a fl exible (Gly-Gly-Gly-Ser)2 linker sequence 
was introduced in the wild-type fUSE5 vector after the second Sfi -I site prior 
to the gene encoding pIII. Wild-type fUSE5 contains an out-frame stuffer 
fragment between the Sfi -I sites, thereby eliminating background phage 
(32). The PCR fragments encoding the randomised T1E gene were cloned into 
the fUSE5/linker phage vector using both Sfi -I sites. Ligation products were 
processed and electroporated into Escherichia coli TG-1 cells (Stratagene) 
for phage production. The number of independent transformants was 
determined by titration on tetracycline-containing plates to estimate the size 
of the library. Randomly picked clones from the library were analysed by cycle 
sequencing (Perkin-Elmer, Applied Biosystems) to confi rm the diversity of 
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codon use and the expected amino acid distribution. Phage preparations were 
carried out following standard polyethylene glycol 8000/NaCl precipitation 
procedures. Titers of fi lter-sterilised phages were estimated by both titration 
and spectrophotometrical determination.
Preparation of ErbB-IgG fusion proteins
 Gene constructs encoding the extracellular domain of human ErbB 
receptors were fused to the hinge and Fc regions of the human IgG1 heavy 
chain (referred to as ErbB-IgG (33)). Subconfl uent HEK-293 cells were 
transfected with the expression vector pCDM7/IgB3 or a mixture of pCDM7/
IgB3 with pCDM7/IgB2 using Lipofectamine2000 (GibcoBRL) according to 
the manufacturer’s protocol. Conditioned culture supernatants containing 
the soluble dimeric IgG fusion proteins were harvested 5-10 days following 
transfection, and purifi ed by affi nity chromatography on a 1 ml Hi-trap Protein 
A-Sepharose column (Pharmacia Amersham Biotech). Purifi ed IgG fusion 
proteins were eluted with 0.1 M citric acid (pH 4.2) into tubes containing 1 M 
Tris pH 9.0. ErbB-IgG preparations were quantifi ed by Fc-ELISA using human 
IgG as a standard, while the purity and presence of dimeric species was 
confi rmed by SDS-polyacrylamide electrophoresis and immunoblotting with 
polyclonal antibodies directed against human Fc (Nordic, Tilburg, NL). 
Phage selection on ErbB3-IgG fusion proteins
 Nunc immunoabsorbant wells were precoated overnight at 4°C 
with 0.2 μg of goat-anti-human Fc-specifi c IgG (Jackson Immunoresearch 
Laboratories, West Grove, PA) in 100 μl PBS (137 mM NaCl/ 2.7 mM KCl/ 1 
mM Na2HPO4/ 2 mM KH2PO4). Wells were washed in PBS/0.05% (v/v) Tween20 
(washing buffer) and blocked for 1 h in 0.2 ml PBS/0.2% (w/v) BSA (blocking 
buffer) at room temperature. Next, wells were coated with 100 ng ErbB3-IgG 
for 2 h in PBS/0.2% BSA/0.05% Tween20 (binding buffer). Wells were rinsed 
twice and incubated with 1-3 ×1010 T1E46-50 phages in 0.1 ml binding buffer. 
After incubation for 2 h, unbound phages were removed by rinsing 12 times 
with washing buffer. Bound phages were eluted by addition of 0.1 ml glycine 
buffer (50 mM glycine/150 mM NaCl pH 2.7) for 10 min, and the eluate was 
neutralised with 25 μl of 1 M Tris/HCl pH 8.0. The elutate was used for phage 
titration and infection of logarithmic cultures of TG-1 cells.
Whole cell phage selection
 Phage selections on MDA-MB-453 cells were carried out by incubation 
of 5-10 × 106 cells in suspension with 1-3 × 1010 tu T1E46-50 phages in 3 
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ml blocking buffer. In the case of ErbB3-IgG depletion, the phages were 
subjected to ErbB3-IgG as described above prior to cell selection. The 
unbound phages from ErbB3-IgG wells were subsequently transferred to 12 
ml Falcon tubes, diluted to 3 ml with binding buffer and added to MDA-MB-
453 cells. After incubation for 2 h on a rowing boat shaker, cells were rinsed 
seven times in washing buffer by spinning for 4 min at 1000 rpm, followed 
by resuspension and a fi nal wash with PBS. Cells were transferred twice to 
clean tubes to remove phages non-specifi cally bound to the plastic. Specifi c 
elution was performed by competition with a 1:1 mixture of the anti-ErbB2 
monoclonal antibodies L26 and L96 (Neomarkers, Fremont, CA (34)) at 50 
μg/ml in binding buffer for 1 h at 4°C on a rowing boat shaker. Cells were 
spun and the supernatant was collected as ErbB2/ErbB3 phage fraction. The 
remaining cell-bound phages were harvested by a 10 min incubation in 1 ml 
acid elution buffer, followed by neutralisation upon adding 0.2 ml 1 M Tris-HCl 
pH 8.0. Cells were spun for 5 min at 1200 rpm, and the eluate was collected 
as ErbB-3 fraction. The distinct eluted fractions were used for phage titration 
and infection of logarithmic cultures of TG-1 cells. 
Phage ELISA
 Small scale phage preparations were used for the screening of 
individual clones in ELISA assays. PEG 8000 precipitates of culture broths of 
clones grown overnight in 2 ml 2xTY supplemented with 12.5 µg/ml tetracyclin 
in 12-wells plates were resuspended in 100 μl PBS, typically resulting in phage 
titers of 1-5 × 1010 tu/ml. Whole cell ELISAs on 32D sublines in suspension 
were performed as described (29). The procedure for ErbB-IgG ELISA was 
similar as described (20), with the following modifi cations: homodimeric 
ErbB3-IgG fusion proteins were coated at 50 ng/well, and heterodimeric 
ErbB2/3-IgG at 100 ng/well in 0.1 ml of binding buffer. 
Cell proliferation assays
 32D cells that coexpress ErbB2 and ErbB3 (D23 cells) were washed in 
RPMI 1640 medium to deprive them of IL-3. Subsequently cells were seeded 
into 96-well tissue culture plates at a density of 5.0 × 104 cells/well in 0.1 ml 
RPMI supplemented with 0.1% BSA, together with serial dilutions of fi lter-
sterilised phages or recombinant growth factors. Cell survival was determined 
after 24 hours of incubation at 37 °C using the 3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyl tetrazolium bromide (MTT) assay, as previously described (29). 
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ABSTRACT
 Epidermal growth factor (EGF)-like growth factors bind their ErbB 
receptors in a highly selective manner, but the molecular basis for this 
specifi city is poorly understood. We have previously shown that certain 
residues in human EGF(Ser2-Asp3) and TGFα (Glu26) are not essential for 
their binding to ErbB1 but prevent binding to ErbB3 and ErbB4. In the present 
study, we have used a phage display approach to affi nity-optimize the C-
terminal linear region of EGF-like growth factors for binding to each ErbB 
receptor and thereby shown that Arg45 in EGF impairs binding to both ErbB3 
and ErbB4. By omitting all these so-called negative constraints from EGF, we 
designed a ligand designated panerbin that binds ErbB1, ErbB3, and ErbB4 
with similarly high affi nity as their wild-type ligands. Homology models, based 
on the known crystal structure of TGFα-bound ErbB1, showed that panerbin 
is able to bind ErbB1, ErbB3, and ErbB4 in a highly similar manner with 
respect to position and number of interaction sites. Upon in silico introduction 
of the experimentally known negative constraints into panerbin, we found 
that Arg45 induced local charge repulsion and Glu26 induced steric hindrance 
in a receptor-specifi c manner, whereas Ser2-Asp3 impaired binding due to 
a disordered conformation. Furthermore, radiolabeled panerbin was used to 
quantify the level of all three receptors on human breast cancer cells in a 
single radio receptor assay. It is concluded that the ErbB specifi city of EGF-
like growth factors primarily results from the presence of a limited number of 
residues that impair the unintended interaction with other ErbB receptors.
INTRODUCTION
 The human genome encodes four ErbB tyrosine kinase receptors, 
designated ErbB1 (HER1 or EGFR receptor), ErbB2, ErbB3, and ErbB4. 
They are activated by a total of 11 different EGF-like growth factors, and 
in combination this set of receptors and ligands plays a crucial role in the 
growth control of mammalian cells and the development of multicellular 
organisms (1). Particularly, ErbB1 and ErbB2 are frequently overexpressed 
in many epithelial tumors, and as a consequence the ErbB signaling network 
is currently one of the main targets for the development of anti-tumor drugs 
(2–5). 
 ErbB receptors show a highly pronounced ligand specifi city, but the 
molecular basis for this binding specifi city is still poorly understood. ErbB1 
binds seven distinct ligands (EGF, TGFα, amphiregulin (AR), epigen (EPGN), 
BTC, epiregulin (EREG), and heparin-binding EGF-like growth factor HB-
EGF), ErbB3 binds only NRG1 (neuregulin 1) and NRG2, and ErbB4 interacts 
with NRG1, NRG2, NRG3, NRG4, BTC, epiregulin, and heparin-binding 
EGF-like growth factor. ErbB2 does not bind ligand but is the preferred 
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heterodimerization partner of all liganded ErbB receptors. It has so far been 
anticipated that the ErbB specifi city of EGF-like growth factors results from 
the presence or absence of specifi c residues that are directly involved in 
receptor binding. However, a large number of site-directed mutagenesis 
studies, particularly on EGF, TGFα, and NRG1β, have identifi ed numerous 
residues that upon mutation reduce the binding affi nity for their respective 
ErbB receptor, but in general these mutations do not affect receptor 
specifi city. This agrees with crystal structure data, which have shown that 
many residues in both EGF and TGFα interact directly with ErbB1 (6, 7). No 
such data are available yet for ErbB3 and ErbB4, since the relevant crystal 
structures are still lacking, but based on the strong homology of the different 
ErbB receptors and the high structural similarity between the various EGF-
like growth factors, it seems unlikely that for binding to these receptors a 
fully different set of ligand residues is involved. Moreover, phylogenetic tree 
analysis has indicated that TGFα and BTC are closely related and may have 
arisen from a common ancestor gene (8), but still TGFα is an ErbB1-specifi c 
ligand, whereas BTC interacts with both ErbB1 and ErbB4. AR and HB-EGF 
are similarly related but also show distinct receptor specifi city. This suggests 
that during evolution, specifi c strategies have been developed to obtain the 
desired receptor specifi city. 
 Previous studies have indicated that the receptor binding specifi city 
of EGF-like growth factors can be compromised by making chimeras of 
different ligands. Barbacci et al. (9) have shown that a chimera between EGF 
and NRG1β, designated biregulin, not only binds with high affi nity to ErbB1 
but also shows low affi nity competition with NRG1β for receptor binding. 
Our previous studies (10) have shown that this is similarly true for various 
chimeras of the ErbB1-specifi c ligands EGF and TGFα. In particular, T1E, 
which is composed of EGF sequences with the N-terminal linear region of 
TGFα, is not only a high affi nity ligand for ErbB1 but also a low affi nity ligand 
for ErbB3 and ErbB4. Subsequent analysis showed that EGF is unable to bind 
ErbB3, because it lacks the His2-Phe3 sequence of TGFα in its N-terminal 
linear region, whereas TGFα is unable to bind ErbB3 because of the bulky, 
negatively charged Glu26 (EGF numbering) in the so-called B-loop (10). In 
contrast, T1E, which contains the His2-Phe3 sequence but lacks Glu26, is 
able to interact with ErbB3. Intriguingly, both crystal structure and mutational 
analysis revealed that these specifi c residues are not essential for high affi nity 
binding to ErbB1. In a more recent study (11), we have further optimized the 
amino acid sequence of T1E in its N- and C-terminal linear region to derive 
a mutant, designated WVR/EGF/IADIQ, that binds ErbB1 with similarly high 
affi nity as EGF and ErbB3 with similarly high affi nity as NRG1β but shows only 
low affi nity for ErbB4. 
 Based on the above observations, we have postulated that EGF-like 
growth factors do not only contain residues that are directly involved in ErbB 
binding (positive constraints) but in addition residues that are not essential 
for binding to their cognate receptor but that prevent their unintended 
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interaction with other ErbB receptors (negative constraints). In the present 
study, we provide evidence that such negative constraints in ligand molecules 
form the primary basis for their ErbB specifi city. Using a phage display 
approach in which the C-terminal linear region of T1E has been randomized, 
we have established the optimal sequences for ligand binding to ErbB1, 
ErbB3, and ErbB4. Our data show that each of these three receptors has 
unique requirements for ligand binding, but that a consensus sequence can be 
derived that permits high affi nity binding to all three receptors. From the data 
obtained, we conclude that T1E is a low affi nity ligand for ErbB3 and ErbB4, 
because Arg45 forms a negative constraint for binding to ErbB3 and ErbB4 
but not to ErbB1. Removal of this arginine from T1E resulted in the generation 
of a ligand, designated panerbin, that binds all three receptors with similarly 
high affi nity as their wild-type ligands. Homology modeling studies showed 
that panerbin binds ErbB1, ErbB3, and ErbB4 in an almost identical manner, 
indicating that ErbB receptors recognize similar positive constraints in their 
ligand molecules. However, introduction of the identifi ed negative constraints 
into panerbin resulted in local charge repulsion, conformational impairment, 
or steric hindrance for binding to ErbB3 and ErbB4 but not for ErbB1, thereby 
providing a molecular basis for their role in receptor specifi city.
MATERIALS AND METHODS
Cell Lines
 Interleukin 3-dependent murine 32D hematopoietic progenitor cells 
transfected with distinct human ErbB encoding plasmids were cultured in 
RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum 
(Invitrogen) and 0.25 ng/ml murine interleukin-3 (Promega, Madison, WI) 
and subsequently kept under continuous selection using 0.6 mg/ml G418 
(Calbiochem). HER-14 cells and T47-14 cells were cultured in gelatinized 
fl asks in Dulbecco’s modifi ed Eagle’s medium supplemented with 10% 
newborn calf serum (12). 
Selection of High Affi nity T1E Variants on ErbB-Fc Fusion Proteins
 Construction of the phage T1E (residues 44–48) library and the 
preparation of ErbB-Fc fusion proteins have been described previously (13). 
Immunoabsorbent 24-well plates were precoated overnight at 4 °C with 0.2 
µg of goat anti-human Fc-specifi c IgG (Jackson Immunoresearch Laboratories, 
West Grove, PA) in 0.2 ml of PBS (137mM NaCl, 2.7mM KCl, 1 mM Na2HPO4, 
2 mM KH2PO4, pH 7.4). Wells were washed with PBS plus 0.05% (v/v) Tween 
20 and subsequently blocked with 0.2 ml of PBS plus 0.2% (w/v) BSA for 1 
h at room temperature to prevent nonspecifi c binding. The wells were then 
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coated with 100 ng of ErbB-Fc for 2 h in PBSplus 0.2% BSA and 0.05% Tween 
20 (binding buffer). Wells were subsequently washed twice with PBS/Tween 
and incubated with 3*108 T1E (residues 44–48) phages in 0.1 ml of binding 
buffer. After incubation for 2 h, unbound phages were removed by rinsing 
the wells 12 times with PBS/Tween. In the fi rst selection round, phages were 
eluted by adding 0.1 ml of glycine buffer (50 mM glycine, 150 mM NaCl, pH 
2.7) for 10 min, and the eluate was neutralized by the addition of 25 µl of 1 
M Tris/HCl, pH 8.0. In subsequent selection rounds, the bound phages were 
eluted specifi cally with 1 µg of murine EGF (for ErbB1) or 1 µg of NRG1β (for 
ErbB3 and ErbB4) in 1 ml of binding buffer for 1 h at room temperature. The 
eluate was used for phage titration and infection of logarithmic cultures of 
Escherichia coli TG-1 cells.
Phage Enzyme-linked Immunosorbent Assay on ErbB-Fc
 Nunc immunoadsorbent 96-well plates were precoated overnight at 
4°C with 0.2 µg of goat anti-human Fc-specifi c IgG (Jackson Immunoresearch 
Laboratories) in 100 µl. Wells were washed in PBS/Tween and blocked for 1 
h in 0.2ml of PBS/BSA at room temperature. Next, wells were coated for 2 
h with 100 ng of ErbB-Fc in binding buffer, subsequently washed twice, and 
incubated with phages in 0.1 ml of binding buffer. After incubation for 2 h, 
unbound phages were removed by rinsing three times with PBS/Tween. For 
detection of bound phages, wells were incubated for 1 h at room temperature 
with peroxidase-conjugated anti-M13 antibody (Amersham Biosciences) 
in PBS/BSA. To remove unbound phages, wells were washed three times 
with PBS. Subsequently, 0.1 ml of substrate, consisting of 0.4 µM 3,3’5,5’-
tetramethyl-benzidine (Sigma) and 0.03% H2O2 in 0.11 M citrate buffer, pH 
5.5, was added to the wells. The reaction was terminated after 5 min by the 
addition of 0.05 ml of 1 M H2SO4. Absorption was read at 450 nm.
Construction of T1E/YYDLL
 Mutations in the C-terminal linear region were made using mutagenic 
oligonucleotide primers with pEZZ/FX T1E as template. Mutant gene products 
were subsequently introduced with the pEZZ vector using the BamHI/SalI 
sites, and the constructs were verifi ed by automated cycle sequencing. 
Recombinant T1E/YYDLL was expressed as a protein A-tagged fusion protein 
in the protease K-defi cient E. coli strain KS474. T1E/YYDLL was purifi ed by 
affi nity chromatography using IgG-Sepharose, followed by FactorX cleavage 
of the protein A tag, an additional round of affi nity chromatography to remove 
the tag, and a fi nal reverse-phase HPLC purifi cation step (10). The amount of 
growth factor was calculated from the peak area (absorption at 229 nm) in 
the reverse-phase HPLC chromatogram, using murine EGF as a standard. 
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Radioactive Ligand Displacement Experiments
 Natural murine EGF (Bioproducts for Science Inc., Indianapolis, IN) 
and recombinant hNRG1β residues 117–246 (R&D Systems, Minneapolis, 
MN) were iodinated enzymatically to a specifi c activity of  1.1 Ci/mol (14). 
Ligand binding displacement studies on HER-14, 32D3, and T47-14 cells 
were performed as described previously (13, 15). For differential binding 
competition analysis, 3.0x105 MCF-7, CAMA-1, or T47D human breast 
cancer cells were seeded in 24-well plates in 1 ml of Dulbecco’s modifi ed 
Eagle’s medium with 10% newborn calf serum. After 2 days, the confl uent 
monolayers were incubated for 2 h on ice with 100µl of 10 ng/ml [125I]T1E/
YYDLL, radiolabeled as above, in the presence of serial dilutions of unlabeled 
T1E/YYDLL, TGFα, NRG1β, or BTC. Cells were subsequently washed twice with 
ice-cold PBS. Cells were lysed in 0.5ml of 1% Triton X-100, and the bound 
radioactivity was measured by γ-counting. 
Homology Modeling of T1E/YYDLL in Complex with ErbB1, ErbB3, and ErbB4
 Homology models were constructed for the extracellular domains of 
ErbB1, ErbB3, and ErbB4, all in complex with T1E/YYDLL. Initial models were 
built using both the ErbB1-EGF complex (7) and the ErbB1-TGFα complex (6, 
16) as a template. Validation of the models with WHAT CHECK (17) identifi ed 
template 1MOX, the ErbB1-TGFα complex solved at a resolution of 2.5 Å (6), 
as the best choice both for receptor and ligand. The amino acid side chains in 
the fi nal models were positioned using SCWRL (17). Subsequently, the models 
were refi ned in YASARA using the Yamber2 force fi eld and the associated 
protocol (18) until the WHAT IF (19) quality indicators (Ramachandran plot, 
backbone conformation, and three-dimensional packing quality) converged. 
Coordinate fi les of the fi nal models are available from the authors upon 
request.
RESULTS
Selection of Optimal C-terminalSequences for ErbB1, ErbB3, or ErbB4 
Binding
 We have previously shown that T1E, obtained by introducing TGFα 
sequences into the N-terminal linear region of EGF, is a broad ErbB-activating 
ligand with high affi nity for ErbB1 and low affi nity for ErbB3 and ErbB4 (10). 
Additional studies have indicated that the affi nity of T1E for ErbB3 can be 
further enhanced by altering the C-terminal linear region (11, 13). To identify 
C-terminal sequences that are optimal for binding of T1E to each of these 
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three ErbB receptors, we expressed T1E on phage whereby the DNA sequence 
encoding residues 44–48 was randomly mutated (residue numbering 
according to EGF; see Fig. 1 for sequences). To select ErbB-specifi c high 
affi nity binders, the resulting phage library was incubated with Fc-ErbB 
fragments of ErbB1, ErbB3, and ErbB4, respectively, during three rounds of 
selection. ErbB2 with its permanent open conformation cannot bind ligand 
(16) and was therefore not included. Supplemental Table 1 summarizes the 
phage input/output ratios during the various selection rounds. Fig. 2 shows 
that in the case of ErbB1, a phage pool with similarly high affi nity as T1E was 
already obtained after a single round of selection, whereas a phage pool with 
strongly enhanced affi nity for both ErbB3 and ErbB4 compared with T1E was 
obtained after 2–3 rounds of selection. From each of the receptor-specifi c 
phage pools obtained after three rounds of selection, multiple clones were 
sequenced (see supplemental Table 2, a–c). T1E variants with distinct amino 
acid sequences were obtained, indicating that multiple C-terminal sequences 
facilitate ErbB-specifi c high affi nity binding. Fig. 3, a–c, show the frequency 
distribution of individual amino acids in the selected variants. Based on these 
frequencies, consensus sequences (occurrence > 50%) for optimal receptor 
binding of T1E (residues 44–48) selectants could be assigned, as follows: for 
ErbB1, XXDLX; for ErbB3, I(F/Y)D(Ar/Hp)X(where Ar represents an aromatic 
and Hp represents a hydrophobic residue); and for ErbB4, YN(D/E)(L/V/I)X. 
These data show that within the context of a T1E background, all three ErbB 
receptors display distinct requirements for high affi nity ligand binding. 
Figure 1. Sequences of EGF, the T1E (residues 44–48) library, and 
panerbin. The conserved cysteines, looped regions, and N- and C-terminal linear 
regions are indicated. Numbering throughout the study is according to hEGF. X 
represents randomized positions. Colored residues represent the sites of direct 
receptor interaction, according to homology models of panerbin with the various 
ErbB receptors. Residues in red are involved in hydrogen bond formation, residues 
in green are involved in hydrophobic interactions, and residues in blue are involved 
in salt bridge formation with the indicated ErbB receptors.
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Selection of a Pan-ErbB Ligand
 To test if the requirements for ligand binding to ErbB1, ErbB3, and 
ErbB4 are mutually exclusive, the phage pool obtained after two rounds of 
selection on Fc-ErbB3 was subsequently selected for high affi nity binders to Fc-
ErbB4 and Fc-ErbB1. Binding analysis indicated that the phage pool obtained 
after two selection rounds on ErbB3 already showed high affi nity for both 
ErbB3 and ErbB1 but only intermediate affi nity for ErbB4 (see supplemental 
Fig. 1). However, after an additional selection round on ErbB4, a phage pool 
with high affi nity for all three ErbB receptors was obtained, although no 
deliberate selection on ErbB1 had been carried out. The amino acid sequences 
of the variants selected after binding to both ErbB3 and ErbB4 are listed in 
supplemental Table 2d, whereas the corresponding frequency distribution of 
residues at each position is presented in Fig. 3d. Based on these frequencies 
a consensus sequence of YYDLX was obtained for the C-terminal linear 
region of the T1E (residues 44–48) selectants that bind with high affi nity to 
ErbB1, ErbB3, and ErbB4. This consensus sequence thus refl ects a unique 
combination of residues for binding to all three receptors. Phage display 
mutational analysis will favor residues that provide a positive constraint for 
receptor binding, whereas negative constraints will be eliminated. According 
to the data presented in Fig. 3, residue Leu47 appears to be a major positive 
constraint in the linear C-terminal region for binding to ErbB1, Asp46 for 
ErbB3, and Tyr44 for ErbB4 (all > 80% occurrence). The main difference 
between T1E/YYDLX and T1E itself is the mutation R45Y, since the residue 
at position 48 appears less important according to the pan-ErbB consensus 
sequence. This suggests that Arg45 forms a negative constraint for binding to 
ErbB3 and ErbB4 but not for interaction with ErbB1. 
Figure 2. Binding characteristics of T1E (residues 44–48) phage pools 
after the indicated rounds of selection on Fc-ErbB-1 (a), Fc-ErbB3 (b), 
or Fc-ErbB4 (c). Phage pools were tested in a phage binding enzyme-linked 
immunosorbent assay. Phage T1E (open circles), native T1E (residues 44–48) 
library (closed circles), fi rst round selection (closed diamond), second round 
selection (closed square), and third round selection (closed triangle). The phage 
input/output ratios of each selection round are shown in supplemental Table 1.
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Characterization of the Recombinant Pan-ErbB Ligand T1E/YYDLL on Living 
Cells
 The sequence T1E/YYDLL was found twice within the phage clones 
characterized, and since it fully corresponds with the obtained consensus 
sequence for a ligand that binds all three ErbB receptors, we subsequently 
tested T1E with YYDLL at positions 44–48 (see Fig. 1) as a purifi ed recombinant 
protein for its ErbB affi nity on living cells. Fig. 4a shows that recombinant T1E/
YYDLL binds with similarly high affi nity as T1E and EGF to ErbB1 on HER14 
cells (IC50 = 40 ng/ml). On 32D cells transfected with ErbB3, the affi nity 
of T1E/YYDLL (IC50 = 15 ng/ml) was increased 60-fold compared with T1E 
(IC50 = 900 ng/ml) and reached almost the same level as the endogenous 
ligand NRG1β (IC50 = 7 ng/ml). The binding affi nity of T1E/ YYDLL (IC50 = 
20 ng/ml) to ErbB4 on T47-14 cells was even higher than that of NRG1β (IC50 
= 50 ng/ml). This shows that, despite the fact that ErbB1, ErbB3, and ErbB4 
have distinct binding requirements, T1E/YYDLL can bind all three receptors, 
with an affi nity for ErbB3 and ErbB4 similar to NRG1β and an affi nity for 
Figure 3. Schematic representation of the amino acid distribution of 
selected T1E (residues 44–48) variants after three rounds of selection on 
Fc-ErbB1 (a), Fc-ErbB3 (b), or Fc-ErbB4 (c) and the combination of two 
rounds on Fc-ErbB3 and one round on Fc-ErbB4 (d). Sequences of individual 
selectants are depicted in supplemental Table 2.
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ErbB1 similar to EGF. Fig. 4b shows that T1E/YYDLL has a similar ability as 
EGF and T1E to induce tyrosine phosphorylation of ErbB1. Since ErbB3 has 
a defective tyrosine kinase domain, the ability of T1E/YYDLL to induce ErbB3 
phosphorylation was tested on 32D23 cells expressing both ErbB2 and ErbB3. 
The data show that T1E/YYDLL induced tyrosine phosphorylation of ErbB3 to 
the same extent as NRG1β, whereas T1E was much less active. On ErbB4, 
T1E/YYDLL was as least as potent as NRG1β in inducing receptor tyrosine 
phosphorylation, again much more so than T1E. Thus, T1E/YYDLL is a pan-
ErbB ligand that is capable of high affi nity binding to all three receptors and 
a potent activator of ErbB1, ErbB3, and ErbB4. We propose to designate this 
ligand panerbin, because it facilitates high affi nity binding and activation of all 
three receptors. 
Homology Modeling of T1E/YYDLL in Complex with ErbB1, ErbB3 and ErbB4 
Explains the Pan-ErbB Character
 The availability of a ligand that binds ErbB1, ErbB3, and ErbB4 with 
high affi nity allows a structural comparison of three different receptors in 
Figure 4. ErbB affi nity of T1E/YYDLL. a, ligand binding displacement analysis of 
T1E/YYDLL on cells expressing distinct ErbB receptors. Displacement of 125I-labeled 
murine EGF binding to HER-14 cells expressing ErbB1 (left), of [125I]NRG1β binding 
toD3cells expressing ErbB3 (middle), and of [125I]NRG1β binding to T47-14 cells 
expressing ErbB4 (right), respectively. EGF (closed circle), T1E (closed square), 
NRG1β (closed diamond), and T1E/YYDLL (closed triangle). Results are the mean of 
at least three independent experiments performed in duplicate. b, receptor tyrosine 
phosphorylation induced by T1E/YYDLL on HER14 cells (left), D23 cells expressing 
both ErbB2 and ErbB3 (middle), and T47-14 cells (right). Cells were stimulated with 
2-fold serial dilutions of unlabeled growth factor starting from 25 ng/ml. Whole cell 
lysates were loaded onto SDS-polyacrylamide gels followed by immunoblotting with 
anti-phosphotyrosine antibodies. The 180-kDa band is shown.
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complex with the same ligand. In order to do so, homology models were 
constructed for the receptor-ligand complexes, based on the published 
crystal structure of the ErbB1-TGFα complex. Crystal structures of ErbB3 and 
ErbB4 are only available in the unliganded, autoinhibited conformation. A 
comparison showed that the L1 and L2 domains of ErbB3 and ErbB4 had similar 
conformations in the obtained homology models as in the crystal structures 
of the autoinhibited conformation (data not shown). When considering the 
amino acids in T1E/YYDLL that directly interact with residues in the receptor, 
only minor differences were observed between ErbB1, ErbB3, and ErbB4 (see 
Fig. 1, colored residues). These differences mainly resulted from the lack of a 
hydrogen bridge or a salt bridge partner in the receptor. These results indicate 
that these three receptors bind T1E/YYDLL in a highly comparable manner, by 
providing similar positive constraints for binding. In order to understand the 
mechanisms whereby negative constraints in EGF-like growth factors induce 
ErbB specifi city, we subsequently compared the existing crystal structures of 
EGF and TGFα in complex with ErbB1, with the homology models of T1E/YYDLL 
bound to ErbB1, ErbB3, and ErbB4. We particularly focused on the receptor 
environment of the ligand residues Arg45, Glu26, and Ser2-Asp3, which are 
negative constraints for binding to ErbB3 and ErbB4 but not to ErbB1. Fig. 5 
Figure 5. Homology models for the structure of EGF, TGFα, T1E, and 
panerbin in complex with the extracellular domain of ErbB1, ErbB3, and 
ErbB4. Top, close-up pictures showing ribbon representations of the B-loop of the 
ligand (blue) upon interaction with the hydrophobic pocket of the L1 domain of the 
indicated receptors (yellow). Bottom, interaction of the C-terminal linear region 
of the ligands with the hydrophobic pocket of the L2 domain of the receptors. The 
amino acid numbering of the ligands is according to that of EGF, and the amino acid 
numbering of the receptors is according to Jorrisen et al. (32).
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(top) shows that in the ErbB1-EGF complex Arg45 of EGF comes within 4Å of 
Ser418 of ErbB1, whereas the corresponding Tyr45 of T1E/YYDLL comes close 
to Ser418 of ErbB1, Lys415 of ErbB3, and Lys418 of ErbB4. This implies that 
when Arg45 is reintroduced into T1E/YYDLL, it would result in considerable 
charge repulsion with the lysines in ErbB3 and ErbB4 but not with the serine 
in ErbB1. This most likely explains why T1E is a high affi nity ligand for ErbB1 
but only a low affi nity ligand for ErbB3 and ErbB4. In fact, Tyr45 in T1E/YYDLL 
may well contribute to hydrophobic interactions and thereby enhance the 
binding affi nity for ErbB3 and ErbB4 as a positive constraint. From mutant 
studies, it is known that Arg45 is not essential for EGF binding to ErbB1 (15), 
and therefore we conclude that Arg45 plays a major role in preventing binding 
of EGF to ErbB3 and ErbB4. Fig. 5 (bottom) shows that in the ErbB1-TGFα 
complex Glu26 of TGFα forms a salt bridge with Arg124 of ErbB1, whereas
Leu26 of T1E/YYDLL can participate in hydrophobic interaction with all three 
receptors. However, upon introduction into T1E/YYDLL, Glu26 would give a 
steric clash with Met97 when complexed to ErbB3. In the case of ErbB4, 
no steric hindrance of Glu26 would take place with Phe97 of the receptor, 
although it cannot contribute to receptor binding in a positive manner as 
observed for Leu26. Crystal structure analysis has shown that the N-terminal 
linear region of EGF is disordered and does not interact with ErbB1, whereas 
in the case of TGFα residues His2 and Phe3 interact with the ErbB1 residues 
Tyr101 and Leu68, respectively (see Fig. 1). Mutational analysis has shown 
that this His2-Phe3 motif is essential for high affi nity ligand binding to ErbB3 
but not to ErbB1 (20). We conclude that the negative constraint Ser2-Asp3 
in EGF impairs binding to ErbB3 and ErbB4, most likely because it does not 
permit the proper β-sheet formation in the N-terminal linear region that is 
essential for binding to ErbB3 and ErbB4.
Determination of the Relative Amount of ErbB Receptors on Breast Tumor 
Cells by a Differential Binding Competition Assay Using 125I-Labeled Panerbin
 Since panerbin binds with high affi nity to ErbB1, ErbB3 and ErbB4, 
it can be applied to determine the relative amount of ErbB receptors on 
tumor cells in a single radioreceptor assay. The assay is based on binding 
of 125I-labeled panerbin and subsequent competition by various unlabeled 
ligands with defi ned ErbB specifi city.We applied this method to analyze the 
ErbB densities of T47D, MCF7, and CAMA-1 human breast tumor cell lines, 
which are known to express different sets of ErbB receptors. In the presence 
of nearly saturating concentrations of 125I-labeled panerbin (10 ng/ml), 
unlabeled TGFα was used to compete for ErbB1-specifi c binding, BTC was 
used to compete for binding to ErbB1 and ErbB4, and NRG1β was used to 
compete for binding to ErbB3 and ErbB4. These receptor specifi cities were 
confi rmed in a binding competition analysis of 125I-panerbin by these ligands 
on cells with known ErbB composition (see supplemental Fig. 2). Based on the 
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amount of 125I-labeled panerbin bound and the differential competition curves 
presented in Fig. 6, we could calculate that T47D cells contain at least 4x104 
ligand binding receptors per cell, of which 41% could be attributed to ErbB1, 
44% to ErbB3, and 15% to ErbB4; MCF7 cells contain a total of 1x105 ligand 
binding receptors/cell, of which 48% were ErbB1, 40% were ErbB3, and 12% 
were ErbB4; and CAMA-1 cells contain 1x105 ligand binding receptors/cell, 
of which 0% were ErbB1, 53% were ErbB3, and 47% were ErbB4. Together 
these data show that the designed EGF-like growth factor panerbin provides a 
new tool for direct analysis of ErbB binding levels in tumor cells, without the 
need of using multiple radiolabeled ligands.
Figure 6. Determination of the ErbB 
status of human breast cancer 
cells. Binding competition assays were 
performed using 10 ng/ml [125I]panerbin 
to occupy at least 50% of available ErbB 
receptors. Bound over added radioactivity 
was 4% (MCF7), 10% (T47D), and 10% 
(CAMA-1), corresponding to a total of 
4.0x104, 1.0x105, and 1.0x105 occupied 
ligand binding sites/cell, respectively. 
Serial dilutions of unlabeled T1E/YYDLL 
(closed diamond), TGFα (closed square), 
NRG1β (open circle), and BTC (closed 
triangle) were added to differentially 
compete for ErbB-selective binding (TGFα 
for ErbB1; BTC for ErbB1 and ErbB4; 
NRG1β for ErbB3 and ErbB4).
98
Chapter 3
DISCUSSION
 EGF-like growth factors show a highly distinct receptor specifi city. In 
the present study, we have shown that these growth factors not only contain 
residues that mediate high affi nity binding to their cognate receptor (positive 
constraints) but in addition have residues that prevent the unintended binding 
to other ErbB receptors (negative constraints). Our results show that Arg45 
in EGF is a major negative constraint for ligand binding to ErbB3 and ErbB4 
but not to ErbB1. In previous studies, we had already identifi ed Ser2-Asp3 in 
EGF and Glu26 in TGFα as negative constraints for binding to ErbB3 (10). By 
systematic release of these three negative constraints, we have now designed 
an EGF-based ligand, designated panerbin, that binds to ErbB3 and ErbB4 
with similarly high affi nity as NRG1β and to ErbB1 with similarly high affi nity 
as EGF. Homology models show that panerbin can undergo similar interactions 
with ErbB1, ErbB3, and ErbB4. Moreover, the models provide an explanation 
for the observed ligand specifi city of ErbB receptors on the basis of negative 
constraints. 
 The homology models indicate that at least 19 of the 55 residues of 
panerbin directly interact with not only ErbB1, but also ErbB3 and ErbB4, by a 
combination of electrostatic, hydrogen bond, and hydrophobic interaction (Fig. 
1). This indicates that the positive constraints for binding of panerbin to these 
three receptors are highly similar. However, when the negative constraint 
Arg45 is introduced into panerbin (corresponding to T1E), a strong charge 
repulsion with Lys415 and Lys418 is predicted by the model for ErbB3 and 
ErbB4, respectively, but not for ErbB1 (Fig. 5, top). These homology models 
also showed that introduction of Glu26 into panerbin will result in a steric 
clash with Met97 of ErbB3, but not with Phe97 of ErbB4, whereas it can form a 
salt bridge with Arg125 of ErbB1. This agrees with the observation that Glu26 
is conserved in the ErbB1- and ErbB4-specifi c ligand BTC. Finally, introduction 
of Ser2-Asp3 into panerbin will disorder the structure of the N-terminal linear 
region, which is known to affect binding to ErbB3 but not to ErbB1. It can 
therefore be concluded that the identifi ed three negative constraints act as 
ErbB selectivity determinants, particularly for ErbB3. For ErbB4 only Arg45 
has been identifi ed experimentally as a negative constraint, whereas for 
ErbB1 binding no negative constraints have been identifi ed yet. Interestingly, 
Hobbs et al. (21) have shown that NRG2β, which contains a phenylalanine at 
position 45, binds ErbB4 with high affi nity, whereas its splice variant NRG2α 
shows only low affi nity for this receptor, because it contains a lysine at this 
position. Based on a homology model, these authors (22) conclude that 
Phe45 contributes positively to ErbB4 binding by hydrophobic interaction 
with Lys438 (Lys418 in our numbering) of the receptor and that this positive 
constraint is lacking in NRG2α. According to our analysis, however, Lys45 in 
NRG2α will also induce charge repulsion with Lys418, thereby providing a 
negative constraint for ErbB4 binding. 
 Also from an evolutionary point of view, the ErbB signaling network 
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is of primary interest. Invertebrates, such as Caenorhabditis elegans (23) 
and Drosophila melanogaster (24), have only a single EGF receptor gene, 
regulated by one or multiple EGF-like growth factors (25). In urochordates, 
two distinct receptor genes have been identifi ed, which have further evolved 
into four ErbB genes in vertebrates. During this evolutionary process, 
selection strategies must have been followed to obtain multiple ligands 
with distinct receptor specifi city. Here we propose that the introduction of 
negative constraints has played a major role during this process of ligand 
diversifi cation. 
 Using panerbin as a radiolabeled ligand, we have been able to 
characterize the ErbB expression profi le of a number of ErbB overexpressing 
human breast tumor cell lines by a single radioreceptor assay. The present 
assay uses relatively high concentrations (10 ng/ml) of 125I-panerbin to 
nearly saturate all ErbB receptors, which allows an estimation of the total 
and relative number of ligand binding ErbB receptors present. The assay 
does not give information, however, on cellular ErbB2 expression levels. 
When comparing with other techniques, Western blotting can only be used to 
compare the density of a specifi c receptor between different cells and not to 
determine the density of different receptors on the same cell. Moreover, not 
all ErbB receptors present in a cell will be able to bind an externally added 
ligand, either because the receptors are present in intracellular organelles or 
because they are present in a conformation that does not allow high affi nity 
ligand binding. Cells can only respond to ligand molecules that bind plasma 
membrane receptors, and therefore the number of ligand binding receptors, 
as determined in the present radioreceptor assay, is the best parameter to 
correlate with the cell’s responsiveness. Finally, quantitative PCR is able to 
determine absolute expression levels for different receptors, but only at the 
mRNA level. 
 The absolute and relative number of ErbB receptors are not only 
important when evaluating anti-tumor drugs designed to target these 
receptors but are also important for diagnosis and prognosis. Overexpression 
of ErbB1, often in combination with continuous secretion of TGFα and 
overexpression of ErbB2, is frequently observed in estrogen-independent 
carcinomas and has been associated with poor prognosis and poor response 
to chemotherapy (3). The clinical signifi cance of ErbB3 and ErbB4 in tumor 
formation is less clear, but there is increasing evidence that overexpression 
of ErbB3 in combination with ErbB2 is associated with tumor growth of the 
breast (26) and the bladder (27). The role of ErbB4 in tumorigenesis is less 
clear, because of the distinct role of the various isoforms of this receptor. 
In a recent publication, it has been shown that the ErbB4 isoform, which is 
cleavable by TACE and γ-secretase but lacks the phosphatidylinositol 3-kinase 
binding motif, is able to promote proliferation of breast cancer cells (28). It 
should be realized that the present binding assay only identifi es the fraction 
of uncleaved ErbB4 receptors. 
 The therapeutic potential of EGF-like growth factors has been 
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demonstrated in wound healing (29), improvement of cardiac function, and 
survival in animals with ischemic, dilated, and viral cardiomyopathy (30) and 
reduction of ischemic-induced brain damage in rats (31). Clinical application 
of EGF-like growth factors, however, may require enhanced receptor 
selectivity particularly to discriminate between the effects mediated by ErbB3 
and ErbB4. We have shown in this study that upon systematic release of 
negative constraints from EGF, a pan-ErbB ligand can be designed that binds 
ErbB1, ErbB3, and ErbB4 with wild type affi nity. It will be a further challenge 
to identify additional negative constraints, particularly for ErbB1 and ErbB4, 
which can then be introduced in a selective manner to design ligands with any 
requested ErbB specifi city and affi nity.
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Supporting information
Table 1. Overview of phage selections on Fc-ErbB with the T1E(44-48) 
library*.
* For each selection round the input and output number of phages is indicated in 
titrating units.
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Table 2a. Amino acid sequences encoded by individual phage clones from the 
T1E(44-48) library after three rounds of selection for ErbB1 binding*.
* The consensus sequence represents the amino acids that are present in more than 
40% of the selected clones. X=random.
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Table 2b. Amino acid sequences encoded by individual phage clones from the 
T1E(44-48) library after three rounds of selection for ErbB3 binding*.
* The consensus sequence represents the amino acids that are present in more than 
40% of the selected clones. Ar = aromatic; Hp = hydrophobic.
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Table 2c. Amino acid sequences encoded by individual phage clones from the 
T1E(44-48) library after three rounds of selection for ErbB4 binding*.
* The consensus sequence represents the amino acids that are present in more than 
40% of the selected clones.
107
Negative constraints underlie the ErbB specifi city of EGF-like ligands 
Table 2d. Amino acid sequences encoded by individual phage clones from the 
T1E(44-48) library after two rounds of selection for ErbB3 binding and one 
subsequent round of selection for ErbB4 binding*.
* Individual phage clones obtained after two rounds of selection on ErbB3 and one 
on ErbB4, were tested for binding affi nity to ErbB1, ErbB3 and ErbB4. Sequences of 
variants that showed high binding affi nity to all three receptors are indicated in white, 
others in gray. The consensus sequence represents the amino acids that are present in 
more than 40% of the selected clones indicated in white.
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Figure 1.
Binding characteristics of 
T1E(44-48) phage pool after 
the 2nd round of selection 
on ErbB3 and ErbB4 and the 
subsequent ErbB3-ErbB4 
cross selection. Second round 
ErbB3 (—¢—), second round 
ErbB4 (—�—) and phage 
pool selected for two rounds 
on ErbB3 (——) and for one 
round on ErbB4 (——).
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Figure 2 a. Displacement of 10 ng/ml [125I]T1E/YYDLL by NRG1β (——) and 
BTC (—�—) on D23 cells expressing ErbB2 and ErbB3, showing that BTC at the 
concentrations used is unable to bind ErbB3. b: Displacement of 10 ng/ml [125I]-
T1E/YYDLL by NRG1β (——) and TGFA (—r— ) on D24 cells expressing ErbB2 
and ErbB4, showing that TGFA at the concentrations used is unable to bind ErbB4. 
For determining the ligand specifi city of ErbB3 and ErbB4, cells were used that 
coexpress ErbB2, since this is known to enhance the affi nity of the competing 
ligands.
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Epidermal growth factor mutant 
with wild-type affinity for both 
ErbB1 and ErbB3 
Biochemistry, 45, 4703-4710 (2006)
Miriam Wingens, Saskia Jacobs-Oomen, Sebastian P. van 
der Woning, Catelijne Stortelers and Everardus J.J. van 
Zoelen
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ABSTRACT 
 The family of epidermal growth factor (EGF)-like ligands binds to 
ErbB receptors in a highly selective manner. Previous studies indicated that 
both linear regions of the ligand play a major role in determining receptor 
selectivity, and phage display studies showed that each region could be 
optimized independently for enhanced affi nity. In this study we broadened 
the ErbB binding specifi city of EGF by introducing the optimal sequence 
requirements for ErbB3 binding in both the N- and C-terminal linear region. 
One such EGF mutant, designated WVR/EGF/IADIQ, gained high affi nity 
for ErbB3 and showed concomitant ErbB3 activation through ErbB2/ErbB3 
heterodimers similar to the natural ErbB3 ligand NRG1β, while the capacity to 
bind and activate ErbB1 was fully maintained. Despite its high affi nity for ErbB1 
and ErbB3, this mutant was unable to activate ErbB1/ErbB3 heterodimers, as 
shown by cell survival and receptor phosphorylation analysis. It is concluded 
that, despite the fact that no naturally occurring ligand exists with this dual-
specifi city, high affi nity binding to both ErbB1 and ErbB3 is not mutually 
exclusive. This mutant can be useful in a direct structural comparison of the 
ligand binding characteristics of ErbB1 and ErbB3.
INTRODUCTION
 The ErbB signaling network consists of a family of peptide ligands 
that bind and activate the ErbB tyrosine kinase receptors ErbB1 (or EGFR), 
ErbB2 (or HER2/Neu), ErbB3 (or HER3), and ErbB4 (or HER4). Ligand binding 
is followed by receptor homo- or heterodimerization, receptor tyrosine 
phosphorylation, and the subsequent recruitment of cytoplasmic molecules, 
thereby initiating a cascade of signaling events (1, 2). The resulting biological 
responses play an important role in the proliferation and differentiation of 
almost all cell types in development. Overexpression of both receptors and 
ligands has been found particularly in epithelial cancers (3) and as a result the 
ErbB signaling network is currently one of the main targets in the development 
of anti-tumor drugs (4, 5).
 Ligand binding is highly receptor specifi c and can be categorized 
into three distinct groups. A fi rst group of ligands, composed of epidermal 
growth factor (EGF), transforming growth factor-α (TGFα), amphiregulin 
(AR), and epigen (EPG), binds only ErbB1. A second group is composed of the 
neuregulins (NRG) with their multiple isoforms, of which NRG1 and NRG2 bind 
both ErbB3 and ErbB4, while NRG3 and NRG4 bind exclusively ErbB4. A third 
group, consisting of epiregulin (EPR), betacellulin (BTC), and heparin-binding 
EGF (HB-EGF), binds both ErbB1 and ErbB4 (6, 7).
 The observation that no natural ligand exists that binds both ErbB1 
and ErbB3, suggests that these two receptors have diverged most during 
evolution in their ligand binding requirements. Important information on the 
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interaction of EGF-like growth factors with ErbB receptors and the mechanism 
of ErbB dimerization has been derived from crystallographic studies on the 
extracellular domain of ErbB1 and ErbB3 (8-11).  In the absence of ligand, 
ErbB3 shows an auto-inhibited conformation maintained by interaction 
between subdomains II and IV. Upon ligand binding to both subdomains 
I and III the receptor conformation changes and the interaction between 
subdomains II and IV is released, as a result of which subdomain II becomes 
available for dimerization with another receptor. In the ligand-bound form 
of ErbB1, the B-loop region of EGF and TGFα, and in the case of TGFα also 
the linear N-terminus, interacts with subdomain I, whereas residues in the 
A-, C-loop and linear C-terminus are in close contact with subdomain III. 
Mutagenesis studies have indicated that particularly residues that interact 
with subdomain III are essential for high affi nity binding to ErbB1 (12-14). 
In contrast, studies on NRG1β have shown that hydrophobic residues in the 
linear N-terminus and B-loop region are important for binding to ErbB3 (15-
17).  Assuming that all EGF-like ligands bind their respective ErbB receptor 
in a similar orientation, this suggests that in the case of ErbB3 particularly 
binding to subdomain I is essential for high affi nity binding. This hypothesis 
is supported by the observation that NRG1β can bind to a soluble fragment of 
ErbB3, which contains subdomain I but not subdomain III (18). Thus, EGF-like 
ligands comprise multiple binding domains for interaction with either domain I 
or domain III of their respective receptor, and the relative contribution of each 
interaction may vary between different receptor-ligand combinations.
 Previous work has indicated that mutant forms of EGF are not only 
able to bind ErbB1, but also ErbB3. In particular the chimeras T1E and 
biregulin, in which the N-terminus of EGF has been replaced by TGFα or 
NRG residues, respectively, exert high affi nity for cells containing both ErbB2 
and ErbB3, although they show only low affi nity for ErbB3 alone (19, 20). 
Subsequently, we have used a phage display strategy to optimize the binding 
affi nity of EGF-like growth factors for ErbB3. In the linear N-terminal region 
of EGF enhanced binding affi nity for ErbB3 could be obtained by exchanging 
the wild-type sequence S2/D3/S4 into W2/V3/R4 (21). Within the C-terminal 
region of T1E, the binding affi nity for ErbB3 could be strongly enhanced by 
introducing the sequence IFDWA or IADIQ at positions 44-48, instead of the 
wild-type sequence YRDLK (22). Thus these phage-bound variants differed 
from T1E in that they exerted also high affi nity to ErbB3 in the absence of 
ErbB2.
 In the present study we have combined the optimal sequences from 
the phage display studies in order to construct a recombinant EGF mutant 
with dual-specifi c high affi nity for both ErbB1 and ErbB3. Our results show 
that particularly WVR(2-4)/EGF/IADIQ(44-48) competes not only effectively 
with EGF for binding to ErbB1, but also with NRG1β for binding to ErbB3. 
This mutant is a strong activator of ErbB1 homodimers and of ErbB2-
ErbB3 heterodimers, but unlike NRG1β it is unable to activate ErbB1-ErbB3 
heterodimers in cells that coexpress ErbB1 and ErbB3, most likely because 
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it preferentially induces the formation of ErbB1 homodimers. Despite a low 
affi nity for ErbB4, this mutant is also able to induce growth stimulation of cells 
containing this receptor. These results indicate that linear N- and C-terminal 
region of EGF-like growth factors cooperate to direct ErbB receptor binding 
specifi city.
MATERIALS AND METHODS
Cell lines and cell culture
 T47-14 (a gift of M. H. Kraus, Birmingham, USA) and HER14 cells 
were cultured in gelatin-coated fl asks in Dulbecco’s modifi ed Eagle’s medium 
(Invitrogen) supplemented with 10% newborn calf serum (NCS). Interleukin 
(IL)-3 dependent murine 32D hematopoietic progenitor cells transfected with 
distinct human ErbB-encoding viral vectors or plasmids (a gift of Y. Yarden, 
Rehovot, Israel) were cultured in RPMI-1640 medium supplemented with 
10% heat-inactivated fetal calf serum (Invitrogen) and 0.5 ng/ml murine IL-
3 (R&D Systems). The 32D sublines used, designated D3 (containing 1.1 x 
104 ErbB3 receptors/cell), D13 (containing 4.8 x 104 ErbB1 receptors/cell and 
1.1 x 104 ErbB3 receptors/cell), D23 (containing ErbB2 and 1.3 x 104 ErbB3 
receptors/cell), and D24 (containing ErbB2 and ErbB4 receptors) were kept 
under continuous selection using 0.6 mg/ml G418 (Invitrogen) and, in the 
case of D13 and D23 cells, in addition 0.4 mg/ml hygromycin B (Invitrogen) 
(23).
 
DNA constructs
 Recombinant mutants of human EGF were constructed by PCR 
techniques using a gene construct encoding synthetic human EGF[1-53] as a 
template (24). The gene was linked at the 5’ end to an IEGR encoding peptide 
sequence corresponding to the recognition sequence for the proteolytic 
enzyme factor Xα and subsequently to a sequence encoding two synthetic 
protein A-derived IgG-binding domains (Z-domains) by cloning into the 
expression vector pEZZ18 (Pharmacia) (25). The exact DNA sequence was 
verifi ed by cycle sequencing (Perkin-Elmer).
 A gene construct encoding the NRG1β EGF-like domain from serine 
177 to serine 228 (a gift from Genentech Inc., San Francisco, CA) was used 
as a template to construct a NRG1β mutant optimized for binding to ErbB3 by 
means of splice overlap extension (SOE)-PCR (26). This mutant, here referred 
to as NRG1b-opt (for sequence see Figure 1), is also known in the literature as 
HRG-58 (17). Primers containing the desired mutations were obtained from 
Eurogentec. After cloning into the pCR2.1 vector (Invitrogen) and sequencing 
(Perkin Elmer), the DNA construct was ligated as an XhoI-SalI fragment into 
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the expression vector pPICZαA (Invitrogen). Subsequently, the expression 
vector was transformed into E.coli XL-2 Blue cells, selected on Zeocin and 
sequenced.
Expression and purifi cation of growth factors 
 
 Recombinant mutant EGF-like growth factors were expressed as 
protein A-tagged fusion proteins in the proteinase K-defi cient E.coli strain 
KS474 and isolated from the periplasmic fraction, as described (25). 
Briefl y, growth factors were isolated by affi nity chromatography using IgG-
sepharose, followed by factor X cleavage of the protein A-tag, an additional 
round of affi nity chromatography to remove the tag, and a fi nal reverse phase 
(RP)-HPLC purifi cation step. The amount of growth factor was calculated from 
the peak area (absorption at 229 nm) in the RP-HPLC chromatogram, using 
natural mEGF as a standard.
 Recombinant NRG1b-opt was expressed in Pichia pastoris as described 
previously (27). In brief, expression of recombinant NRG1β-opt was induced 
by growing a selected Mut+ clone on BMMY (1% yeast extract, 2% peptone, 
100 mM potassium phosphate pH 6.0, 1.34% YNB, 0.04% biotin, and 0.5% 
methanol) for four days at 30ºC with additional supplies of methanol every 
day. NRG1β-opt was purifi ed from the collected culture medium by cation 
exchange chromatography (SP-550, Tosoh Biosciences). After dialysis against 
0.5 M HAc, a fi nal RP-HPLC purifi cation step was performed (27).
Ligand binding displacement experiments 
 
 Natural mEGF (Bioproducts for Science Inc.), recombinant  NRG1β-opt 
and WVR/EGF/IADIQ were radiolabeled using the Iodogen method (Pierce) 
according to the manufacturer’s protocol for indirect labeling. NRG1b-opt was 
used in ligand binding displacement experiments on cells expressing ErbB3 
or ErbB4, because this high affi nity human NRG mutant is much more stable 
as radiolabeled ligand than the natural NRG1β, most likely because of the 
mutation of a methionine into isoleucine at the position equivalent to Leu47 in 
EGF. Ligand binding displacement studies on HER14 cells and 32D cells were 
performed as described previously (19, 25). Briefl y, HER14 cells were grown 
to confl uency and serial dilutions of unlabeled growth factors were added in 
the presence of 1 ng/ml of [125I]-mEGF. After incubation for 2 h, cells were 
washed three times with phosphate-buffered saline (PBS) to remove unbound 
label, and incubated for 1 h in 1% Triton X-100 at room temperature prior 
to γ–counting. For D3, D13, and D23 cells, serial dilutions of growth factors 
were added in the presence of 1 ng/ml of [125I]-NRG1β-opt and incubated 
for 2 h at 4ºC, after which unbound label was removed by centrifugation of 
the cells through a serum cushion. Cell bound radio-activity was measured 
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by γ–counting. In the case of [125I]-WVR/EGF/IADIQ binding to D13 cells, 
radiolabeled ligand was added at 10 ng/ml.
Cell proliferation assay 
 For cell survival assays, D13, D23, and D24 cells were washed in 
RPMI-1640 medium to deprive them from IL-3. Subsequently, cells were 
seeded into 96-well tissue culture plates at a density of 5.0 × 104 cells/well 
in 0.1 ml of RPMI supplemented with 0.1% BSA, together with serial dilutions 
of recombinant growth factors. Cell survival was determined after 24 h of 
incubation at 37ºC using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay, as described previously (28).
 For mitogenic stimulation assays, HER14 and T47-14 cells were 
seeded into 24-wells plates at a density of 6.0 x 104 HER14 cells/well or 1.5 
x 105 T47-14 cells/well, and grown for 24 h in serum-containing medium. 
The cells were serum-starved for 48 h, and subsequently serial dilutions of 
growth factor were added in 100 ml DMEM/BES. After 8 h (HER14) or 20 h 
(T47-14), 0.5 mCi of [3H]-thymidine (TdR) was added in 50 ml of Ham’s F12 
medium and incorporation of [3H]-TdR was determined 24 h after growth 
factor induction. Cells were then washed twice with PBS and incubated with 
methanol at room temperature. After 15 min the methanol was aspirated, 
and the dried cells were lysed in 1.0 ml of 0.2 N NaOH for 30 min at 37ºC as 
described (29). [3H]-TdR incorporation was determined by liquid scintillation 
counting.
Western blotting 
 32D cells were serum-starved for 2 h prior to stimulation. Cells were 
exposed to growth factors for 3 h at 37 ºC and subsequently lysed in RIPA 
buffer containing freshly added protease inhibitors (50 mM Tris-HCl pH 8.0, 
150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 1.5 mM EGTA, 
1.5 mM MgCl2, 1 mM PMSF, 5 mg/ml pepstatin A, 0.15 units/ml aprotinin, 
5 mg/ml leupeptin, 2 mM Na3VO4). Lysates were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 8% 
polyacrylamide gels, and proteins were transferred to 0.45 mm nitrocellulose 
membranes at 300 mA for 1 h. Nonspecifi c binding sites were blocked by 
incubation for 1 h with 5% nonfat dry milk in Tris/HCl-buffered saline/Tween 
(TBST; 10 mM Tris, 137 mM NaCl, 0.1% Tween-20, pH 7.6). The membrane 
was then incubated overnight with a fi rst antibody (1:2500 dilution in 5% 
nonfat dry milk in TBST or 5% bovine serum albumin in TBST) at 4 ºC, 
followed by a 1 h incubation with a peroxidase-conjugated secondary antibody 
(1:5000 dilution in 5% nonfat dry milk in TBST). After each incubation step, 
blots were washed three times in TBST with constant agitation. Blots were 
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developed using the enhanced chemi-luminescence (ECL) method. Standard 
molecular weight markers (range: 10-250 kDa; BioRad) were exposed to 
the same procedure. Antibodies used in this study are: anti-phosphorylated 
HER3/ErbB3 (Tyr1289) monoclonal antibody and anti-phosphorylated Akt 
(Ser473) polyclonal antibody, both from Cell Signaling Technology.
RESULTS
Generation of an EGF mutant with wild type affi nity for ErbB1 and ErbB3 
receptors
 Previous phage display studies have shown that the binding affi nity of 
EGF and of the EGF/TGFα chimera T1E for ErbB3 can be strongly enhanced by 
optimization of residues in both the N-terminal and C-terminal linear region. 
In the present study we have combined the optimized sequences of both 
linear regions from these phage display studies to construct recombinant 
EGF mutants with high affi nity for both ErbB3 and ErbB1. Figure 1 shows 
the amino acid sequence alignment of the mutants used in this study. The 
generated mutants, which will be referred to as WVR/EGF/IFDWA and WVR/
EGF/IADIQ, were produced as recombinant proteins in E.coli and tested for 
activity as fully purifi ed, homogeneous proteins.
 To analyze the effects of the introduced mutations on the affi nity for 
ErbB1, a receptor binding competition study with [125I]-mEGF was carried 
out on HER14 cells, a 3T3 cell line overexpressing human ErbB1. Figure 2A 
demonstrates that WVR/EGF/IADIQ shows similar ligand binding competition 
as wild type EGF. In contrast, WVR/EGF/IFDWA has only low binding affi nity 
for ErbB1, even when compared with T1E. Most likely this results from the 
absence of a leucine or isoleucine at position 47 of the IFDWA-mutant, which 
is known to be essential for high affi nity ErbB1 binding (13, 14, 30). No [125I]-
mEGF binding competition was observed with NRG1b or its affi nity optimized 
mutant form NRG1β-opt (data not shown).
 Figure 2B shows displacement curves for binding of [125I]-NRG1β-opt 
to 32D cells expressing ErbB3 (D3 cells). The data show that WVR/EGF/IADIQ 
Figure 1. Alignment of amino acid sequences of hEGF, the EGF-like domain of 
human NRG1β, and the mutants used in this study.
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competes for ErbB3 binding with near similar affi nity as unlabeled NRG1β 
(half maximum concentration around 200 ng/ml), while EGF is fully inactive. 
T1E showed only low binding affi nity, in agreement with previous data (19), 
while WVR/EGF/IFDWA behaved very similar to T1E. Unlabeled NRG1β-opt 
itself competed on these cells with a half maximum concentration of 10 ng/ml 
(not shown). In the case of 32D cells expressing both ErbB2 and ErbB3 (D23 
cells), WVR/EGF/IADIQ and NRG1β showed again high binding affi nity, while 
EGF and WVR/EGF/IFDWA showed no or only low binding affi nity, as shown in 
Figure 2C. Thus, WVR/EGF/IADIQ has similarly high affi nity as EGF for binding 
Figure 2. Ligand binding displacement 
analysis on cells expressing different 
ErbB receptors. (A) Displacement 
of [125I]-mEGF binding to HER14 
cells expressing human ErbB1; (B) 
Displacement of [125I]-NRG1β-opt 
binding to 32D cells expressing 
ErbB3 (D3 cells); (C) Displacement of 
[125I]-NRG1β-opt binding to 32D cells 
expressing ErbB2 and ErbB3 (D23 
cells). Cells were incubated for 2 h 
at 4ºC with radiolabeled ligand in the 
presence of serial dilutions of unlabeled 
EGF (closed triangles), NRG1β (open 
squares), T1E (open circles), mutant 
WVR/EGF/IADIQ (closed circles), or 
mutant WVR/EGF/IFDWA (asterisks). 
Experiments were performed three 
times in duplicate, and are presented 
as mean ± sem.
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to ErbB1, and as NRG1β for binding to ErbB3 and ErbB2-ErbB3 heterodimers. 
In this respect WVR/EGF/IADIQ therefore differs from T1E and biregulin 
which bind with high affi nity to ErbB1 and ErbB2-ErbB3, but show only low 
binding affi nity for ErbB3 alone. In contrast, the mutant WVR/EGF/IFDWA 
showed only low binding affi nity to both ErbB1 and ErbB3, in spite of the 
fact that both the WVR sequence in the N-terminal and the IFDWA sequence 
in the C-terminal linear region gave rise to enhanced ErbB3 affi nity in EGF 
mutants bound on phage. This indicates that sequences derived from affi nity 
selected phage mutants cannot always be combined to produce recombinant 
EGF mutants with enhanced receptor affi nity. 
WVR/EGF/IADIQ effi ciently activates both ErbB1 and ErbB3 receptors, but is 
unable to induce ErbB1-ErbB3 heterodimers 
 To test the ability of WVR/EGF/IADIQ to induce cell proliferation, 
mitogenic stimulation and cell survival assays were performed on cells 
carrying either ErbB1 or ErbB3 receptors. Figure 3A shows that WVR/EGF/
IADIQ is equally potent as EGF in inducing [3H]-thymidine incorporation into 
HER14, while NRG1β is fully inactive.
 ErbB3 has an impaired kinase activity, and therefore its biological 
activity can only be assayed in cells containing a heterodimeric partner such 
as ErbB2. Figure 3B shows that WVR/EGF/IADIQ is even more potent than 
NRG1b in inducing cell survival of 32D cells containing both ErbB2 and ErbB3 
(D23 cells), while EGF is fully inactive in this assay. In combination, these 
data show that the mutant WVR/EGF/IADIQ is at least as active as wild-type 
ligands in activating both ErbB1 and ErbB3 receptors, in agreement with the 
wild-type affi nity of this mutant for both receptor members. In parallel with 
its low binding affi nity for ErbB3, WVR/EGF/IFDWA appeared only a poor 
activator of ErbB2/ErbB3 heterodimers (data not shown).
 Previous ErbB tyrosine phosphorylation assays have indicated that 
NRG1β is able to induce the formation of ErbB1/ErbB3 heterodimers in 
absence of an ErbB1 binding ligand (31). Since WVR/EGF/IADIQ can bind 
both receptors with high affi nity, we examined if this mutant can induce 
the formation of ErbB1/ErbB3 heterodimers. Binding analysis on 32D cells 
carrying exclusively ErbB1 and ErbB3 (D13 cells), revealed that WVR/EGF/
IADIQ fully competes with [125I]-EGF for binding to ErbB1 (Figure 4A), and 
with [125I]-NRG1β-opt for binding to ErbB3 (Figure 4B). This demonstrates 
that WVR/EGF/IADIQ can bind to both ErbB1 and ErbB3 on these cells. In 
order to show that this ligand can bind each of these receptors at the same 
time, [125I]-WVR/EGF/IADIQ was added to D13 cells at a concentration of 
10 ng/ml to occupy the majority of available receptors. Figure 4C shows 
that upon subsequent addition of unlabeled WVR/EGF/IADIQ full binding 
competition was obtained, compared to only 75-80% binding competition 
with saturating concentrations of EGF and 20-25% binding competition with 
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saturating concentrations of NRG1β. This shows that WVR/EGF/IADIQ is able 
to bind both receptors on these cells, and is selectively removed from ErbB1 
by EGF and from ErbB3 by NRG1β. Quantitatively, these data agree with the 
known four-fold excess of ErbB1 over ErbB3 receptors in the cell line.
 Figure 5A shows in an MTT assay that NRG1β is a potent inducer of cell 
survival in D13 cells, as a result of the formation of  ErbB1/ErbB3 heterodimers 
in which only ErbB3 is ligand-occupied. EGF itself is much less potent in the 
this assay than NRG1β, particularly at concentrations above 10 ng/ml, which 
indicates that in these cells NRG-induced ErbB1/ErbB3 heterodimers generate 
more potent survival signals than EGF-induced ErbB1 homodimers. Figure 5A 
also shows that WVR/EGF/IADIQ is unable to induce the potent cell survival 
levels of NRG1β in D13 cells, but instead mimics the behavior of EGF. This 
indicates that WVR/EGF/IADIQ may bind both ErbB1 and ErbB3 in these cells, 
but is unable to form functional ErbB1/ErbB3 heterodimers. The low affi nity 
mutant WVR/EGF/IFDWA induced similar effects as EGF and WVR/EGF/IADIQ, 
but only when added at elevated concentrations (data not shown).
 To examine if ligand binding to ErbB1 interferes with the NRG1β-
induced ErbB1/ErbB3 heterodimer formation, we administered NRG1β in 
combination with either EGF or WVR/EGF/IADIQ to D13 cells. Figure 5B shows 
that WVR/EGF/IADIQ behaves similar to EGF and is able to impair the NRG1β-
induced high cell survival in D13 cells in a dose-dependent manner, with a 
Figure 3. Survival and proliferation 
analysis on cells expressing different 
ErbB receptors. (A) Mitogenic stimulation 
of HER14 cells expressing human ErbB1 
as monitored by incorporation of [3H]-
thymidine between 8 and 24 h after ligand 
addition; (B) Cell survival of 32D cells 
expressing both ErbB2 and ErbB3 (D23 
cells) as measured in an MTT assay after 
24 h. Cells were serum-starved before 
addition of serial dilutions of EGF (closed 
triangles), NRG1β (open squares), or the 
mutant WVR/EGF/IADIQ (closed circles). 
Experiments were performed twice in 
duplicate, and a representative experiment 
is shown.
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half maximum effect at 1-2 ng/ml. Pretreatment of D13 cells with NRG1β for 
1 h did not affect the inhibitory effect of EGF or WVR/EGF/IADIQ (data not 
shown). So, in spite of the fact that WVR/EGF/IADIQ can bind both ErbB1 and 
ErbB3, it is unable to mimic and even blocks the cell survival signals induced 
by NRG1β in D13 cells. Most likely both EGF and WVR/EGF/IADIQ induce 
the formation of ErbB1 homodimers in these cells and thereby inhibit the 
formation of NRG1β-induced ErbB1/ErbB3 heterodimers. 
 Figure 6 (upper panel) shows that NRG1β is able to induce tyrosine 
phosphorylation of ErbB3 in D13 cells, most likely as a result of activation of 
Figure 4. Ligand displacement analysis 
on 32D cells expressing both ErbB1 and 
ErbB3 (D13 cells). (A) Displacement of 
[125I]-mEGF binding by unlabeled EGF 
(closed triangles), NRG1β (open squares), 
or the mutant WVR/EGF/IADIQ (closed 
circles). Cells were incubated for 2h at 
4ºC with 1 ng/ml radiolabeled ligand in 
the presence of serial dilutions of the 
above unlabeled growth factors. Unbound 
ligand was removed by sedimentation 
of the cells through a serum cushion, 
after which cell-bound radioactivity was 
determined. (B) Displacement of 1 ng/ml 
of [125I]-NRG1β-opt binding by unlabeled 
EGF, NRG1β or WVR/EGF/IADIQ (symbols 
as above). (C) Displacement of [125I]-
WVR/EGF/IADIQ binding by unlabeled 
EGF, NRG1β or WVR/EGF/IADIQ (symbols 
as above). Cells were incubated with 
10 ng/ml of  [125I]-WVR/EGF/IADIQ to 
saturate available ErbB1 and ErbB3 
receptors. Experiments were performed 
three times in duplicate, and are 
presented as mean ± sem.
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the ErbB1 tyrosine kinase in the ErbB1/ErbB3 complex. Upon addition of EGF, 
the NRG1β-induced phosphorylation of ErbB3 decreased in a dose-dependent 
manner, whereas the downstream Akt phosphorylation remained unchanged. 
This indicates that EGF is indeed able to dissociate ErbB1 receptors from 
existing ErbB1/ErbB3 heterodimers, in favor of the formation of ErbB1 
homodimers. Figure 6 (lower panel) shows that WVR/EGF/IADIQ on its own 
is unable to induce ErbB3 tyrosine phosphorylation in these cells. So although 
WVR/EGF/IADIQ can bind to both ErbB1 and ErbB3 independently, it is unable 
to form a functional ErbB1/ErbB3 heterodimeric complex. This fi gure also 
shows that WVR/EGF/IADIQ mimics EGF in its ability to block NRG1β-induced 
phosphorylation of ErbB3 in a dose-dependent manner, which indicates 
that in D13 cells WVR/EGF/IADIQ binds both ErbB1 and ErbB3, but only 
signals through ErbB1 homodimers. It thus appears that active ErbB1/ErbB3 
heterodimers are exclusively formed when ErbB3 is present in its liganded 
form and ErbB1 as coreceptor in an unliganded conformation.
Figure 5. Growth factor- induced survival 
of 32D cells expressing both ErbB1 and 
ErbB3 (D13 cells). Growth factors were 
added to serum-starved D13 cells, and 
cell survival was measured after 24 h 
in an MMT assay. (A) Addition of  serial 
dilutions of EGF (closed triangles), NRG1β 
(open squares), or the mutant WVR/EGF/
IADIQ (closed circles). (B) Combined 
addition of 50 ng/ml of NRG1β with 
serial dilutions of EGF (closed triangles), 
the mutant WVR/EGF/IADIQ (closed 
circles), or without additional ligand (open 
squares). Experiments were performed 
twice in duplicate, and a representative 
experiment is shown.
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WVR/EGF/IADIQ can induce proliferation via ErbB4 
 Since the requirements in NRG1 for ErbB3 and ErbB4 binding 
are largely overlapping, we next analyzed the binding and activation 
characteristics of WVR/EGF/IADIQ towards cells expressing ErbB4. In 
ligand binding displacement experiments on T47-14 cells, a 3T3 cell line 
overexpressing human ErbB4, and D24 cells, which contain both ErbB4 and 
ErbB2, we did not detect any displacement of [125I]-NRG1β-opt binding by 
WVR/EGF/IADIQ up to concentrations of 500 ng/ml (data not shown). In spite 
of this very low binding affi nity for ErbB4, we observed that WVR/EGF/IADIQ 
induced similar mitogenic activity in T47-14 cells as NRG1β, while EGF was 
inactive (Figure 7A). Moreover, in D24 cells WVR/EGF/IADIQ induced similar 
cell survival levels as NRG1β, while EGF was only weakly active (Figure 7B). 
So, in spite of its low binding affi nity WVR/EGF/IADIQ is able to activate signal 
transduction pathways through ErbB4. In combination with the above data it 
thus appears that WVR/EGF/IADIQ behaves similar to NRG1β and unlike EGF 
in ErbB4 containing cells (D24 and T47-14), whereas in D13 cells it behaves 
similar to EGF and unlike NRG1β.
Figure 6. Growth factor-induced inhibition of NRG1β-induced ErbB3 activation in 
cells expressing ErbB1 and ErbB3 (D13 cells). Cells were stimulated for 3 h without 
(-) or with 50 ng/ml (+) of either NRG1β, EGF or WVR/EGF/IADIQ; in addition 
cells were treated with a combination of 50 ng/ml of NRG1β (+) and increasing 
concentrations (0.1-0.25-0.5-0.75-1.0-2.5-5-10-25-50 ng/ml) of EGF (upper 
lane) or WVR/EGF/IADIQ (lower lane). Immunoblotting of whole cell lysates was 
performed with an anti-p-ErbB3 antibody or an anti-p-Akt antibody.
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DISCUSSION
 In this study we show that the N- and C-terminal linear regions of EGF-
like growth factors play an important role in their receptor binding specifi city. 
An EGF mutant containing N-terminal and C-terminal sequences optimized for 
ErbB3 binding, designated WVR/EGF/IADIQ, gained wild-type affi nity for cells 
expressing ErbB3, while it maintained wild-type affi nity for ErbB1. Similar to 
the natural ligands, this dual-specifi c mutant is fully capable to activate ErbB1 
homodimers and ErbB2/ErbB3 heterodimers, while it is also active on cells 
expressing ErbB4. In cells expressing both ErbB1 and ErbB3, WVR/EGF/IADIQ 
could compete with both EGF and NRG1β for receptor binding, but induced 
only EGF-like survival activity, most likely because it prefers the formation 
of ErbB1 homodimers over ErbB1/ErbB3 heterodimers. Apparently the dual-
specifi c binding property of this mutant does not contribute to the formation of 
functional ErbB1/ErbB3 heterodimers. These data furthermore show that high 
affi nity binding to both ErbB1 and ErbB3 is not mutually exclusive, in spite of 
the fact that no naturally occurring ligand exists with this dual specifi city.
 From site-directed mutagenesis studies on EGF and TGFα, much 
information is known about residues that are essential for high affi nity binding 
to ErbB1 (12-14). In the linear C-terminal region particularly the leucine at 
position 47 is of central importance. For binding to ErbB3, we observed in 
Figure 7. Survival and proliferation 
analysis on cells expressing only ErbB4 
(T47-14) or 32D cells expressing 
both ErbB4 and ErbB2 (D24). (A) 
Mitogenic stimulation of T47-14 cells 
as monitored by incorporation of 
[3H]-thymidine between 8 and 24 h 
after ligand addition; (B) Cell survival 
of D24 cells as measured in an MTT 
assay 24 h after ligand addition. Cells 
were serum-starved before addition 
of serial dilutions of EGF (closed 
triangles), NRG1β (open squares), or 
the mutant WVR/EGF/IADIQ (closed 
circles). Experiments were performed 
twice in duplicate, and a representative 
experiment is shown.
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our phage display study a preference for isoleucine or tryptophan at the 
equivalent position (22). The observation that WVR/EGF/IADIQ retained 
wild-type affi nity for ErbB1 whereas WVR/EGF/IFDWA showed strongly 
decreased affi nity, results therefore most likely from the fact that at position 
47 a tryptophan is much less well tolerated than an isoleucine for high affi nity 
ErbB1 binding. The observation that WVR/EGF/IFDWA is only a low affi nity 
ligand for ErbB3 is puzzling, since the N-terminal sequence WVR and the C-
terminal sequence IFDWA have been selected individually in phage display 
studies as requirements for high binding affi nity to ErbB3.  
 Intriguingly, in spite of its high affi nity to both ErbB1 and ErbB3, 
WVR/EGF/IADIQ is unable to activate ErbB1/ErbB3 heterodimers. ErbB3 
differs from other ErbB members in that it has an impaired tyrosine kinase, 
and as a result it depends for activity on heterodimerization with another 
ErbB member. The orphan ErbB2 is the preferred coreceptor for ErbB3, and 
ErbB2 heterodimer formation strongly enhances the binding affi nity of ligands 
to ErbB3. As a consequence, even low affi nity ErbB3 ligands such as NRG1α, 
T1E and biregulin, are potent activators of ErbB2/ErbB3 heterodimers. 
However, only high affi nity ErbB3 ligands, such as NRG1β, are able to recruit 
ErbB1 as dimerization partner and to activate cells expressing both ErbB3 
and ErbB1, even in absence of ErbB2 (31). Since NRG1β has no detectable 
affi nity for ErbB1, this coreceptor must be present in an unliganded form in 
the ErbB1/ErbB3 complex. It remains unclear how ErbB1 is recruited into 
this complex. Crystallographic studies have shown that in the absence of 
ligand, ErbB receptors are in a closed conformation and thereby unable to 
dimerize. However, it has been suggested that a fraction of unliganded ErbB1 
receptors may already exist in an open although inactive conformation (32). 
It could be speculated that upon NRG1β binding ErbB3 receptors undergo a 
change from a closed to an open conformation, and subsequently are able 
to heterodimerize with available unliganded ErbB1 receptors in the open 
conformation. Formation of such a ErbB1/ErbB3 heterodimeric complex 
could subsequently stabilize the open conformation of ErbB1 and activate its 
tyrosine kinase. Although theoretically possible, ErbB1/ErbB3 heterodimeric 
complexes are not observed when ErbB1 and ErbB3 are both liganded, either 
by treatment with WVR/EGF/IADIQ or in the presence of both NRG1β and EGF. 
Pinkas-Kramarski and coworkers found that EGF is able to impair the NRG1β-
induced survival in D13 cells when added simultaneously, probably through 
a preference for ErbB1 homodimers (23). Here, we show that even existing 
ErbB1/ErbB3 heterodimeric complexes formed in the presence of  NRG1β are 
dissociated upon addition of EGF or WVR/EGF/IADIQ, although this latter 
ligand shows wild-type affi nity for both ErbB1 and ErbB3. It will be interesting 
to determine if the amount of ErbB1/ErbB3 heterodimeric complexes induced 
by NRG1β is indeed limited by the fraction of ErbB1 receptors that, in the 
unliganded state, is present in an open conformation.
 The ligand binding displacement curves in Figure 4A indicate that half-
maximum saturation of ErbB1 receptors in D13 cells requires 10-20 ng/ml of 
126
Chapter 4
EGF. In contrast, these concentrations of EGF are more than suffi cient to fully 
withdraw ErbB1 receptors from NRG1β-induced ErbB1/ErbB3 heterodimers, 
as shown in Figure 5B. This suggests that in the presence of 10-20 ng/ml of 
EGF, unliganded ErbB1 receptors are still present that are, however, unable 
to form heterodimers with NRG1β-bound ErbB3 receptors. One explanation 
could be that the unliganded ErbB1 receptors in the open conformation 
have a higher EGF binding affi nity than the bulk of ErbB1 receptors in the 
closed conformation, and that consequently relatively low concentrations of 
EGF are enough to bind this subset of receptors and induce them to form 
ErbB1 homodimers. Alternatively, ErbB1 receptors in the open conformation 
could obtain their enhanced binding affi nity due to the stabilization of their 
conformation in the ErbB1/ErbB3 complex. Finally, there is increasing 
evidence that ErbB receptors can be distributed in a heterogeneous manner 
in the plasma membrane, e.g. by accumulation in lipid rafts (33). It can 
therefore also not be excluded that ErbB3 receptors are present in membrane 
microdomains that also contain ErbB1 receptors with enhanced binding 
affi nity.   
 Crystallographic data in combination with site-directed mutagenesis 
studies have indicated that subdomain III of ErbB1 is essential for high 
affi nity binding of EGF, while in the case of ErbB3 subdomain I is of primary 
importance for NRG1β binding (12-18). This suggests that ErbB1 and ErbB3 
bind their ligands in a different manner. Crystal structures have been published 
of EGF- and TGFα-liganded ErbB1 receptors, but so far only the conformation 
of unliganded ErbB3 is known. Because of its high binding affi nity to both 
ErbB1 and ErbB3, WVR/EGF/IADIQ would be an ideal candidate to compare 
the ligand binding characteristics of ErbB1 and ErbB3 by studying their crystal 
structures bound to the same ligand.
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ABSTRACT
 EGF-like growth factors bind their ErbB receptors in a highly selective 
manner. Recently we have shown that the sequence YYDLL in the C-terminal 
linear region is compatible with binding to all ligand-binding ErbB receptors. 
In the present study we show that introduction of the YYDLL sequence into 
the ErbB1 specifi c ligands EGF and TGFα broadened their receptor specifi city 
towards ErbB4. Upon introduction of the YYDLL sequence into EREG, which 
by itself binds ErbB1 and ErbB4 but not ErbB3, its binding specifi city 
was broadened to ErbB3, concomitant with enhanced affi nity for ErbB4. 
Introduction of the YYDLL sequence into NRG1β resulted in a ten-fold increase 
in affi nity for ErbB3, without affecting its receptor specifi city. Remarkably, 
the strongly enhanced affi nity for ErbB3 negatively infl uenced their mitogenic 
activity towards cells coexpressing ErbB2 and ErbB3. These observations are 
discussed in terms of the optimized ErbB affi nity, selectivity and mitogenic 
potential that have taken place during evolution.  
INTRODUCTION 
 The epidermal growth factor (EGF) family of polypeptide growth 
factors and their corresponding ErbB receptors show an interesting pattern 
of evolutionary diversifi cation. The eleven growth factor and four receptor 
genes observed in mammals have evolved from a single receptor-ligand 
signaling complex, that is still present in invertebrates such as C. elegans. 
Studies on the structure-function relationship of EGF-like growth factors have 
indicated that during evolution optimisation of receptor binding specifi city 
has not coincided with optimisation of receptor binding affi nity (1-3). As a 
consequence, the molecular basis for receptor binding affi nity and specifi city 
of EGF-like growth factors is still poorly understood.  
The ErbB family of receptor tyrosine kinases consists of ErbB1, 
ErbB2, ErbB3 and ErbB4, which all play a crucial role in the growth control 
of mammalian cells and the development of multicellular organisms (4). 
Depending on their ErbB binding specifi city,  EGF-like growth factors can be 
divided into three subfamilies: EGF, transforming growth factor-α (TGFα), 
amphiregulin (AREG) and epigen (EPGN) form a subfamily that binds 
exclusively to ErbB1, while the subfamily consisting of betacellulin (BTC), 
epiregulin (EREG) and heparin-binding EGF (HB-EGF) binds not only ErbB1, 
but also ErbB4. Finally the neuregulins form a subfamily of which NRG1 and 
NRG2 bind both ErbB3 and ErbB4, while NRG3 and NRG4 appear specifi c 
for ErbB4 (5). ErbB2 does not bind ligand by itself, but is the preferred 
heterodimerization partner for all liganded ErbBs and is particularly important 
for ErbB3 signaling which has a defective tyrosine kinase domain (6). 
Phylogenetic tree analysis of vertebrate ErbB genes suggests that 
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during evolution an initial whole genome duplication has resulted in the 
generation of two receptor types, i.e. an ErbB1/ErbB2 ancestor and an 
ErbB3/ErbB4 ancestor (Stein and Staros 2000). A subsequent whole genome 
duplication has facilitated the formation of the current four distinct receptor 
genes. Based on similar analysis it has also been proposed that TGFα  and BTC 
have arisen from a common ancestor gene, similarly as AREG and HB-EGF, as 
well as EPGN and EREG (7). Remarkably in all these three cases the ancestral 
gene has evolved into a gene encoding an ErbB1–specifi c ligand and a gene 
encoding a ligand that binds both ErbB1 and ErbB4. Apparently, ligands and 
receptors have coevolved under evolutionary pressure to maintain multiple 
sets of ligands with similar ErbB binding diversity (1). 
EGF-like growth factors consist of approximately 50 amino acids and 
share a conserved spacing of six cysteines that form three disulphide bridges, 
thereby giving rise to an N-terminal linear region, an A-loop, B-loop and C-
loop, and a C-terminal linear region (8-9). From crystal structure analysis 
of the EGF/ErbB1 and the TGFα/ErbB1 complex, it is known that EGF-like 
growth factors contain approximately 20 residues that directly interact with 
their receptor (10-11). These residues, which we have referred to as positive 
constraints, form the basis for the observed high affi nity receptor interaction. 
However, in a previous study we have provided evidence that EGF-like 
growth factors contain in addition a limited number of residues that are not 
essential for high affi nity binding to their cognate receptor, but that prevent 
the unintended binding to other ErbB receptors (1). These residues, which we 
have referred to as negative constraints, appear to be conserved in evolution, 
and therefore we have hypothesized that negative constraints form the basis 
for the observed receptor specifi city of EGF-like growth factors (1). 
In previous studies we have identifi ed three such negative constraints 
in EGF and TGFα, which prevent them from binding to ErbB3 and ErbB4. Using 
domain-exchange strategies, we have shown that  mutation of Ser2/Asp3 in 
the N-terminal linear region of EGF into the corresponding residues His2/Phe3 
from TGFα is suffi cient to give EGF considerable affi nity for ErbB3 and ErbB4 
(2). Similarly the point mutation E26L in the B-loop of TGFα has been shown 
to broaden its affi nity to at least ErbB3 (12). Based on a phage display affi nity 
optimisation of the C-terminal linear region, we have recently shown that 
Arg45 in EGF facilitates binding to ErbB1, but acts as a negative constraint for 
binding to ErbB3 and ErbB4 (1). Moreover, we could show that the sequence 
YYDLL in the C-terminal linear region optimizes positive constraints and 
releases negative constraints for ligand binding to ErbB1, ErbB3 and ErbB4. 
Upon elimination of all known negative constraints from EGF, we subsequently 
designed a mutant designated T1E/YYDLL, which had lost all receptor binding 
selectivity and displayed high affi nity interaction with all ligand binding ErbB 
receptors. This designed ligand, also referred to as panerbin, appeared very 
useful for determination of the density of the various ErbB receptors on tumor 
cells in a single radio-receptor assay (1). 
In the present study we have investigated the role of the C-terminal 
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linear region on ErbB binding affi nity and specifi city in more detail. We 
therefore introduced the optimised sequence YYDLL into an number of 
naturally occurring EGF-like growth factors and studied the effects on ErbB 
affi nity and specifi city. Our results show that introduction of this sequence 
into NRG1β strongly enhanced its affi nity for ErbB3, without affecting 
receptor specifi city. In the case of the ErbB1-specifi c ligands EGF and TGFα, 
it broadened receptor specifi city towards ErbB4, without affecting their ErbB1 
binding affi nity. A combination of the two effects was observed for EREG, 
which by itself binds ErbB1 and ErbB4 with intermediate affi nity, but lacks 
affi nity for ErbB3. Upon introduction of the YYDLL sequence, EREG broadened 
its binding specifi city towards ErbB3 and enhanced its affi nity for ErbB4. Using 
homology modeling of receptor-ligand complexes we could show that EREG 
with its aberrant conformation (13) contains less positive constraints for ErbB 
binding, which in the case of ErbB3 and ErbB4 is enhanced upon introduction 
of the YYDLL sequence. These observations are discussed in terms of the 
molecular mechanisms that have resulted in optimization of ErbB binding 
affi nity, selectivity  and mitogenic potential, as has been maintained during 
evolution.
EXPERIMENTAL
Cell lines
 Interleukin 3-dependent murine 32D hematopoietic progenitor cells 
transfected with distinct human ErbB-encoding plasmids were cultured in 
RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf 
serum (Invitrogen) and 0.25 ng/ml interleukin-3 (Promega, Madison, WI) 
and subsequently kept under continuous selection using 0.6 mg/ml G418 
(Calbiochem). In this study we used D3 cells (32D cells transfected with the 
human ErbB3 gene), D23 cells (32D cells transfected with both the human 
ErbB2 and ErbB3 gene) and D24 cells (32D cells transfected with both the 
human ErbB2 and ErbB4 gene). HER14 cells (mouse fi broblasts overexpressing 
human ErbB1) and T47-14 cells (mouse fi broblasts overexpressing human 
ErbB4) were cultured in gelatinized fl asks in Dulbecco’s modifi ed Eagle’s 
medium (DMEM) supplemented with 10% newborn calf serum (NCS). 
MTT assay
 32D cells were deprived of interleukin-3 by washing and subsequently 
resuspended in serum-free RPMI 1640 medium supplemented with 0.1% 
bovine serum albumin (BSA). Cells were seeded in 96-wells plates at a 
density of 5.0x104 cells/well in a total volume of 0.1 ml, in the presence or 
absence of serial dilutions of recombinant growth factors. Cell survival was 
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determined after 24 hours of incubation at 37oC using the colorimetric 3-(4,5-
dimethylthiazzol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Two 
hours after the addition of 50 mg/well of MTT, cells were lysed in 0.1 ml acidic 
isopropanol and carefully resuspended. Plates were read at 550-655 nm, and 
duplicate data points were plotted as fold induction over untreated control 
wells. 
Mitogenic Assays
 DNA replication of T47-14 cells upon ligand stimulation was monitored 
by [3H]-thymidine incorporation. Cells were seeded in 24-wells plates at a 
density of 3.0×104 cells/well in 1 ml of DMEM supplemented with 10% NCS. 
After 24 hours, the medium was replaced by 1 ml of DF medium (1:1 mixture 
of DMEM and Ham’s F12 medium), supplemented with 30 nM Na2SeO3, 10 
μg/ml human transferrin, and 0.5% BSA. Cells were thus serum-starved for 
an additional 24 hours, after which serial dilutions of growth factors were 
added in 50 μl of BES-buffered DMEM/0.1%BSA (pH 6.8), as described (van 
der Burg and others 1988). Eight hours later, 0.5 μCi of [3H]-thymidine 
was added in 50 μl of Ham’s F12 medium, and incorporated thymidine was 
determined 24 hours after growth factor addition. Cells were incubated for 15 
min with methanol to remove non-incorporated cytoplasmic [3H]-thymidine 
and subsequently lysed by addition of 1 ml of 2 N NaOH for 1 hour at 37oC. 
Radioactivity was determined by liquid scintillation counting.
Expression and Purifi cation of Mutant Growth Factors
 Recombinant mutant growth factors were expressed as protein A-
tagged fusion proteins in the protease K-defi cient Escherichia coli strain KS474 
and isolated from the periplasmic space as described (14). Growth factors 
were purifi ed by means of affi nity chromatography using IgG-Sepharose, 
followed by Factor-X cleavage, an additional round of affi nity chromatography 
to remove the protein A-tag and a fi nal reverse phase (RP)-HPLC purifi cation 
step to remove disulphide bridge mismatches. The amount of growth factor 
was calculated from the peak area (absorption at 229 nm) in the RP-HPLC 
chromatogram, using natural mEGF as a standard. The affi nity for ErbB1 was 
measured in an [125I]-mEGF binding competition assay on HER14 cells. Affi nity 
for ErbB3 or ErbB4 was determined in an  [125I]-NRG1β binding competition 
assay on D3, D23 and D24 cells, respectively.
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Ligand Binding Displacement Experiments
 Recombinant EGF and NRG1β were radiolabeled enzymatically to a 
specifi c activity of 1.1 Ci/μmol (15). Ligand binding displacement analyses 
were performed either using a suspension of 5.0×106 32D cells or confl uent 
monolayers of HER14 or T47-14 cells. 32D cells were washed once with RPMI 
supplemented with 0.5% BSA and subsequently incubated for 2 hours at 4 
oC with serial dilutions of unlabeled ligand in the presence of 0.17 nM [125I]-
NRG1β. Cells were then washed once with binding buffer and loaded onto a 
serum cushion to remove the unbound label. Subsequently, cells were quickly 
spun down at 2000 rpm, and cell surface-bound radioactivity was determined 
by γ-counting. HER14 or T47-14 cells were grown to confl uency, and serial 
dilutions of unlabeled growth factors were added in the presence of 0.17 nM 
of [125I]-mEGF or 0.17 nM [125I]-NRG1β, respectively. After incubation for 2 
hours at 4 oC, the cells were washed three times with phosphate-buffered 
saline (PBS) in order to remove the unbound label and subsequently incubated 
for 1 hour in 1% Triton X-100 at room temperature prior to γ-counting.
Homology modeling of EREG in complex with ErbB receptors
 Homology models for ErbB-ligand complexes were based on the 
published crystal structures of the ErbB1-EGF and ErbB1-TGFα (10-11) 
complex as a template. Validation of the models with WHAT CHECK (Hooft 
and others 1996) identifi ed template 1MOX, obtained from the ErbB1-TGFα 
complex, as the best choice of both receptor and ligand. The amino acid side 
chains in the fi nal models were positioned using SCWRL (16). Subsequently, 
the models were refi ned in YASARE using Yamber2 force fi eld and associated 
protocol (17) until the WHAT IF (18) quality indicators (Ramachandran plot, 
backbone conformation, and three-dimensional packing quality) converged. 
For analysis of EREG in complex with ErbB receptors, use was made of the 
energy-minimized average NMR structure of EREG (PDB 1K37). For ErbB 
complexes with NRG1β and EREG/YYDLL the TGFα crystal structure 1MOX 
was used. Coordinate fi les of the fi nal models are available from the authors 
upon request. 
135
Role of the C-terminal linear region of EGF-like growth factors in ErbB specifi city
RESULTS
Exchange of the C-terminal linear region of EGF-like growth factors by YYDLL 
affects their ErbB affi nity and specifi city
 In order to investigate the effect of the C-terminal linear region on 
the ErbB specifi city and affi nity of EGF-like growth factors, we introduced the 
YYDLL sequence into EGF, TGFα, NRG1β, EREG and the EGF/TGFα chimera 
T1E, whereby the existing Glu or Gln residue following the sixth cysteine was 
maintained. T1E is an artifi cial ligand that consists of TGFα sequences N-
terminal and EGF sequences C-terminal of the fi rst cysteine (19). T1E/YYDLL 
has previously been characterised by us as a ligand that binds ErbB1, ErbB3 
and ErbB4 with high affi nity (1) .  
Figure 1A shows the ability of the wild-type ligands to compete with 
radiolabeled EGF for binding to the ErbB1 overexpressing cell line HER14. 
EGF, TGFα and T1E are high affi nity ligands for ErbB1, while EREG showed 
intermediate and NRG1β no affi nity for this receptor (see Table I for IC50 
values). Introduction of the YYDLL sequence (Figure 1B) hardly affected the 
binding affi nity of these ligands for ErbB1 (Table I), indicating that the wild-
type sequence of the C-terminal linear region of EGF and TGFα is already 
optimal for ErbB1 binding, while the affi nity of EREG and NRG1β for ErbB1 
appears to be limited by residues outside the C-terminal linear region.   
Figures 1C and 1D show the relative binding affi nity of this set 
of ligands for ErbB3, as measured in a binding competition assay with 
radiolabeled NRG1β to 32D cells expressing only ErbB3 (D3 cells). Of the wild 
type ligands only NRG1β showed clear binding affi nity, while upon introduction 
of the YYDLL sequence a considerable gain in affi nity was observed for EREG, 
T1E and NRG1β itself (Table I). On the other hand, EGF and TGFα did not 
show any affi nity for ErbB3, also not after introduction of the YYDLL sequence. 
Thus, both the unstructured N-terminal linear region of EGF and the presence 
of Glu26 in TGFα appears suffi cient to prevent the unintended binding to 
ErbB3. The observation that introduction of YYDLL into NRG1β resulted in a 
more than ten-fold increase in affi nity for ErbB3, leading to an extremely low 
IC50 of 0.06 nM, confi rms previous studies that the affi nity of NRG1β for its 
native receptor ErbB3 can be strongly increased by optimizing its C-terminal 
sequences (2). It remains unclear, however, why not a similar increase in 
affi nity is observed for binding to ErbB2/ErbB3 heterodimers. In addition our 
data show that also the ErbB1 and ErbB4 specifi c ligand EREG gains affi nity 
for ErbB3 upon introduction of the YYDLL sequence in the C-terminal linear 
region.   
Figure 1E shows the ability of the various ligands to compete with 
radiolabeled NRG1β for binding to the well-characterized ErbB4 overexpressing 
cell line T47-14. With the exception of TGFα, the wild-type ligands showed 
detectable affi nity for ErbB4, in the following order: NRG1β > T1E > EREG > 
EGF. Introduction of an YYDLL tail into TGFα (Figure 1F) also allowed binding 
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of this ligand to ErbB4, making this the fi rst TGFα mutant that binds ErbB4. 
Both EGF and EREG changed from a low to a high affi nity ligand for ErbB4 upon 
introduction of the YYDLL sequence (IC50 < 35 nM; Table I). Introduction of 
this sequence into T1E enhanced its affi nity for ErbB4 to the level of NRG1β. 
In contrast to the observation on ErbB3, the affi nity of NRG1β for ErbB4 
could not be further enhanced by introduction of the YYDLL sequence. These 
data combined show that introduction of an YYDLL C-terminal tail particularly 
affects the ability of ligands to bind ErbB3 and ErbB4. More specifi c, NRG1β 
gained affi nity without altering its receptor specifi city, while EREG broadened 
its receptor specifi city towards ErbB3, and EGF and TGFα towards ErbB4. 
ErbB2 controls the affi nity and mitogenic potential of ErbB3 binding ligands
 We have previously shown that the mitogenic potential of ErbB1 
ligands is a complex function of receptor affi nity, receptor density and 
ligand depletion (20). In the case of ErbB3, mitogenic activation requires 
heterodimer formation with ErbB2. We therefore fi rst studied the effect of 
Figure 1 Binding affi nity of wild-type EGF-like growth factors and YYDLL 
mutants for ErbB1, ErbB3 and ErbB4
(A,B) Ligand binding displacement analysis on ErbB1 over-expressing HER14 cells 
treated with 0.17 nM  [125I]-EGF. (C,D) Ligand binding displacement analysis on 
ErbB3 overexpressing D3 cells treated with 0.17 nM [125I]-NRG1β. (E,F) Ligand 
binding displacement analysis on ErbB4 overexpressing T47-14 cells treated with 
0.17 nM [125I]-NRG1β. Cells were incubated with increasing amounts of the ligands 
EGF (   ¿   ), EGF/YYDLL (─¯─), TGFα  (   p   ), TGFα /YYDLL (─r─), EREG (   ¢   ), 
EREG/YYDLL (─�─), NRG1β (      ), NRG/YYDLL (──), T1E (   ¯   ) and T1E/YYDLL 
(─¿─). Values of bound radiolabeled ligand without competition of unlabeled ligand 
was set on 100%. Results are the mean of at least two independent experiments 
performed in duplicate.
137
Role of the C-terminal linear region of EGF-like growth factors in ErbB specifi city
introduction of the YYDLL sequence on the binding affi nity of NRG1β and T1E 
towards cells containing both ErbB2 and ErbB3 (D23 cells), and subsequently 
measured their mitogenic potential towards these cells. Figure 2A shows that 
wild-type NRG1β and NRG/YYDLL bind with equally high affi nity to D23 cells 
(see Table I for IC50 values). This implies that introduction of the YYDLL 
sequence into NRG1β does not result in enhanced ErbB3 affi nity, following 
the formation of ErbB2/ErbB3 heterodimers. The IC50 of both NRG1β and 
NRG/YYDLL on D23 cells is around 0.5 nM, which is 10-fold higher than that 
of NRG/YYDLL on D3 cells (Figures 1C and 1D). This is remarkable since 
according to current models heterodimer formation with ErbB2 will stabilize 
ErbB3-ligand interaction, resulting in enhanced binding affi nity. 
In contrast, the IC50 of T1E for binding to ErbB2/ErbB3 heterodimers 
is reduced 10-fold upon introduction of the YYDLL sequence, indicating that 
the affi nity of T1E for ErbB2/ErbB3 heterodimers is suboptimal. Figure 2B 
shows that the mitogenic activity of NRG1β (EC50 50 pM) is reduced upon 
introduction of YYDLL (EC50 250 pM), while that of T1E (EC50 250 pM)  is 
enhanced upon introduction of YYDLL (EC50 33 pM). These data indicate that 
the mitogenic activity of ligands for ErbB2/ErbB3 heterodimers is not a direct 
refl ection of the their receptor binding affi nity. Since the ErbB2-ErbB3 is the 
only possible signaling dimer on D23 cells, these results indicate that NRG/
YYDLL is less effi cient than NRG1β in inducing ErbB2-ErbB3 heterodimers. 
Table I  Overview of IC50 values obtained from ligand binding competition 
analyses and EC50 values of mitogenic assays. Levels of 50% binding 
competition (IC50 values) and mitogenic assays (EC50 values) were estimated 
graphically from  the highest and lowest values experimentally obtained. ND, Not 
Determined. *, 35 nM is close to the IC50. -, no measurable binding affi nity. 
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Increased ErbB4 affi nity correlates with increased mitogenic activity
 ErbB2 is known to affect both the affi nity and selectivity of ligand 
binding to ErbB4. Figure 3A shows the effect of introducing the YYDLL sequence 
into NRG1β and T1E on the binding affi nity towards D24 cells, which contain 
both ErbB2 and ErbB4. On these cells NRG1β and NRG/YYDLL are equally 
potent with an IC50 around 1 nM, while also T1E and T1E/YYDLL  are equally 
potent with an IC50 around 4 nM. The relatively high affi nity of T1E for ErbB2/
ErbB4 heterodimers, in comparison with ErbB2/ErbB3 heterodimers (Figure 
2A), thus appears to limit the effect of introducing the YYDLL sequence. 
Figure 3B shows that  NRG1β (EC50 70 pM) is a potent activator of 
ErbB2/ErbB4 heterodimers in D24 cells, but interestingly NRG/YYDLL (EC50 
140 pM) appears less active. Similarly, T1E/YYDLL (EC50 1 nM) appears 
less active on these cells than T1E (EC50 280 pM), in spite of their similar 
Figure 2 Binding affi nity and 
mitogenic activity of wild-type 
ligands and YYDLL mutants on 
ErbB2-ErbB3 heterodimers
(A) Ligand binding displacement 
analysis on ErbB2 and ErbB3 
overexpressing D23 cells treated 
with 0.17 nM [125I]-NRG1β. 
(B) Dose-dependent mitogenic 
activation of D23 cells, measured 
by MTT analysis. Cells were treated 
with increasing concentrations of 
the ligands NRG1β (      ), NRG/
YYDLL (──), T1E (   p   ) and 
T1E/YYDLL (─r─). Fold induction 
was calculated compared to 
unstimulated D23 cells. Maximum 
stimulation corresponded to  2.78-
fold induction. Results are the 
mean of at least two independent 
experiments performed in 
duplicate.
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Figure 3 Binding affi nity and 
mitogenic activity of wild-type 
ligands and YYDLL mutants 
on ErbB4 homodimers and 
ErbB2/ErbB4 heterodimers
(A) Ligand binding displacement 
analysis on ErbB2 and ErbB4 
overexpressing D24 cells treated 
with 0.17 nM [125I]-NRG1β. 
(B) Dose-dependent mitogenic 
activation of D24 cells, measured 
by MTT analysis. Fold induction 
was calculated compared to 
unstimulated D24 cells. Maximum 
stimulation corresponded to 10-
fold induction (C) Dose-dependent 
mitogenic activation of T47-14 
cells, measured by [3H]-thymidine 
incorporation. Cells were treated 
with increasing concentrations of 
the ligands NRG1β (      ), NRG/
YYDLL (──), T1E (   p   ) and 
T1E/YYDLL (─r─). The highest 
value experimentally obtained 
was set on 100%. Results are the 
mean of at least two independent 
experiments performed in 
duplicate.
binding affi nity. Unlike ErbB3, ErbB4 can also be mitogenically stimulated 
in the absence of ErbB2. When studying the mitogenic potential of these 
ligands for T47-14 cells, which contain ErbB4 in the absence of ErbB2, an 
opposite behaviour is seen (Figure 3C). Although it cannot be excluded that 
T47-14 cells contain low levels of endogenous mouse ErbB1 receptors, we 
have previously shown that these cells are not mitogenically stimulated by 
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EGF (Wingens and others  2006). Therefore the observed mitogenic effects of 
T1E/YYDLL on T47-14 cells must result from activation of ErbB4. 
The observation that is these cells YYDLL mutants are more active, is 
in agreement with their increased binding affi nity (EC50: NRG 0.4 nM, NRG/
YYDLL 0.3 nM, T1E 2.5 nM and T1E/YYDLL 0.9 nM), as shown in Figures 1E 
and 1F. Interestingly, the EC50 values of  NRG1β and T1E/YYDLL differ by a 
factor of 15 on D24 cells, but only by a factor of 2-3 on T47-14 cells. Thus, for 
reasons which are not well understood, ligands which share the same affi nity 
and mitogenic activity towards ErbB4 homodimers can differ in their ability to 
activate ErbB2-ErbB4 heterodimers. 
Homology modeling of EREG in complex with the ErbB receptors
 We have previously shown that positive constraints involved in ErbB-
ligand interaction can be studied from homology models of ligand-receptor 
complexes (van der Woning and others 2006). Such bioinformatic models 
have been based on the available crystal structure of TGFα-liganded ErbB1, 
whereby the backbone structure of TGFα has been used for all ligands and 
that of ErbB1 for all receptors (1). However, NMR analysis has shown that the 
A1-loop of EREG (region between the fi rst and second cysteine) has a different 
conformation from all other mammalian EGF-like growth factors, while in 
addition EREG lacks the anti-parallel β-sheet that is formed by residues in the 
C-loop and C-terminal linear region (11,13). We have therefore investigated 
if this altered conformation affects the ability of EREG to interact with various 
ErbB receptors. 
 Figure 4 provides a survey of the positive constraints (electrostatic 
interactions, hydrophobic interactions and hydrogen bridges), which are 
predicted from such homology models for all combinations of ligands and 
receptors studied here that show detectable affi nity. For ligands that do 
not show interaction with a specifi c ErbB receptor, experimentally identifi ed 
negative constraints are indicated. In the case of EREG use was made of 
its specifi c NMR structure to model interaction with ErbB1 and ErbB4, while 
binding of EREG/YYDLL to the various ErbB receptors was modeled according 
to TGFα in its complex with ErbB1.
Our homology models show that EREG makes less interactions 
(hydrogen bounds, salt bridges or Van-der Waals interactions) with ErbB1 
than the high affi nity ligands EGF, TGFα and T1E (Figure 4). Although the 
relative contribution of each interaction site to the total binding affi nity cannot 
be predicted by homology modeling, the lower number of interactions could 
explain why EREG binds with lower affi nity to ErbB1 than the other ligands. 
Compared to EGF, EREG lacks the hydrogen bond at Asp11 (as depicted in 
Figure 5A), the charge interaction of Lys28, the hydrogen bond of Glu40, and 
the hydrophobic interaction of Tyr44 (EGF numbering is used throughout the 
manuscript). However, the lower number of interaction sites does not seem to 
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result from the specifi c conformation of EREG, since similar interactions were 
observed for residues 1-46 of EREG when modeled according to its own NMR 
structure (EREG) and according to TGFα (EREG/YYDLL).    
Introduction of the YYDLL sequence into EREG provides additional 
interaction sites with ErbB1 (Figure 4), but our experimental data show that 
this results in only a small increase in binding affi nity for this receptor (Figure 
1A,B). The observation that introduction of additional positive constraints into 
a ligand with moderate ErbB1 affi nity does not increase this binding affi nity, 
Figure 4 Interaction sites for binding of EGF-like growth factors to ErbB1, 
ErbB3 and ErbB4, based on bioinformatics homology models
Presented sequences are of human EGF, TGFα , T1E, EREG and NRG1β, as well as 
of their YYDLL mutants. Conserved cysteines are numbered and are depicted in 
bold. EGF numbering is used throughout this study. Residues in red are involved in 
hydrogen bond formation, residues in green are involved in hydrophobic interactions, 
and residues in blue are involved in salt bridge formation with the indicated ErbB 
receptors. For ligands lacking ErbB interaction, negative constraints are depicted in 
grey, when known. Different ligands may share a residue on the same position in 
the linear representation, of which the one interacts with a receptor and the other 
does not, because of differences in rotamer positions of the amino acids determined 
by the surrounding sequences. 
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suggests that the affi nity of EREG for ErbB1 is limited by the presence of so 
far unidentifi ed negative constraints outside the C-terminal linear region, 
which may result from the aberrant conformation of EREG. Domain-exchange 
mutants between EGF and EREG will have to indicate to what extent the 
aberrant conformation of EREG in the A1- and C-loop is indeed responsible for 
its relatively low affi nity for ErbB1. 
The observation that the affi nity of EREG for ErbB3 and ErbB4 is 
strongly enhanced upon introduction of the YYDLL sequence in the C-terminal 
linear region, suggests that for binding to these receptors the number 
of positive constraints in EREG is limiting its affi nity. This is illustrated in 
Figures 5B and 5C, which show that additional interaction sites are formed 
by Tyr44, Tyr45  and Asp46 in EREG/YYDLL upon binding to ErbB3 and ErbB4 
respectively. The possibility cannot be excluded, however, that the YYDLL 
sequence does not only enhance the number of positive constraints in EREG, 
but also relieves a sofar unidentifi ed negative constraint in the C-terminal 
linear region of this ligand, similar to our previous observation for EGF binding 
to ErbB3 and ErbB4 (van der Woning and others 2006). Our homology models 
do not provide any indication, however, that His44 and Phe46 may be involved 
in any such negative constraint (Figures 5B and 5C).
Figure 5 Homology models for the structure of EREG, EREG/YYDLL and EGF 
in complex with the extracellular domains of ErbB1, ErbB3 and ErbB4
Close-up pictures of ribbon representations are shown for the involvement of (A) 
the A1 loop of EGF and EREG upon ErbB1 interaction, (B) interaction of the C-
terminal linear region of EREG/YYDLL and EREG with ErbB3, (C) idem with ErbB4. 
ErbB receptors are depicted in grey, EGF and EREG/YYDLL in green and EREG itself 
in red. Yellow dotted lines represent hydrogen bounds. The amino acid numbering 
of the ligands is according to that of EGF, and the amino acid numbering of the 
receptors is according to Jorissen et al. (26). Rotamers of the amino acid side 
chains were positioned using SCWRL (16), refi ned in YASARE and checked with 
WHAT IF(18) quality control indicators. 
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DISCUSSION
 In present study we have investigated the role of the C-terminal linear 
region of EGF-like growth factors in their binding affi nity and selectivity for 
ErbB receptors. We have previously shown that the C-terminal sequence YYDLL 
is compatible with binding to all three ligand binding ErbB receptors (van der 
Woning and others 2006). Here we have shown that introduction of the YYDLL 
sequence has only minor effects on the binding affi nity of ligands for ErbB1, 
but strongly enhances the binding affi nity of NRG1β for ErbB3.  Furthermore, 
introduction of the YYDLL sequence can alter receptor specifi city, as a result 
of which TGFα gains affi nity for ErbB4 and EREG for ErbB3. For reasons that 
are not well understood within the current models of ErbB-ligand interaction, 
NRG/YYDLL showed a much higher affi nity for binding to ErbB3 than to 
ErbB2/ErbB3 heterodimers. Furthermore the mitogenic activity of ligands for 
ErbB2/ErbB3 did not parallel their binding affi nity for these heterodimers. In 
contrast, the mitogenic activity of ligands for ErbB4 homodimers and ErbB2/
ErbB4 heterodimers largely paralleled their binding affi nity. In combination 
these data show that the C-terminal linear region of EGF-like growth factors 
plays a crucial role in ErbB affi nity and selectivity.
 We have previously postulated that EGF-like growth factors contain 
a limited number of residues that are not essential for high affi nity receptor 
binding, but that prevent the unintended binding to other ErbB receptors. 
These so-called negative constraints thereby form the molecular basis for the 
observed ligand specifi city of receptor binding. In previous studies we have 
shown that binding to ErbB3 is strongly impaired by the ligand residues Glu26 
(in the B-loop) and Arg45 (in the C-terminal linear region), a well as by the 
absence of beta-sheet forming residues in the linear N-terminal region. Based 
on our present and previous studies, we propose that the main difference in 
binding requirement between ErbB3 and ErbB4 is located in the ligand’s N-
terminal linear region. This is indicated by the observation that introduction 
of a WVR sequence into the N-terminal linear region allows the mutant WVR/
EGF/IADIQ to bind to ErbB1 and ErbB3, but not to ErbB4 (21). 
 It has been postulated that during evolution a single parental ErbB 
gene has been segregated into an ErbB1/ErbB2 and an ErbB3/ErbB4 ancestor 
gene. Activation of those receptors would require a TGFα-type ErbB1 specifi c 
ligand and a NRG-type ErbB3/ErbB4 specifi c ligand. The observation that no 
natural ligand exists that binds both ErbB1 and ErbB3, suggests that known 
ErbB1/ErbB4 bispecifi c ligands (BTC, EREG, HB-EGF) developed after a second 
whole genome duplication which resulted in the generation of four different 
ErbB genes. It is speculative whether during this evolutionary process some 
ErbB1-specifi c ligands gained affi nity for ErbB4, or that some ErbB1/ErbB4 
bispecifi c ligands lost affi nity for ErbB4. In our view on the role of negative 
constraints in ligand binding specifi city, the second option seems more 
feasible, since it would require only a few inactivating mutations to release 
an existing negative constraint for ErbB4. Still there appears to have been a 
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strong evolutionary pressure to generate and maintain ErbB1/ErbB4 bispecifi c 
ligands, since the  TGFα/BTC, EPGN/EREG and AREG/HBEGF ancestors have 
all three diversifi ed to both an ErbB1 specifi c ligand and an ErbB1/ErbB4 
bispecifi c ligand. 
 Many studies have been performed on the structure-function 
relationship of the ErbB1 specifi c ligands EGF and TGFα, but much less is 
known about the requirements for binding of NRGs to ErbB3 and ErbB4. 
Alanine scanning mutagenesis and phage display affi nity optimisation studies 
have shown that the requirements of NRG1β for binding to ErbB3 and ErbB4 
partly overlap, but are not identical (2,22). Still it has proven impossible 
sofar to design NRG mutants that specifi cally bind to either ErbB3 or ErbB4 
(23). In contrast, mutants that are specifi c for either ErbB3 or ErbB4 can 
readily be made on the basis of the primary structure of EGF, although always 
concomitant with high affi nity for ErbB1 (21). 
Crystal structure analysis has indicated that ErbB dimerisation stabilizes 
high affi nity ErbB/ligand complexes. Such complexes can either consist of two 
liganded ErbB receptors, or a single liganded ErbB receptor in complex with 
the orphan ErbB2. Our current observation that  NRG/YYDLL binds with much 
higher affi nity to cells containing only ErbB3 than to cells containing both 
ErbB2 and ErbB3 is therefore puzzling. Possibly, NRG/YYDLL can avidly bind 
to putative pre-existing ErbB3 homodimers on the cell surface. However, the 
ability of ErbB3 to form homodimers has been disputed, particularly based 
on experimental studies with the soluble extracellular domain of ErbB3 (24). 
Alternatively, the affi nity of NRG/YYDLL for ErbB3 monomers may be so high, 
that no further gain of affi nity is observed upon receptor dimerisation. 
In contrast to ErbB3, the affi nity of NRG1β for ErbB4 could not be 
improved by introduction of the YYDLL sequence. This must imply that either 
the affi nity of NRG1β for ErbB4 is already optimal and cannot be further 
enhanced by mutations, or that the C-terminal linear region of this ligand 
does not provide an important contribution to ErbB4 binding. However, various 
natural isoforms of the NRGs exist which differ in their C-terminal linear 
region. These isoforms differ strongly in their binding affi nity for ErbB3 and 
ErbB4. Particularly for NRG2 it has been shown that Lys45 in the C-terminal 
linear region of the low affi nity isoform NRG2β impairs high affi nity binding 
to ErbB4 (25). This residue is absent in the high affi nity isoform NRG2α and 
therefore acts as a negative constraint for this receptor. On the other hand 
various studies, including the present one, have shown that the affi nity of 
NRG1β for ErbB3 can be enhanced 10-100 fold by directed mutations in the 
B-loop and C-terminal linear region (2). This implies that during evolution 
EGF-like growth factors may not have evolved for optimal binding affi nity, 
particularly not for binding to ErbB3. It remains unclear, however, why low 
affi nity EGF-like growth factors, such as EREG for ErbB1, and  NRG1α and 
NRG2β for ErbB3 and ErbB4, are maintained during evolution. 
In the case of ErbB3 it could be argued that high affi nity ligands will 
favour the formation of inactive ErbB3 homodimers, while low affi nity ligands 
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will favour the formation of biologically active ErbB2/ErbB3 heterodimers. 
This hypothesis is strengthened by our observation that NRG/YYDLL, with 
its very high binding affi nity for ErbB3 alone, shows lower mitogenic activity 
than NRG1β on cells containing both ErbB2 and ErbB3. Moreover, introduction 
of YYDLL enhances the binding affi nity of T1E for ErbB2/ErbB3 heterodimers, 
although the affi nity is still lower than that of NRG1β. Still, in a mitogenic 
assay T1E/YYDLL shows equally high activity as NRG1β.  Therefore it appears 
that the natural ligand NRG1β combines an optimal binding affi nity for ErbB3 
with the highest mitogenic activation of ErbB2/ErbB3 heterodimers. 
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ABSTRACT
ErbB3 transactivation can make tumor cells resistance to ErbB1/ErbB2 
targeting drugs. This urges for a reliable method to determine cell surface 
ErbB3 levels, but in our hands iodinated NRG1β is unstable and tends to 
underestimate the number of ErbB3 receptors in a radio-receptor assay. Here 
we show by the use of a radio-labeled high affi nity neuregulin mutant NRG/
YYDLL that ErbB3 levels can be determined in a reliable manner by Scatchard 
analysis. Furthermore we show by differential competition with unlabeled 
NRG/YYDLL and betacellulin that the number of ErbB3 and ErbB4 receptors 
can be quantifi ed separately on cultured human breast cancer cells. 
INTRODUCTION 
 The ErbB signaling network is currently one of the main targets for the 
development of anti-cancer drugs. The ErbB family of type 1 transmembrane 
receptor tyrosine kinases consists of four members: ErbB1 (EGFR), ErbB2, 
ErbB3 and ErbB4. ErbB1 and ErbB2 are frequently overexpressed in epithelial 
cancers, where they are involved in autonomous cell proliferation, invasion 
and metastasis. In recent years FDA-approved drugs have been developed, 
including ErbB1-specifi c tyrosine kinase inhibitors (erlotinib, gefi tinib) and 
ErbB specifi c antibodies (cetuximab, trastuzumab), which are widely used 
in treatment of e.g. breast, lung, colorectal and head-and-neck cancers [1]. 
Although such treatments can be very successful, their long term application 
is limited by the observation that many patients may eventually develop 
resistance to applied drugs [2; 3]. 
Recent data show that activation of ErbB3 provides one of the 
mechanisms whereby tumor cells can escape from ErbB1 and ErbB2-directed 
therapy [4]. ErbB3 has an impaired tyrosine kinase domain, but after binding 
of its endogenous ligand NRG1β it can form strongly active heterodimers 
with ErbB2, and to a lesser extent also with ErbB1 or ErbB4 [5]. ErbB3 is 
frequently overexpressed in breast cancers, where it can be transactivated 
by the concomitantly overexpressed ErbB1 and ErbB2. Recent data also show 
that ErbB2 and ErbB3 are both more active in cetuximab-resistant than in 
cetuximab-responsive non-small cell lung carcinoma cells, indicating that 
other receptors than ErbB1 contribute to the resistance of tumor cells for 
anti-ErbB1 therapies [6]. Moreover, it has been shown that direct targeting 
of ErbB3 by siRNA in resistant cells restores cetuximab sensitivity to these 
cells [6]. This observation suggests that ErbB3 may sequester ErbB1 into a 
biologically active ErbB1/ErbB3 complex, which is insensitive to inhibition by 
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cetuximab.   
These observations indicate that determination of ErbB3 levels in 
tumor tissue may be critical in the selection of patients for ErbB-directed 
therapy, as well as for their prognostic potential. ErbB receptor densities can 
be determined at the mRNA level by quantitative PCR analysis or fl uorescence 
in situ hybridization, and at the protein level by fl ow cytometric analysis or 
immunoblotting using receptor specifi c antibodies. However, these methods 
do not readily allow quantifi cation of receptor numbers. The density of ErbB1 
receptors in both intact cells and cellular extracts is routinely determined by 
a radio-receptor assay employing the ErbB1-specifi c ligand epidermal growth 
factor (EGF) as radiolabeled [125I] ligand. NRG1β  is a high affi nity ligand for 
both ErbB3 and ErbB4, but binding studies using [125I]-NRG1β  are scarce 
in the literature [7; 8]. One of the reasons might be that, according to our 
experience, NRG1β rapidly loses its high binding affi nity for ErbB receptors 
following iodination, possibly due to sulfoxidation of methionine residues. In 
contrast to EGF, NRG1β contains a methionine (residue 47 according to EGF 
numbering) at a position which is essential for high affi nity ErbB3 binding. 
Although direct experimental evidence is lacking, we propose that the 
observed instability of NRG1β  upon iodination results from sulfoxidation of 
Met47.  
 We have recently shown that exchange of the fi ve most C-terminal 
residues of NRG1β into the sequence YYDLL enhances its binding affi nity for 
ErbB3. In the present study we show that with NRG/YYDLL as radioligand 
5-10 fold higher bound/added values are detected on ErbB3 containing cells 
than with  [125I]-NRG1β, resulting in signifi cantly higher receptor numbers 
and lower Kd-values in Scatchard plots. Using this radioligand we were 
subsequently able to quantify the number of ErbB3 and ErbB4 receptors on a 
set of cultured human breast cancer cell lines.
MATERIALS AND METHODS
Cell lines 
 Murine 32D hematopoietic progenitor cells transfected with distinct 
human ErbB-encoding plasmids (ErbB3 for D3 cells; both ErbB1 and ErbB3 
for D13 cells) were cultured in RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal calf serum (FCS) (Invitrogen, Paisley, UK) and 0.25 
ng/ml murine interleukin-3 (Promega, Madison, WI), and were subsequently 
kept under continuous selection using 0.6 mg/ml G418 (Calbiochem, La Jolla, 
CA). Human breast cancer cell lines T47D and MCF7 were grown in Dulbecco’s 
modifi ed Eagle’s medium (DMEM) supplemented with 10% newborn calf 
serum (NCS) (Perbio, Logan, UT). CAMA1 cells were grown in RPMI 1640 
medium supplemented with 10% heat-inactivated FCS.
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Radioligand displacement analysis 
 Human NRG1β (R&D Systems, Mineapolis, MN) and its mutant NRG/
YYDLL (Van der Woning et al., submitted) were iodinated enzymatically to a 
specifi c activity of approximately 1.2 Ci/μmol [9]. For ligand displacement 
studies on human breast cancer cells, 5.0x105 T47D, MCF7 and CAMA1 
cells were seeded in 24-wells plates in 1 ml of DMEM/NCS. After 2 days of 
culture, cells were incubated for 2 hours on ice in 100 μl of HEPES-buffered 
DMEM/NCS, containing 5 ng/ml of [125I]-NRG/YYDLL in additional presence of 
serial dilutions of unlabeled NRG/YYDLL or betacellulin (R&D Systems). Cells 
were subsequently lysed in 0.5 ml of a 1% Triton X-100 solution, and the 
bound radioactivity was measured by γ-counting. Scatchard analysis binding 
studies on D3 and D13 cells were performed in suspension, whereby 5.0x106 
cells were suspended in 150 μl of HEPES-buffered RPMI/FCS, supplemented 
with 1 ng/ml of radiolabeled ligand. After incubation for 2 hours on ice, cells 
were washed twice with serum-free RPMI medium, and spun down for 20 
seconds at 13,000 rpm after which bound radioactivity was measured by γ-
counting. Radioligand displacement curves were analyzed following the linear 
subtraction method [10] and data for specifi c binding subsequently presented 
in a Scatchard plot.
Western blotting
 For immunodetection of ErbB3 receptors, 1.0x106 D1 or D13 cells 
cells were lysed in RIPA buffer supplemented with proteinase inhibitors 
aprotein, leupeptin, pepstatin and PMSF (Sigma, St. Louis, MO). Following gel 
electrophorsis, immunoblotting was performed using anti-ErbB3 antibodies 
from Cell Signaling (Beverly, CA). 
Flowcytometric analysis 
 For determination of ErbB3 expression level on 32D cells, 5.0x105 
cells were Fc-blocked by treatment with 1 μg of human IgG/105 cells for 15 
minutes at room temperature and subsequently stained for 1 hour with  5 
μg/ml phycoerythrin-labeled anti-ErbB3 antibodies (R&D Systems) in the 
same buffer. Cells were then washed twice and resuspended in ice-cold PBS/
1%NCS before fl uorescence was analyzed at 488 nm on the FACScan system 
(Beckman Coulter, Fullerton, CA).
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Real-time quantitative PCR 
 mRNA levels for ErbB3 were determined following TriZol (Invitrogen) 
treatment of 1.0x106 32D cells, according manufacturer’s protocol. cDNA 
was produced from 1 μg of RNA using Superscript Reverse Transcriptase 
(Invitrogen). Real-time quantitative PCR was performed on the 7500-real-
time PCR system from Applied Biosystems and data were analyzed using 7500 
SDS software. mRNA levels were expressed relative to that of the household 
gene GAPDH.
RESULTS
Quantifi cation of ErbB3 receptor levels by ligand binding analysis 
 Following NRG1β binding, ErbB3 can form stable heterodimers with 
the orphan receptor ErbB2, but there is increasing evidence that active 
complexes can also be formed with unliganded ErbB1 receptors [11]. In 
the present study we have determined the binding affi nity of NRG1β and 
its mutant form NRG/YYDLL for cells containing only ErbB3 (D3 cells) or 
both ErbB1 and ErbB3 (D13 cells) receptors. Figure 1A shows ligand binding 
displacement curves for both cell lines, using either 1 ng/ml of freshly labeled 
[125I]-NRG1β or [125I]-NRG/YYDLL as radioligand. The data show that D13 
cells bind 1.5-2.5 times more labeled ligand than D3 cells, while in the case 
of [125I]-NRG/YYDLL 4.5-7.5 times more radioactivity was bound than with 
[125I]-NRG1β as labeled ligand. In all cases the binding of labeled ligand was 
fully competed by addition of a 200-fold excess of either unlabeled NRG1β or 
NRG/YYDLL.
Figure 1B shows the corresponding Scatchard plots for specifi c receptor-
ligand binding. The Scatchard plots all show a linear behavior, indicating that 
within the range of ligand concentrations used there is no evidence for the 
presence of both high and low affi nity sites, as is generally observed for 
ligand binding to ErbB1 [12]. Figure 1C gives a survey of the apparent ligand 
binding dissociation constants (Kd) and ErbB3 receptor densities, obtained 
from these Scatchard plots. The data show that using [125I]-NRG/YYDLL as 
a label 5-10 fold higher levels of ErbB3 receptors/cell were observed than 
with [125I]-NRG1β, concomitant with a 3-fold lower Kd-value. The enhanced 
affi nity of NRG/YYDLL for ErbB3 may result from the introduced mutations in 
the C-terminal linear region, but the much higher ErbB3 levels identifi ed by 
NRG/YYDLL binding most likely indicates that the actual receptor numbers 
are underestimated when NRG1β is used as a labeled ligand. The observation 
that binding of [125I]-NRG/YYDLL can be fully competed by an excess of 
unlabeled NRG1β (data not shown) implies that NRG/YYDLL does not bind to 
additional ErbB3 binding sites compared to NRG1β. These data are therefore 
best understood if it is assumed that under the conditions tested some 80-
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90% of the labeled NRG1β is no longer biologically active and unable to bind 
ErbB3 with high affi nity, possibly due to sulfoxidation of Met47. Moreover, 
no signifi cant difference in Kd was observed for ligand binding to D1 and 
D13 cells, indicating that heterodimerization with ErbB1 does not appear to 
enhance the affi nity of  NRG1β for its native receptor.
Figure 1. Determination of the ErbB3 receptor levels on 32D cells. (A) Ligand 
binding displacement curves on D1 and D13 cells, treated with 1 ng/ml of the 
indicated labeled ligand and increasing concentrations of the same unlabeled 
ligand. (B) Scatchard plots for NRG1β and NRG/YYDLL binding to D1 and D13 cells, 
each underneath its corresponding displacement curve. Specifi c ligand binding 
(Bsp) has been expressed in fmoles/106 cells, and free ligand concentration (F) in 
nM. (C) Survey of apparent ligand binding affi nities and receptor numbers obtained 
from Scatchard analysis for D3 (grey) and D13 (black) cells. Bound/added values of 
labeled ligand were: 4% (D3-NRG1β); 10% (D13-NRG1β); 49% (D3-NRG/YYDLL) 
and 69% (D13-NRG/YYDLL). Data Presented are the average of two independent 
experiments in duplicate.
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Comparison of ErbB3 levels on D1 and D13 cells by fl owcytometric analysis, 
Western blotting and real-time quantitative PCR
 The above binding studies in which [125I]-NRG1β was used as a 
radiolabeled ligand, suggest that D13 cells may contain twice the number of 
ErbB3 cell surface receptors as D3 cells, while no such difference in receptor 
density was observed when [125I]-NRG/YYDLL was used as radioligand. 
Subsequent fl ow cytometric analysis (Fig.2A) of cells labeled with anti-ErbB3 
antibodies showed a similar cell surface receptor density on D3 and D13 
cells, while as a negative control D12 cells (containing exclusively ErbB1 and 
ErbB2) were devoid of cell surface staining. Although receptors cannot readily 
be quantifi ed by this technique, the data confi rm the results obtained from 
the [125I]-NRG/YYDLL binding studies. Quantitative real time PCR analysis 
Figure 2. Determination of 
the ErbB3 expression level in 
32D cells. (A) Flow cytometric 
analysis of ErbB3 levels, using 
a PE-conjugated anti-ErbB3 
antibody, on D12 (white), D3 
(grey) and D13 (black) cells. (B) 
ErbB3 mRNA levels, determined 
by quantitative PCR and 
expressed relative to GAPDH. 
(C) Western blotting analysis 
of ErbB3 levels in whole cell 
lysates, detected by anti-ErbB3 
antibodies. 
156
Chapter 6
(Fig. 2B) showed that the ErbB3 mRNA level is 1.7-fold higher in D3 cells than 
in D13 cells, while Western blot analysis (Fig. 2C) indicated that whole cell 
lysates of D13 cells contain at least twice the amount of ErbB3 protein present 
in D3 cells. These data indicate that ErbB3 mRNA levels cannot directly be 
related to protein levels. Moreover, it appears that signifi cant amounts of 
ErbB3 receptors may be located intracellularly, where they cannot be reached 
by extracellularly added ligands or antibodies. 
Discrimination between NRG/YYDLL binding to ErbB3 and ErbB4
 The present study indicates that binding studies with radiolabeled 
NRG/YYDLL provide a robust method for quantifying ErbB receptor densities, 
but it should be taken into account that NRG/YYDLL binds with high affi nity 
to both ErbB3 and ErbB4, albeit not to ErbB1. Figure 3 shows that ErbB3 
specifi c binding can be quantifi ed when [125I]-NRG/YYDLL binding to cells is 
not only competed by increasing concentrations of unlabeled  NRG/YYDLL, but 
in parallel also with unlabeled betacellulin (BTC), an EGF-like growth factor 
that binds both ErbB1 and ErbB4, but not ErbB3. Unlabeled NRG/YYDLL will 
compete for binding of [125I]-NRG/YYDLL to both ErbB3 and ErbB4, while BTC 
will compete only for binding to ErbB4. When applied to human breast cancer 
cell lines in tissue culture using a high concentration (5 ng/ml) of  [125I]-NRG/
YYDLL to assure at least 50% receptor occupancy, it is shown in Fig. 3 that 
on T47D cells 40% of bound labeled ligand could be competed with BTC and 
Figure 3. Determination of the ErbB3 and ErbB4 levels on human breast cancer 
cells. Binding of 5 ng/ml [125I]-NRG/YYDLL was competed by unlabeled NRG/YYDLL 
(closed triangles) or BTC (closed circles). Bound/added values of labeled ligand 
were 5% (T47D), 2.5% (MCF7), and  5% (CAMA-1). Data presented are the 
average of two independent experiments in duplicate.
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100% by NRG/YYDLL, indicating that the 60% of the NRG1β binding sites 
are ErbB3 and 40% ErbB4. Similarly, MCF7 cells contain 70% binding sites 
for ErbB3 and 30% for ErbB4, while CAMA-1 cells have a similar density of 
ErbB3 and ErbB4 receptors. Based on the total amount of [125I]-NRG/YYDLL 
bound, this corresponds to 1.5x104 ErbB3 and 1.0x104 ErbB4 receptors on 
T47D cells; 8.75x103 ErbB3 and 3.75x103 ErbB4 receptors on MCF7 cells; and 
1.25x104 ErbB3 and 1.25x104 ErbB4 receptors on CAMA-1 cells.
DISCUSSION
 There is increasing interest in the role of ErbB3 in tumorigenesis. 
ErbB3 is overexpressed in many epithelial tumors, but since ErbB3 lacks 
intrinsic tyrosine kinase activity, drug design has mainly been focussed on 
ErbB1 and ErbB2. The recent observation that high ErbB3 expression levels 
can make tumor cells resistant to ErbB1-directed tyrosine kinase inhibitors 
[4], urges for a reliable method to quantify ErbB3 levels on the cell surface. 
In the present study we have shown that a radiolabeled mutant of neuregulin 
(NRG/YYDLL) provides a stable and reliable ligand for quantifi cation of both 
ErbB3 and ErbB4 levels on the surface of human breast cancer cell lines. 
Although ErbB3 lacks tyrosine kinase activity, it can be tyrosine 
phosphorylated by active ErbB1 and ErbB2 receptors, which results in a 
strong activation of particularly the PI3K-pathway. It is well established that 
upon NRG1β binding ErbB3 is able to bind ErbB2, upon which both receptors 
become tyrosine phosphorylated [13; 14]. Moreover, we and others have 
shown that, upon NRG1β binding, ErbB3 can also form a mitogenic complex 
with ErbB1, even in the absence of an ErbB1 binding ligand such as EGF [11]. 
It has been speculated that a small fraction of unliganded ErbB1 receptors in 
the so-called open conformation is involved in this ErbB1/ErbB3 heterodimer 
formation [15]. It is currently unclear if this fraction of ErbB1 receptors is 
sensitive to the tyrosine kinase inhibitors erlotinib and gefi tinib. It is also 
unclear if ErbB3-mediated resistance to these inhibitors requires the presence 
of NRG1β. Interestingly, ErbB1/ErbB3 complexes are readily dissociated 
in the presence of an ErbB1 activating ligand [11]. It can therefore be 
anticipated that cetuximab, which prevents ligand binding to ErbB1, may 
stabilize the activity of such ErbB1/ErbB3 heterodimers. Determination of the 
exact number of ligand binding ErbB3 molecules on tumor cells is a fi rst step 
towards our understanding of ErbB3-mediated resistance to ErbB1 and ErbB2 
targeting drugs. This information will be very important for choosing the 
proper therapy for treatment of ErbB overexpressing cancers and will predict 
the risk of escape from ErbB1 and ErbB2-targeted therapies.  
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ABSTRACT
 ErbB ligands bind their receptors in a highly specifi c manner. In 
previous reports we demonstrated that negative constraints in EGF and TGFA 
prevent the interaction with ErbB3 and ErbB4. Still it is unknown why NRG1β 
does not bind ErbB1. In this chapter we attempted to answer this question by 
a bioinformatics approach in which the amino acid interactions between EGF 
and TGFA with ErbB1 were compared with the interactions between NRG1β 
with ErbB3 and ErbB4. Although there are some minor differences, NRG1β-
ErbB3/ErbB4 interaction is very similar to EGF/TGFA-ErbB1 interaction. 
Furthermore, based on these comparisons no indication was obtained for 
steric clashes or charge repulsions between NRG1β and ErbB1. Experimental 
domain exchange studies between panerbin and NRG1β showed that the A1-
loop and C-loop of NRG1β contain sequences that impair ErbB1 interaction. It 
remains unclear, however, by what mechanism the A1 and C-loop of NRG1β 
prevent ligand interaction with ErbB1. 
INTRODUCTION
The ErbB signaling network is highly conserved in multicellular 
organisms and has evolved from a single receptor-ligand complex, as is still 
present in invertebrates such as C. elegans, to a complex system consisting 
of multiple ErbB receptors and a variety of EGF-like ligands in mammals 
(Van Leeuwen, unpublished). The high degree of receptor specifi city of EGF-
like ligands allows the ErbB signaling network to play an important role in 
many distinct developmental processes. The four mammalian receptors, 
ErbB1, ErbB2, ErbB3 and ErbB4, bind a total of eleven different ligands. The 
ligands epidermal growth factor (EGF), transforming growth factor-alpha and 
heparin-binding epidermal growth factor (HB-EGF) bind exclusively to ErbB1, 
while amphiregulin (AREG), betacellulin (BTC) and epiregulin (EREG) bind 
both ErbB1 and ErbB4. The large family of neuregulins (NRG1-4) with their 
multiple splice variants binds exclusively to ErbB3 and ErbB4. There is great 
interest in understanding the specifi city of receptor-ligand interactions. The 
multiple players in the ErbB network do not only allow an understanding why 
certain ligands bind their specifi c receptor, but also why they do not bind to 
highly related receptors.
Although the specifi city of natural EGF-like ligands for binding to 
ErbB receptors is high, we and others have shown that a limited number of 
mutations in ligand molecules is suffi cient to broaden their ErbB receptor 
specifi city. EGF binds exclusively to ErbB1, but exchange of its N-terminal 
linear region with that of NRG1β (biregulin) or TGFA (T1E) is suffi cient to make 
EGF also a low affi nity ligand for ErbB3 and ErbB4 (1). In fact, introduction of 
only two residues from the N-terminal linear region of TGFA into EGF (S2H/
D3F) is suffi cient to make EGF a ligand that binds multiple ErbB receptors (2). 
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A different observation was made when intercysteine regions are exchanged 
between EGF and NRG1β. Introduction of a single intercysteine region of EGF 
into NRG1β leaves the latter’s affi nity for ErbB3 and ErbB4 intact, but does 
not result in detectable affi nity for ErbB1 (1). In contrast, introduction of a 
single intercysteine region of NRG1β into EGF strongly reduces the affi nity for 
ErbB1, without a detectable gain in affi nity for ErbB3 and ErbB4(1).
Crystal structure analysis of liganded and unliganded ErbB receptors 
have provided detailed information about the requirements for receptor-
ligand binding. Unliganded ErbB1, ErbB3 and ErbB4 have a highly similar 
conformation, in spite of considerable differences in their primary structure. 
EGF-like ligands have a very tight conformation, due to the presence of 
three disulphide bridges, which is not signifi cantly altered upon receptor 
binding. Crystal structures of the EGF/ErbB1 and TGFA/ErbB1 complexes 
have provided detailed information about the ligand residues that directly 
contact their receptor (3, 4). These residues, collectively referred to as 
positive constraints, directly contribute to high affi nity receptor binding by a 
combination of hydrogen bridges, electrostatic and hydrophobic interaction 
(2, 5). Based on these experimental structures we have subsequently derived 
homology models for a variety of other ligands in complex with ErbB1, in 
particular for the artifi cial ligand panerbin (T1E/YYDLL) which binds all three 
ligand-binding ErbB receptors with high affi nity (5). 
No such crystal structures have been obtained yet for NRG1β alone 
or in complex with ErbB3 or ErbB4. As a result much less is known about the 
interaction of ligands with these two receptors. An NMR structure of NRG1α 
has been published, which shows high similarity with the three-dimensional 
conformation of EGF and TGFA (6). In the present study we have made a 
homology model for binding of NRG1β to ErbB3 and ErbB4, based on the 
the published TGFA/ErbB1 crystal structure. Using this approach putative 
interaction sites between NRG1β and its receptors could be identifi ed. These 
potential positive constraints in NRG1β were highly similar to the ones 
identifi ed for EGF and TGFA upon binding to ErbB1. The observation that 
NRG1β cannot bind ErbB1 does therefore not appear to result from a lack of 
positive constraints, but more likely from the presence of residues that impair 
binding to ErbB1 as a so-called negative constraint. To experimentally identify 
such negative constraints, we have tested in this study a set of chimeras 
between NRG1β and panerbin for binding to ErbB1. NRG1β binds exclusively 
to ErbB3 and ErbB4, while panerbin binds in addition to ErbB1. Our data show 
that introduction of particularly the A1-and C-loop of panerbin allows NRG1β 
to bind ErbB1, although with low affi nity, without impairing its affi nity for 
ErbB4.    
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MATERIALS AND METHODS
Cell Lines
 HER-14 cells and T47-14 cells were cultured in gelatinized fl asks in 
Dulbecco’s modifi ed Eagle’s medium supplemented with 10% newborn calf 
serum (12).
Expression and Purifi cation of Mutant Growth Factors
 Recombinant EGF-like growth factors were expressed as protein A-
tagged fusion proteins in the protease K-defi cient Escherichia coli strain KS474 
and isolated from the periplasmic space as described (7). Growth factors were 
purifi ed by means of affi nity chromatography using IgG-Sepharose, followed 
by Factor-X cleavage, an additional round of affi nity chromatography to 
remove the protein A-tag and a fi nal reverse phase (RP)-HPLC purifi cation 
step to remove disulphide bridge mismatches. The amount of growth factor 
was calculated from the peak area (absorption at 229 nm) in the RP-HPLC 
chromatogram, using natural mEGF as a standard. The affi nity for ErbB1 
was measured in an [125I]-mEGF binding competition assay on HER14 cells, 
and for ErbB4 in an [125I]-NRG1β binding competition assay on T47-14 cells, 
respectively.
Ligand Binding Displacement Experiments
 Recombinant EGF and NRG1β were radiolabeled enzymatically to a 
specifi c activity of 1.1 Ci/μmol (8). Ligand binding displacement analyses 
were performed either using a suspension of 5.0×106 32D cells or confl uent 
monolayers of HER14 or T47-14 cells. 32D cells were washed once with RPMI 
supplemented with 0.5% BSA and subsequently incubated for 2 hours at 4oC 
with serial dilutions of unlabeled ligand in the presence of 1 ng/ml of [125I]-
NRG1β. Cells were then washed once with binding buffer and loaded onto a 
serum cushion to remove the unbound label. Subsequently, cells were quickly 
centrifuged at 2000 rpm, and cell surface-bound radioactivity was determined 
by γ-counting. HER14 or T47-14 cells were grown to confl uency, and serial 
dilutions of unlabeled growth factors were added in the presence of 1 ng/ml 
of [125I]-mEGF or 1 ng/ml of [125I]-NRG1β, respectively. After incubation for 
2 hours at 4 oC, the cells were washed three times with phosphate-buffered 
saline (PBS) in order to remove the unbound label and subsequently incubated 
for 1 hour in 1% Triton X-100 at room temperature prior to γ-counting.
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Homology Modeling of NRG1β in Complex with ErbB3 and ErbB4 
 Homology models were constructed for the extracellular domains of 
ErbB3 and ErbB4, all in complex with NRG1β. Initial models were built using 
both the ErbB1-EGF complex (3) and the ErbB1-TGFA complex  as a template. 
Validation of the models with WHAT CHECK (9) identifi ed template 1MOX, the 
ErbB1-TGFA complex solved at a resolution of 2.5 Å (3), as the best choice 
both for receptor and ligand. The amino acid side chains in the fi nal models 
were positioned using SCWRL (9). Subsequently, the models were refi ned 
in YASARA using the Yamber2 force fi eld and the associated protocol (10) 
until the WHAT IF (11) quality indicators (Ramachandran plot, backbone 
conformation, and three-dimensional packing quality) converged.
RESULTS
Homology model of NRG1β binding to ErbB3 and ErbB4
 Based on the backbone structure of TGFA and ErbB1, as determined 
by X-ray analysis of their complex, we derived a homology model for the 
interaction of NRG1β with ErbB3 and ErbB4. Table 1 surveys  the potential 
positive constraints in NRG1β that mediate binding to ErbB3 and ErbB4. In 
the case of ErbB3, these are located within the N-terminal linear region (H2/
L3), A1-loop (K11/F13), A2-loop (V15, N16), B-loop (F21, V23, L26, S27, 
N28, P29, R31, Y32), C-loop (N38, E39, T41, D43, R44) and C-terminal 
linear region (Q46, N47, Y48, M50, A51), giving rise to a total of 24 residues 
that can potentially form a hydrogen bridge, a salt bridge, or a hydrophobic 
interaction site with residues in this receptor. The interaction sites for binding 
of NRG1β to ErbB4 were found to be highly similar to those for binding to 
ErbB3, in agreement with data from Luo et al. (8). An overview of positive 
and negative constraints is shown in Figure 1. We have previously shown that 
exchange of the C-terminal linear region of NRG1β for the sequence YYDLL 
enhances its binding affi nity for ErbB3. Homology modeling shows that this 
C-terminal sequence enhances the total amount of positive constraints with 
this receptor (Figure 1). 
 A comparison between the homology structure of NRG1β/ErbB3 
and the experimental structure of  TGFA/ErbB1 shows that the residues 
that mediate high affi nity binding with their receptor are located at similar 
positions in both ligand molecules. So, although the primary structure of 
these positive constraints in EGF and  NRG1β are not necessarily conserved, 
in general the hydrogen bridges, salt bridges and hydrophobic pockets are 
located on the same positions in the receptor-ligand complex. However, a 
more close comparison also shows interesting differences. First of all, the B-
loop of NRG1β is three amino acids longer than that of EGF, and as a result 
NRG1β can form two additional hydrogen bounds with the L1 domain of ErbB3 
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Figure 1. Interaction sites for binding of EGF-like growth factors to ErbB1, 
ErbB3 and ErbB4, based on bioinformatics homology models. Presented 
sequences are of human EGF, TGFA , T1E, and NRG1β, as well as T1E/YYDLL 
(panerbin) and NRG/panerbin chimeras. Conserved cysteines are numbered and 
depicted in bold. Residues in red are involved in hydrogen bond formation, residues 
in green in hydrophobic interactions, and residues in blue in salt bridge formation 
with the indicated ErbB receptors. Negative constraints are depicted in grey, when 
known. Different ligands may share a residue on the same position in the linear 
representation, of which one interacts with a receptor and the other does not, 
because of differences in rotamer positions of the amino acids determined by the 
surrounding sequences. Indicated interactions of N3P4N6P and N1P2N3P4N6P with 
ErbB1 are predicted on basis of the homology models of panerbin with ErbB1. 
Ligands indicated with an asterisk do not show detectable binding affi nity for the 
indicated ErbB receptor. The putative positive constraints of these ligands are 
counteracted by the presence of negative constraints.
167
Why does NRG1β bind exclusively to ErbB3 and ErbB4, and not to ErbB1?
(Figure 1). Interestingly the corresponding residues in ErbB1 would not allow 
the formation of such additional hydrogen bridges with a ligand containing 
a 13-amino acids B-loop (Figure 2). Moreover, mutation studies have shown 
that reducing the length of the B-loop of NRG1β from 13 to 10 residues, 
thereby deleting this so-called omega loop, does not impair its binding affi nity 
Figure 2. Interaction of B-loop residues with the L1 domain of the ErbB 
receptors. (A) Interaction of  NRG1β with ErbB3. S27 in NRG1β can makes a 
hydrogen bond to E129 in ErbB3. N28 in NRG1β makes a hydrogen bond with Y125 
in ErbB3. (B) Interaction of EGF with ErbB1. Corresponding residues of S27 and 
N28 in NRG1β and E127 and Y125 in ErbB3 are depicted in similar colors in EGF 
and ErbB1, respectively. S127 and R125 the corresponding residues of E127 and 
Y125 in ErbB3 are not involved in hydrogen bond formation with EGF and will also 
be unable to make hydrogen bonds with NRG1β. 
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for ErbB3 and ErbB4 (12). These data therefore show that the length of the 
B-loop is not the decisive factor in the receptor specifi city of NRG1β. 
Secondly, ErbB1 has a relatively deep hydrophobic pocket in each of 
its two ligand binding domains (L1 and L2) in which the EGF residues I23 
(L23 in TGFA) and L47 can penetrate deeply (Figure 3). The corresponding 
hydrophobic pocket in the L1 domain of in ErbB3 and ErbB4 is less deep, and 
fi lled with the smaller hydrophobic residue V24 of NRG1β.  Introduction of the 
I23V mutation in EGF results in a 2-fold lower affi nity for ErbB1, indicating 
that the depth of the hydrophobic pocket in the L1 domain does not explain 
why NRG1β does not bind ErbB1.
 Thirdly, we have shown in a number of studies that sequences in the 
C-terminal linear region of EGF-like growth factors greatly affect their ErbB 
affi nity and  selectivity. Phage display analysis of ligands with a randomized 
C-terminal liner region have indicated that the residues D46 and L47 in EGF 
and TGFA are very important for high affi nity binding to ErbB1 (5). These 
two positive constraints are missing in NRG1β, which has a valine and a 
methionine residue instead. Both the EGF mutant D46V and L47M has a 
Figure 3. Hydrophobic pockets. (A and C) Ras-Mol representations of a close-up 
of the homology model of ErbB1 in complex with EGF based on the crystal structure 
of ErbB1 with TGFA (3). (B and D) Ras-Mol representations of a close-up of the 
homology model of ErbB3 in complex with NRG1β based on the crystal structure of 
ErbB1 with TGFA (3). (A) I23 of EGF (cyan) binds to the hydrophobic pocket of the 
ErbB1 L1 domain. (B) V24 of NRG1β (purple) binds to the hydrophobic pocket of the 
ErbB3 L1 domain. (C) L47 of EGF (yellow) binds deeply into the hydrophobic pocket 
of the ErbB1 L2 domain. (D) M50 of NRG1β (yellow) lies on top of the hydrophobic 
domain of the ErbB3 L2 domain.
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strongly reduced binding affi nity for ErbB1, indicating that the C-terminal 
linear region of NRG1β does not permit high affi nity binding to ErbB1. On 
the other hand we have shown that a C-terminal linear region consisting of 
the residues YYDLL is compatible with high affi nity binding to all three ligand 
binding ErbB receptors. Still we observed that the mutant NRG1/YYDLL, which 
has enhanced affi nity for ErbB3, is fully unable to bind ErbB1. These data 
indicate that the primary sequence of the C-terminal linear region of NRG1β 
alone does not explain why it is not a ligand for ErbB1.  
 Exchange of each ErbB3 residue in the NRG1β/ErbB3 homology model 
for the corresponding ErbB1 residue, while maintaining the overall backbone 
structure, did not result in a steric clash between the ligand and the receptor 
molecule. Furthermore, almost all positive constraints between NRG1β and 
ErbB3 were maintained upon introducing ErbB1 residues. It therefore appears 
that the inability of NRG1β or NRG1/YYDLL to bind ErbB1 does not result from 
a lack of positive constraints. 
A1-loop and C-loop sequences of NRG1β prevent interaction with ErbB1
 In order to identify potential negative constraints in NRG1β for binding 
to ErbB1, we fi rst introduced the 10-amino acids B-loop of EGF and the 
generally applicable C-terminal linear region YYDLL into NRG1β. The resulting 
mutant, designated N3P4N6P (in which P stands for panerbin with sequence 
T1E/YYDLL), did show high affi nity for ErbB4, but fully lacked affi nity for ErbB1 
(Figure 4A and 4B). Amino acid sequences of the chimeric growth factors and 
an overview of their positive and negative constraints are shown in Figure 1. 
We subsequently introduced additional intercysteine domains of panerbin into 
N3P4N6P, in order to test which regions of NRG1β prevent binding to ErbB1. 
The rationale behind this approach is that both panerbin and N3P4N6P bind 
ErbB3 and ErbB4 with high affi nity, while only panerbin binds in addition to 
ErbB1. Mutants obtained by introducing domains from panerbin into N3P4N6P 
will therefore retain their affi nity for ErbB3 and ErbB4, while gaining affi nity 
for ErbB1. Figure 4A shows the binding affi nity of the mutant ligands, tested 
as protein A-fusion proteins, for ErbB4 and Figure 4B for ErbB1. All mutants 
tested have high affi nity for ErbB4, as expected, although for unknown 
reasons the shape of the displacement curve differs from mutant to mutant. 
Figure 4B shows that introduction of A1-loop (mutant N1P2N3P4N6P) or 
C-loop (mutant N3P4N5P) of panerbin into N3P4N6P, results in a gain of 
affi nity for ErbB1, although not to the level of panerbin itself. Protein A-fusion 
proteins may contain an unknown fraction of misfolded protein, and therefore 
we purifi ed the active A1-loop mutant (N1P2N3P4N6P) to full homogeneity 
by cleavage of the protein A–tag and subsequent purifi cation by RP-HPLC. 
Figure 4C shows that N1P2N3P4N6P has a similarly high affi nity for ErbB4 
as N3P4N6P, while fi gure 4D shows that N3P4N6P has no affi nity for ErbB1 
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Figure 4 Binding affi nities of panerbin-NRG1β chimeras for ErbB1 and 
ErbB4. (A and C) Ligand binding displacement analysis on ErbB4 overexpressing 
T47-14 cells treated with 1 ng/ml [125I]-NRG1β. (B and D) Ligand binding 
displacement analysis on ErbB1 over-expressing HER14 cells treated with 1 ng/ml 
[125I]-EGF. (A and B) Cells were incubated with increasing amounts of the unlabeled 
ligands: NRG1β (─¢─), Panerbin (T1E/YYDLL) (─¯─),  N3P4N6P (─p─) and 
N1P2N3P4N6P (──). (A and B) Cells were incubated with increasing amounts of 
Protein A-tagged ligands: protein A-EGF (─¿─), protein A-NRG1β (─¢─), protein A-
panerbin (T1E/YYDLL) (─¯─),  protein A-N3P4N6P (─p─), protein A-N1P2N3P4N6P 
(──) and protein A-N3P4N5P (─r─). Values of bound radiolabeled ligand in the 
absence of unlabeled ligand was set on 100%. Results are the mean of at least two 
independent experiments performed in duplicate.
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and  N1P2N3P4N6P approximately 10% of the affi nity of panerbin. These data 
indicate that negative constraints in the A1-loop and C-loop of NRG1β impair 
its interaction with ErbB1. 
DISCUSSION
 Many studies have been performed on the receptor selectivity of EGF-
like growth factors. The requirements for binding of EGF and TGFA to ErbB1 
have been studied in particular detail, while we have focussed in previous 
studies on the question why EGF and TGFA are unable to bind ErbB3 and 
ErbB4. We have shown both experimentally and by homology modeling that 
EGF and TGFA can form suffi cient interaction sites with ErbB3 and ErbB4 to 
allow high affi nity binding, but that interaction with these receptors is impaired 
by a number of specifi c ligand residues, which we have referred to as negative 
constraints. Relieve of these negative constraints (S2D3 and R45 in EGF; E26 
in TGFA) appeared suffi cient to give both ligands considerable binding affi nity 
for ErbB3 and ErbB4, while maintaining wild-type affi nity for ErbB1. In the 
present study we have used a similar approach to understand why  NRG1β 
is able to bind ErbB3 and ErbB4, but not ErbB1. Our homology models show 
that binding of NRG1β to ErbB1 is not impaired by a steric clash between 
ligand and receptor, while in addition suffi cient potential positive constraints 
appear present to allow considerable binding affi nity of NRG1β to ErbB1. 
Furthermore, by exchanging domains between NRG1β and panerbin, we have 
shown experimentally that NRG1β contains putative negative constraints for 
binding to ErbB1 within its A1-loop and C-loop.
 The most conspicuous difference between EGF or TGFA  and  NRG1β 
is the length of the B-loop. However, it has been established previously that 
reducing the length of the NRG B-loop from 13 to 10 residues, similarly as in 
EGF, does not affect its binding affi nity for ErbB3 and ErbB4 (12). Moreover, 
it is known from mutational analysis that the C-terminal linear sequence 
of NRG1β (NYVMAS) does not facilitate high affi nity binding to ErbB1 (1), 
particularly due to the lack of D46 and L47 as in EGF and  TGFA. However,, 
various studies have shown that this wild-type sequence is also not optimal 
for binding to ErbB3 (12). Exchange of this sequence to YYDLL, which has 
been found by us as the optimal C-terminal linear region for binding to all 
three ligand-binding ErbB receptors, enhances the binding of  NRG1β to 
ErbB3, but does not allow this ligand to bind ErbB1 (12). In fact, our present 
results show that introduction of the B-loop of EGF, in combination with the 
YYDLL sequence into the C-terminal linear region (mutant N3P4N6P), is not 
suffi cient to allow any binding of NRG1β to ErbB1.     
 Upon introduction of further panerbin (or EGF) sequences into 
N3P4N6P, we derived two mutants with detectable binding affi nity for 
ErbB1. The ligand with the highest binding affi nity for ErbB1 was obtained 
by introducing the A1-loop of EGF into N3P4N6P, giving rise to the mutant 
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N1P2N3P4N6P. This suggests that the A1-loop of EGF may contain a strong 
positive constraint or that the A1-loop of NRG1β contains a strong negative 
constraint for ErbB1. Two amino acids in the EGF A1-loop are directly involved 
in ErbB1 binding; D11 and Y13. D11 makes a hydrogen bound with S354 of 
ErbB1, and mutation of D11 into an isoaspartic acid, which will most likely 
disrupt the hydrogen bond, results in a fi ve–fold loss of affi nity (13). The 
corresponding residue of D11 in NRG1β is K11, but it is currently unclear if 
K11 forms a negative constraint for ErbB1. Furthermore, Y13 in EGF makes 
a ring stacking with F355 in ErbB1, which may be shared by F13 in NRG1β. 
Intriguingly, however, the other residues in the A1-loop are oriented away 
from the receptor molecule and are therefore not directly involved in receptor-
ligand binding.
Introduction of the C-loop of EGF in N3P4N6P also resulted in a mutant 
(N3P4N5P) with detectable affi nity for ErbB1. Two residues of the EGF C-loop 
are directly involved in ErbB1 interaction; E40 and R41. The corresponding 
positions in the NRG1β C-loop contain  D40 and R41. Both of these residues 
would be able to make similar interactions with ErbB1. So other residues 
within the NRG1β C-loop (sequence PNEFT) are most likely responsible for the 
negative constraint which prevents binding of NRG1β to ErbB1. Again these 
residues in the C-loop are oriented away from the receptor. More detailed 
studies will be needed to clarify the role of the A1- and C-loop in the receptor 
selectivity of  NRG1β.
It can be speculated that the A1-loop and C-loop play a, so far not 
recognized, subtle role in the conformation of the ligand and thereby directly 
affects receptor-binding affi nity. It should be emphasized that the homology 
models used in this study have been based on the backbone structure of 
TGFA in complex with ErbB1, and not on the solution structure NRG1α. These 
structures are highly similar, but subtle differences cannot be excluded. 
It appears that the lack of binding affi nity of NRG1β for ErbB1 is not 
due to the presence of a limited number of residues that act as negative 
constraint, as observed for the lack of binding of EGF and TGFA to ErbB3. Our 
data indicate that for reasons not well understood each of the intercysteine 
domains contributes to a certain extent to the lack of binding affi nity of NRG1β 
to ErbB1. The more domains from panerbin are introduced into NRG1β, the 
higher the affi nity for ErbB1, but so far it has not been possible to pinpoint 
a few residues that due to steric hindrance or electrostatic interaction impair 
NRG binding to ErbB1.     
 Exchange of single amino acids between the EGF and NRG1β A1-loop 
or C-loop will identify those residues in the NRG1β A1-loop and C-loop that 
prevent ErbB1 binding. Identifi cation of negative constraints in NRG1β for 
ErbB1 and subsequently the nature of this negative constraint (steric clash, 
charge repulsion or subtle change of conformation) will contribute to our 
understanding of how receptor selectivity of ErbB ligands is regulated.
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Table 1.
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ABSTRACT
 The EGF receptor signaling network in Drosophila melanogaster 
consists of a single receptor (DER), which can be activated by four distinct 
ligands, designated Spitz, Keren Gurken and Vein. The overall structure of 
these ligands is very similar to that of human EGF, but so far there is no 
indication that human and Drosophila EGF-like growth factors are able to bind 
to each other’s receptors. In this study we have made the four Drosophila 
EGF-like growth factors as recombinant proteins and have shown that none 
of them is able to bind human ErbB1. Furthermore, we showed that human 
EGF cannot bind DER. In order to understand the receptor specifi city of EGF 
and Spitz, we made chimeras by exchanging intercysteine domains between 
the two proteins. Our data show that EGF in which the region between the 
third and the fi fth cysteine has been replaced by Spitz sequences, binds with 
low affi nity to both ErbB1 and DER, and is able to induce MAPK activation in 
both DER overexpressing S2DER cells and ErbB1 overexpressing HER14 cells. 
Our results indicate that the receptor specifi city of Spitz and DER does not 
result from structural differences between these ligands and their receptors, 
but more from evolutionary differences in individual amino acids that impair 
binding to each other’s receptors. 
INTRODUCTION
 The ErbB signaling network is highly conserved among multicellular 
organisms and plays an important role in growth and development. During 
evolution the ErbB signaling network has evolved from a relatively simple 
receptor-ligand complex to a complicated multi-component system. 
Invertebrates such as Caenorhabditis elegans contain one EGF receptor gene 
(let-23) which is activated by a single ligand (lin-3) (1). The fruitfl y Drosophila 
melanogaster (2) also contains a single EGF receptor gene (DER), but this 
receptor is regulated by four distinct EGF-like growth factors, designated 
Spitz, Keren, Gurken, and Vein (3). In urochordates two distinct receptor 
genes have been identifi ed, most likely as a result of a fi rst whole genome 
duplication (Van Leeuwen et al., unpublished). A second whole genome 
duplication has resulted in the four ErbB receptors present in mammals 
(ErbB1-4), which can be activated by a total of eleven distinct ligands. 
ErbB1 can be activated by a.o. EGF and TGFA and is expressed in almost 
all tissues. Studies with knockout mice have shown that ErbB1 functions in 
the development of lung, epidermis, placenta and mammary gland (4-6). 
Furthermore, ErbB1 is overexpressed in many, particularly epithelial tumors, 
and is therefore an important target for anti-tumor drugs.  
 The Drosophila EGF receptor DER plays an important role in eye and 
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wing development of the fl y. The key regulatory step for activation of this 
receptor is the proteolytic processing of membrane-bound Spitz, Keren and 
Gurken by proteolytic enzymes, including Star and Rhomboid. Spitz and Keren 
are ubiquitously expressed during Drosophila development, while Gurken is 
only transcribed in germline cells and activates DER in the follicle cells of the 
ovary. Finally, Vein is a secreted ligand with weaker activation capacity and 
is involved in muscle attachment. Furthermore, the Drosophila EGF receptor 
system is unique in that it contains in addition a secreted antagonist, named 
Argos. This antagonist has an EGF-like structure and prevents DER binding of 
a.o. Spitz. (7)
 The extracellular domain of ErbB receptors contains two leucine-rich 
domains (L1 and L2) that are involved in ligand binding and are spaced by two 
cysteine-rich domain (C1 and C2), followed by a transmembrane region and 
an intracellular tyrosine kinase domain. Upon ligand binding ErbB receptors 
undergo a conformational change from an auto-inhibited to an open state, 
and consequently the C1 domain becomes available for receptor dimerization 
(8). DER resembles the mammalian family members in its overall structure 
but for unknown reasons its second cysteine-rich domain is extended as a 
result of duplication (9). 
 All EGF-like growth factors share an overall structure of approximately 
50 amino acids with a conserved spacing of cysteines that form three bridges 
and thereby give rise to three looped regions, designated A-, B- and C-loop. 
From crystal structure analysis of the EGF/ErbB1 and the TGFA/ErbB1 complex, 
it is known that EGF-like growth factors contain approximately 20 residues 
that directly interact with their receptor (10, 11). These residues, which we 
have referred to as positive constraints, form the basis for the observed high 
affi nity receptor interaction. Spitz and human EGF show 32% and the ligand 
binding domains of DER and ErbB1 more than 40% sequence homology. 
Although the primary structure of Spitz resembles its mammalian orthologues 
to a large extent, Spitz does not appear to bind human ErbB receptors. This 
might be due to the fact that it is unable to fulfi ll suffi cient positive constraints 
with mammalian ErbB receptors for high affi nity interaction, or because it 
contains residues that by steric hindrance or charge repulsion prevent binding 
to these receptors.      
 In present study we have investigated  the compatibility between 
the human ErbB system and the DER system. Therefore we stimulated 
DER overexpressing S2DER cells with several ErbB ligands and stimulated 
ErbB1 overexpressing cells with recombinant Spitz, Keren, Vein and Gurken. 
To determine why human EGF does not bind and activate DER and why 
Drosophila Spitz does not bind and activate human ErbB1, we designed several 
hEGF-Spitz chimeras. Based on these functional studies in combination with 
homology models of the Spitz-DER complex, we have identifi ed a number of 
amino acids in Spitz that impair its binding to ErbB1. 
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EXPERIMENTAL PROCEDURES
Cell lines
 Interleukin 3-dependent murine 32D hematopoietic progenitor cells 
transfected with distinct human ErbB-encoding plasmids were cultured in 
RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum 
(FCS, GibcoBRL Life Technologies) and 0.25 ng/ml murine interleukin 3 (mIL-
3, Promega), and kept subsequently under continuous selection by addition of 
0.6 mg/ml G418 (Calbiochem). ErbB1 overexpressing HER-14 fi broblasts (12) 
and ErbB4 overexpressing T47-14 fi broblasts, both derived from the parental 
murine NIH3T3 cell line, were cultured in gelatinized fl asks in Dulbecco’s 
modifi ed Eagle’s medium (DMEM) supplemented with 10% newborn calf 
serum (NCS).
Production of EGF-Spitz chimeras
 DNA encoding Spitz-EGF chimeras were constructed using splice 
overlap extension PCR (13), using human EGF and Drosophila Spitz cDNA 
(kindly provided by Dr. Matthew Freeman, MRC-Laboratory of Molecular Biology, 
Cambridge, UK) as templates. The 5’-primer contained a linker (sequence: 
GGATCCATTGAAGGTCGT) with a BamH1 restriction site as well as a sequence 
encoding the amino acid sequence IEGR, that can be cleaved by the Factor X 
endoprotease, while the 3’-primer (sequence: GTCGACTTA) contained  a stop 
codon and a SalI restriction site. The inserts were introduced into the pEZZ 
vector using the BamHI and SalI sites, and the obtained constructs verifi ed 
by automated cycle sequencing. Recombinant ligands were expressed as 
a protein A-tagged fusion proteins in the protease K-defi cient E.coli strain 
KS474. Chimeras were purifi ed by affi nity chromatography using an IgG-
sepharose column followed by RP-HPLC. The amount of protein A-tagged 
Spitz-EGF chimera was calculated from the peak area (absorption at 229 nm) 
in the RP-HPLC chromatogram, using murine (m)EGF as a standard.
Production, purifi cation and quantifi cation of myc-tagged DER ligands
 Since we did not succeed in producing Vein and Gurken in E.coli we 
used the Pichia pastoris protein expression system (Invitrogen) in order to 
produce all four DER agonists. Thereto, cDNA of the DER ligands (all kindly 
provided by Dr. Ben-Zion Shilo, Department of Molecular Genetics, Weizmann 
Institute, Israel) was cloned into the P. pastoris expression vector pPICZ_A. 
(Spitz aa F71-K129, Keren aa F57-T113, Gurken aa I178-Y234 and Vein aa 
A561-V610) The primers used for PCR introduced a 5 prime XhoI and a 3 
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prime XbaI restriction site permitting directional cloning of the amplifi ed 
DNA in frame with the α-factor signal sequence in the pPICZ_A expression 
vector. Recombinant DER ligands were expressed in Pichia pastoris with an 
N-terminal cleavable Myc-His-Genenase-1 tag, as described previously (14). 
In brief, expression of recombinant DER ligands was induced by growing 
a selected Mut+ clone on BMMY (1% yeast extract, 2% peptone, 100 mM 
potassium phosphate pH 6.0, 1.34% yeast nitrogen base, 0.04% biotin and 
0.5% v/v methanol) for four days at 30oC with additional supplies of methanol 
every day. DER ligands were purifi ed using Ni-NTA beads (Invitrogen) and 
dialyzed against 0.5 M HAc, using a dialysis bag with a cut off smaller than 
3.5 kDa. The concentration of Myc-tagged recombinant growth factor present 
in the dialyzed Ni-NTA eluate was quantifi ed by spotting serial dilutions on 
a nitrocellulose membrane followed by detection with anti-Myc antibodies. 
Staining was compared with that of a serial dilution of a known amount of Myc 
peptide (R&D systems).
 Receptor phosphorylation and MAPK activation
 DER expression was induced  in S2DER cells by treating these cells 
overnight with 0.6 μM CuSO4 in Schneider’s medium supplemented with 0.5% 
FCS . A total of 1.0x106 S2DER cells were subsequently stimulated for 5 min 
at 30oC with 20 ng recombinant DER ligand in a 100 μl cell suspension. Cells 
were then spun down and washed with ice-cold PBS after which they were 
rapidly lysed in 100 μl of lysis buffer supplemented with protease inhibitors (50 
mM Tris-HCl pH 8.0, 150 mM NaCl, 15 mM Na-deoxycholate, 0.1% SDS, 1.5 
mM MgCl2, 1 mM PMSF, 5 μg/ml pepstatin A, 0.15 units/ml aprotein, 5 μg/ml 
leupeptin, 2mM Na3VO4). Lysates were analyzed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE), using 8%  acrylamide gels, 
followed by a 1 hour transfer at 300 μA to a nitrocellulose membrane, wetted 
in Tween containing Tris-buffered saline (TBST: 10 mM Tris-HCl pH 7.6, 137 
mM NaCl, 0.1% Tween-20) with 5% BSA. Subsequently the membranes were 
cut horizontally in two pieces at a height corresponding to the 100 kDa region, 
after which the upper part was incubated overnight at 4oC  with a 1:2.000 
dilution of PY20 anti-phosphotyrosine antibodies  (Upstate Biotechnology), 
while the lower part was incubated for 1 hour at 4oC with a 1:2.000 dilution 
of anti-phosphorylated MAPK antibodies (Cell Signaling) in TBST/BSA. Both 
incubations were followed by a 1 hour treatment with a 1:10.000 dilution of 
peroxidase-conjugated rabbit-anti-goat antibodies (Cell Signaling) in TBST/
BSA. After each incubation step the membranes were washed in TBST with 
constant agitation. Blots were visualized using enhanced chemoluminiscence 
(ECL). Dual stain molecular weight markers (range 10-250 kDa) were 
obtained form BioRad.
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Radioligand displacement analysis
 Natural mEGF (Bioproducts for Science) and recombinant protein 
A-tagged Spitz were iodinated enzymatically to a specifi c activity of 1.1 Ci/ 
μmol (15). Ligand binding displacement studies on HER14 were performed 
as described previously (16). Ligand binding displacement studies on S2DER 
cells were performed in suspension. To 2.5x106 CuSO4- treated S2DER cells in 
0.1 ml Schneider’s Medium/10% BSA, 0.1 ng of [125I]-protein A-tagged Spitz 
was added in the additional presence of serial dilutions of unlabeled ligand. 
After incubation for 2 hours at room temperature, cells were spun for 1 min 
in a microcentrifuge and washed to remove unbound [125I]-protein A-tagged 
Spitz. Cells were then resuspended in 0.5 ml of Schneider’s medium with 10% 
FCS and 2% BSA, loaded onto a cushion of 0.7 ml undiluted FCS and spun 
down in a microcentrifuge for 1 min at 13.000 rpm. Radioactivity in the cell 
pellets was measured by γ-counting.
RESULTS
 
DER ligands form high molecular weight complexes in Pichia pastoris
 We have previously shown that mammalian EGF-like growth factors 
can be functionally expressed in Pichia pastoris. In order to obtain recombinant 
DER ligands we used a similar approach after linking their genes to a cleavable 
Genenase I-Myc-His tag. Figure 1A shows that after isolation on Ni-NTA beads 
from the culture supernatant, the various DER ligands showed high molecular 
weight complexes with apparent sizes of 25-75 kDa, far exceeding the 
expected size of approximately 8.5 kDa. In contrast to mammalian EGF-like 
growth factors, Spitz, Gurken and Vein contain potential glycosylation signals 
in their EGF-like domain and since Pichia pastoris is known for its extensive 
mannose glycosylation, we determined whether the obtained recombinant 
ligands were glycosylated. Figure 1B and 1C show that cleavage of the sugar 
chains by  endoglycosydase F treatment resulted in  reduced molecular 
sizes of 15-25 kDa for Spitz, Gurken and Vein, while the molecular size of 
Keren, which lacks a glycosylation site,  was  unaffected by endoglycosidase 
F treatment. Furthermore it appeared that the obtained ligands showed 
intramolecular disulphide bridges, since their apparent molecular sizes were 
signifi cantly reduced when the SDS gels were run under reducing conditions 
(Figure 1B). These data show that recombinant expression of DER ligands in 
Pichia pastoris is far more complex than previously observed for mammalian 
EGF-like growth factors.   
 In order to quantify the amount of Myc-tagged recombinant DER 
ligands, serial dilutions of Ni-NTA elute were spotted onto blotting paper, 
together with a known amount of Myc peptide, and stained with anti-Myc 
antibodies.  Figure 1D shows the chemiluminescence intensity of DER ligands 
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and Figure 1E the conversion of microliters culture medium to nanomoles of 
Myc-tagged DER ligand. In this way we determined a concentration of 2 nM 
Spitz, 6 nM Keren, 15 nM Vein and 15 nM Gurken in the NI-NTA elutes. 
Figure 1. Expression of DER ligands in Pichia pastoris. A. Western blot of Myc-
tagged recombinant DER ligands under non-reducing conditions. Molecular sizes are 
indicated in kDa. B. Effect of beta-mercapto-enthanol (β-ME) and endoglycosidase 
F treatment on the electrophoretic behaviour of Spitz (S). C. Effect of β-ME and 
endo F on the electrophoretic behaviour of Keren (K), Vein (V) and Gurken (G). D. 
Quantifi cation of Myc-tagged recombinant DER ligands after Ni-NTA purifi cation and 
spot-blotting of the Ni-NTA elutes as detected by anti-Myc antibodies. Calibration 
was carried out by spotting the indicated amounts of Myc-peptide E. Quantifi cation 
of DER ligands based on dose-dependent Myc staining intensity as measured 
by densitometry. Levels of 50% Myc-tag staining (IC50 value) were estimated 
graphically from the highest and lowest values obtained experimentally. The 
following concentrations of the myc-tagged DER ligands were deduced from the 
IC50 values: Myc peptide (─○─), Gurken (─●─) 20 nM, Spitz (─♦─) 2 nM, Vein 
(─■─) 20 nM, Keren (─▲─) 6 nM.
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Detection of the relative binding affi nity of Spitz, Keren, Gurken and Vein for 
DER and ErbB receptors
 To determine the relative affi nity of these Drosophila ligands for DER, 
we determined their ability to compete with radiolabeled protein A-tagged 
Spitz for binding to DER overexpressing S2DER cells. Figure 2A shows that 
based on Myc-equivalents Spitz (IC50 = 8 nM) has the highest binding affi nity 
for DER, followed by Keren (IC50 = 30 nM) and Gurken (IC50 = 70 nM). 
At the concentrations tested no binding competition was observed for Vein. 
Figure 2B shows that Spitz strongly induces DER phosphorylation and MAPK 
phosphorylation in S2DER cells, while Keren, Gurken and Vein showed only 
weak effects. Interestingly, also Vein was active in these assays, in spite of 
the fact that its binding affi nity was below detection. 
In order to determine whether the DER ligands are able to activate 
the various human ErbB receptors, HER14 cells (ErbB1), D23 cells (ErbB2 and 
ErbB3) and T47-14 cells (ErbB4) were stimulated with Spitz, Keren, Gurken 
and Vein but, as shown in Figure 3, none of the DER ligands was able to 
induce phosphorylation of one of these ErbB receptors. Furthermore the data 
Figure 2.
Determination of the 
binding affi nity of 
Spitz, Keren, Gurken 
and Vein for DER. A. 
[125I]-protein A-Spitz 
binding competition 
assays on S2DER cells. 
Vein (─●─), Gurken 
(─▲─), Keren (─■─), 
Spitz (─♦─). B. Ligand-
induced tyrosine 
phosphorylation and 
MAPK phosphorylation. 
S2DER cells were 
stimulated with 20 
nM ligand for 10 
min. BSA was used 
as negative control. 
GAPDH was tested 
as a loading control.
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show that none of the mammalian ErbB ligands appeared able to activate DER 
in a phospho-tyrosine or MAPK assay. 
Identifi cation of EGF and Spitz domains involved in binding specifi city for DER 
and ErbB1
 In order to identify experimentally which regions in EGF and Spitz 
are discriminative for receptor binding, we made a set of chimeras between 
EGF and Spitz, and tested their affi nity for both ErbB1 and DER. Chimeras 
Figure 3. Activation of DER and ErbB1 by mammalian and Drosophila EGF-
like growth factors, as measured by induced tyrosine phosphorylation and 
phosphorylation of MAPK. HER14, T47-14, D23 and S2DER cells were stimulated 
with 20 nM Spitz (S), 20 nM Keren (K), 20 nM Gurken (G), 20 nM Vein (V), 100 
ng/ml EGF (E), 100 ng/ml TGFΑ (T), 100 ng/ml NRG1β (N), 100 ng/ml BTC (B), 100 
ng/ml EREG (Er) and 100 ng/ml of the chimera E3S5E (ES) for 10 min. BSA (Bl) was 
used as a negative control. 
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were made by exchanging domains bordered by the third and fi fth cysteine of 
both ligands.  Figure 4A shows that in EGF the sequences N-terminal of the 
third cysteine can be replaced for the corresponding sequences of Spitz (S3E) 
without loss of binding affi nity for ErbB1. However, exchange of the B-loop 
and hinge region (E3S5E) or of the C-loop in combination with the linear C-
Figure 4. Determination of the binding affi nity of Spitz-EGF chimeras for 
DER and ErbB1. A. [125I]-mEGF binding competition assay on HER14 cells. B [125I]-
protein A-Spitz binding competition assays on S2DER cells. Unlabeled EGF (─♦─), 
Spitz (─■─), E3S (─∆─), S3E (─○─), E5S (─◊─), S5E (─●─), E3S5E (─▲─) and 
S3E5S (─□─) were added at the indicated concentrations. Results are presented as 
mean of at least three independent experiments performed in duplicate. C. Relative 
affi nities of the EGF-Spitz chimeras for DER and ErbB1, based on the IC50. Data 
are expressed relative to EGF (for ErbB1) and Spitz (for DER). Ligands that did not 
reach 50% binding competition within the concentration range tested are indicated 
as NMA (no measurable affi nity).
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terminal region (E5S) by Spitz sequences reduced the affi nity of EGF for ErbB1 
to 10-15%. Figure 4B shows that introduction of EGF sequences N-terminal 
of the third cysteine of Spitz (E3S) reduced the affi nity of the latter for DER 
to 15%, while EGF with only the B-loop and hinge region of Spitz (E3S5E) 
showed only 2% of the affi nity of Spitz for DER. None of the chimeras tested 
showed high affi nity binding to both DER and ErbB1. Nevertheless, E3S5E 
showed low but detectable binding affi nity for both DER and ErbB1, and was 
the only ligand that was able to induce ErbB1 phosphorylation and MAPK 
phosphorylation in both HER14 cells and S2DER cells, as shown in Figure 3. 
Figure 5. Interaction sites of EGF-Spitz chimeras with ErbB1 and DER, 
based on homology models. Amino acid numbering  is indicated for EGF and 
Spitz. Colored residues represent the direct interaction sites between the indicated 
ligand and receptor, as predicted by homology models based on the crystal structure 
of the TGFΑ-ErbB1 complex. Residues marked in red in the ligand sequences are 
involved in hydrogen bond formation, residues in green are involved in hydrophobic 
interactions, and residues in blue are involved in salt bridge formation with the 
indicated receptors.
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It can be concluded that binding to ErbB1 and DER is not mutually exclusive, 
but that with the current approach no high affi nity ligands were obtained for 
both receptors. 
E35N and I50L mutation is not suffi cient for Spitz interaction with ErbB1
 In order to understand at the molecular level why Spitz is unable to 
bind ErbB1 and EGF to bind DER, we used a bioinformatics approach in which 
the Spitz/DER complex was modeled and subsequently compared to that of 
EGF/ErbB1. For homology modeling we have made use of the experimental 
crystal structure of the TGFΑ-ErbB1 complex (10). We have previously shown 
that the high affi nity interaction between EGF and ErbB1 is mediated by three 
salt bridges, eight hydrogen bonds and eight hydrophobic interactions. A 
similar analysis on the Spitz/DER complex showed that Spitz can form two 
salt bridges, eight hydrogen bonds and eleven hydrophobic bonds with DER 
(Figure 5). Based on amino acid sequence homology between EGF and Spitz 
we assume that a large number of salt bridges and hydrogen bonds cannot 
be formed between Spitz and ErbB1, particularly in the hinge region and in 
the C-terminal linear region. However, no putative charge repulsions or steric 
clashes were predicted which could impair the binding of Spitz to ErbB1. 
Figure 6. Determination of the ErbB1 binding affi nity of Spitz/E33N/I49L. 
A. [125I]-protein A-Spitz binding competition assays on S2DER cells. B [125I]-mEGF 
binding competition assay on HER14 cells. EGF (─♦─), Spitz (─■─) and Spitz E35N 
I50L (─○─). Results are presented as mean of three independent experiments 
performed in duplicate. 
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Compared to EGF, Spitz contains an Asp instead of N33 in the hinge 
region, which in EGF makes a hydrogen bond with Q18 in ErbB1, and an Ile 
instead of L47 in the C-terminal linear region, which is known to be essential 
for high affi nity binding of ErbB1. Single amino acid mutations in EGF have 
shown that the mutation N33D results in a four-fold decrease (17) and the 
mutation L47I in a six-fold decrease (18)  in ErbB1 affi nity. We therefore 
tested the mutant Spitz/E35N/I50L for binding affi nity to both ErbB1 and 
Figure 7. Overlay of EGF domain structures. Unbound (grey) and Argos-bound 
(green) Spitz are shown overlaid with crystallographically derived (sEGFR-bound) 
structures of EGF  (cyan) and TGFA (yellow), diphtheria toxin-bound HB-EGF (blue/
purple), and a NMR structure of free NRG1α (28) (magenta). Note that Spitz most 
closely resembles NRG1α in the length and approximate conformation at the end of 
the B-loop. The tip of the B-loop is also the only region in which clear differences 
between free (grey) and bound (green) Spitz can be discerned. Figure adapted 
from Klein et al. (24), including data for EGF (11), TGFA (10), HB-EGF (27) and 
NRG1α (28).
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DER. Figure 6 shows that introduction of these two mutations in Spitz did 
not affect its binding affi nity to DER, but the double mutant did not show any 
detectable binding affi nity to ErbB1. It can therefore be concluded that the 
E35N and I50L mutations in Spitz are not suffi cient to make it a high affi nity 
ligand for both ErbB1 and DER. 
DISCUSSION
 In this study we have shown that recombinant Drosophila EGF-like 
growth factors are able to activate DER but cannot bind to human ErbB 
receptors. Similarly, all human ErbB ligands tested, in particular EGF, TGFΑ, 
NRG, BTC and EREG, were unable to activate DER. Domain-exchange studies 
between EGF and Spitz resulted in a chimera E3S5E with detectable, but still 
low binding affi nity to both DER and ErbB1.  
 Binding competition analysis on S2DER cells showed that Spitz is 
the Drosophila ligand with the highest binding affi nity for DER, while Vein is 
only a low affi nity binder. This is consistent with literature data in which is 
has been shown that Spitz is the main DER activation ligand in vivo, while 
Vein as a weak activator is used in tissues where only low levels of  DER 
activation are required (19). None of the DER ligands was able to activate 
any of the human ErbB receptors in the concentration range tested. In a 
recent study we have shown that the positively charged R45 in the TGFΑ-
EGF chimera T1E is a negative constraint for binding to both ErbB3 and 
ErbB4 (20). Furthermore, Hobbs et al. (21) have shown that K48 in NRG2α 
prevents interaction with ErbB3 while the K48F mutation in NRG2α results in 
a gain of function for binding to ErbB3. In chapter 4 we showed that R45 in 
EGF causes a charge repulsions with K415 in ErbB3 and with K418 in ErbB4. 
Therefore we assume that K48 in Spitz, the corresponding residue of R45 in 
EGF, will prevent binding to ErbB3 or ErbB4. Remarkably, DER contains a Lys 
on the corresponding position of K415 of ErbB3, while a Lys on position 48 
is conserved in all four DER activating ligands. However, homology modeling 
shows that the conserved K48 in DER ligands will make a salt bridge with 
E379 and will not cause a charge repulsion with K415 in DER. 
 In the homology model of Spitz in complex with DER we made use 
of the existing crystal structure of TGFΑ in complex with EGFR. While the 
backbone structure was left unchanged the side chains were replaced by 
those of Spitz and DER, whereby optimal rotamers of the side chains were 
calculated by SCWRL (22) and checked by WHATIF (23). Overlay of the 
backbone structure obtained from the recently published crystal structure of 
Spitz (24) with that of EGF in complex with ErbB1 showed that both ligands 
adopt a mostly similar folding, except for the backbone structure of the B-
loop (Figure 7). This mainly results from the fact that the Spitz B-loop is 
two residues longer than that of EGF. As a consequence modeling Spitz on 
the TGFΑ backbone will introduce errors particular in the B-loop structure. 
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The difference in backbone structure of the B-loop of Spitz and EGF alone, 
however, does not explain why Spitz does not interact with ErbB1 since the 
complementary chimera S3E5S, in which the B-loop sequences of Spitz were 
exchanged for the corresponding sequences of EGF, did not interact with the 
human ErbB1. 
 We succeeded in designing a Spitz-EGF chimera, E3S5E, with binding 
affi nity for human ErbB1 and DER, which was able to induce MAPK activation 
in both DER overexpressing S2DER cells and human ErbB1 overexpressing 
HER14 cells. The relative binding affi nities of E3S5E for DER and ErbB1 
are however not very high. Remarkably, based on the primary amino acid 
sequence and comparison of the crystal structures and homology models 
of ligand-receptor complexes, we are still unable to understand why Spitz 
does not bind to ErbB1. Now we found that E3S5E is a low affi nity ligand for 
both DER and ErbB1 attempts can be made to model the interaction between 
E3S5E and ErbB1, and E3S5E and DER, based on the available experimental 
crystal structure of TGFA in complex with ErbB1. 
ORIGINAL INTEREST
 It was the initial intention of the above study to obtain a Spitz/EGF 
chimera with high binding affi nity for both ErbB1 and DER. Based on the 
initial assumption that Argos could act as a receptor antagonist by inhibiting 
binding of Spitz, we planned to design a humanized version of Argos that 
could act as a receptor antagonist for ErbB1. In order to do so, we intended 
to exchange domains between the above DER and ErbB1 bispecifi c agonist 
and the DER selective antagonist Argos. These considerations were based on 
the observation that Argos has an EGF-like domain, and the studies by Jin 
et al. (25) had shown that Argos binds directly to DER and prevents Spitz-
induced DER dimerisation and activation. Furthermore, Howes et al. (26) had 
demonstrated that the Argos B-loop and linear C-terminal region are essential 
for the antagonistic activity of Argos, and that the C-loop of Argos could be 
exchanged for that of Spitz. Recent studies have shown that Argos most likely 
acts by scavenging Spitz, rather than by binding to DER (24). Still studies 
on the binding affi nity of Spitz-EGF chimeras are interesting, since they may 
give information on the evolutionary diversifi cation of ligands in their ability 
to bind their receptor.
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9.1 Introduction 
 The ErbB signaling network is involved in the development of many 
tissues in the human body. The four receptors of the human ErbB family 
are each activated by a different subset of in total eleven ErbB ligands. 
Upon ligand binding receptors dimerize resulting in transphosphorylation 
and subsequently the activation of several signal transduction pathways. 
The kinase-defi cient ErbB3 is dependent on the orphan ErbB2 co-receptor 
to form an active dimeric complex (1). This thesis focuses on the molecular 
basis that underlies the affi nity of the ligand-receptor interaction, as well as 
on the ErbB specifi city and mitogenic potential of their ligands. Based on our 
results and those of others, we conclude that affi nity is mediated by a large 
number of residues that are directly involved in receptor binding, collectively 
referred to as positive constraints (2). ErbB selectivity, however, is mainly 
determined by residues that are not essential for high affi nity binding to their 
cognate receptor but that even in presence of suffi cient positive constraints 
prevent or strongly impair the unintended binding to other ErbB receptors. 
These residues, which we collectively refer to as negative constraints, 
can prevent receptor-ligand interaction either by charge repulsion, steric 
hindrance or by changing the structure of the ligand. The relation between 
receptor affi nity and mitogenic potential of ligands is very complex and is 
not completely understood. On many cells, there appears no direct relation 
between ligand affi nity and mitogenic activity. For ErbB1-binding ligands 
the mitogenic activity has been shown to depend in addition on the on/off 
rate of the ligand-receptor complex (3), the pH sensitity of the internalised 
receptor-ligand complex and on the rate of ligand depletion from the medium 
as a result of receptor binding and internalisation (4). Heterodimerization of 
ErbB1 with ErbB2 decreases the rate of internalisation of ErbB1-bound ligands 
(5) and promotes ErbB1 recycling, but it remains unclear if this fully explains 
the enhanced mitogenic effect of ErbB1/ErbB2-bound ligands. The difference 
between receptor affi nity and mitogenic activity of ErbB3 and ErbB4 binding 
ligands is even much less clear, and will be discussed here.
It is remarkable that during evolution low affi nity ErbB ligand have 
maintained themselves. It has been proposed that low affi nity ligands 
might preferentially induce the formation of ErbB2-containing heterodimers, 
suggesting that there must be evolutionary pressure on the maintenance of 
such heterodimeric signaling. This can particularly be understood for ErbB3 
binding ligands, assuming that low affi nity ligands preferentially induce 
biologically active ErbB2-ErbB3 heterodimers, while high affi nity ligands 
may preferentially induce biologically inactive ErbB3 homodimers (6). We 
will describe a model in which signaling through ErbB2-ErbB3 heterodimers 
is determined by the ratio and distribution of ErbB2 and ErbB3 on the cell 
surface, as well as the affi nity of the ligand for ErbB3. Finally, activation of 
ErbB4 signaling depends in a complex manner on the ligand binding affi nity 
and receptor heterodimerisation with ErbB2. In addition, however, ErbB4 
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signaling is dependent on its specifi c isoform and signaling mechanism 
(canonical vs non-canonical), as well as on  the presence of TACE and γ-
secretase enzymes that can cleave the ErbB4 receptor. This chapter discusses 
the above-mentioned conclusions and provides suggestions for further 
research. 
9.2 Molecular basis of binding affi nity and specifi city
 The interaction of EGF and TGFA with ErbB1 has been studied 
extensively by a variety of techniques. Crystallographic data of EGF and TGFα 
in complex with ErbB1 (7, 8) have revealed the amino acids that are directly 
involved in receptor binding, while mutagenesis studies have indicated the 
relative contribution of individual  residues in terms of receptor binding 
affi nity (9). This type of studies has resulted in the identifi cation of positive 
constraints in ligand-receptor interaction. On the other hand, domain-exchange 
strategies have provided essential information for our understanding of the 
ligand specifi city of ErbB receptors, and have resulted in the identifi cation of 
so-called negative constraints in ligand-receptor interaction. This concept has 
been based initially on our observation that human TGFA is a high affi nity 
ligand for both the human and the chicken EGF receptor, while human EGF is 
only a high affi nity ligand for human ErbB1, but has a 10-50 fold lower affi nity 
for the chicken EGF receptor (10). Our domain-exchange studies have shown 
that exchange of R45 from EGF into A45 from TGFA is suffi cient to make EGF 
a high affi nity ligand for the chicken EGF receptor. Since the R45A mutation 
does not affect the affi nity of EGF for ErbB1 (10), it must be concluded that 
R45 does not signifi cantly contribute to the binding affi nity of EGF to its 
receptor, but can impair the binding to other, related receptors.      
The resulting concept of negative constraints gained further relevance 
by our  observation that T1E, a chimera between EGF and TGFA, does not 
only bind ErbB1, but has broadened its receptor specifi city by binding to 
ErbB3 and ErbB4  (11). Subsequent phage display approaches resulted in the 
identifi cation of mutant forms in which positive constraints were enhanced 
and negative constraints depleted. In the present studies we have focused on 
the role of the C-terminal linear region, and thereby identifi ed a mutant form 
of EGF, designated panerbin (T1E/YYDLL), which binds with high affi nity to all 
three ligand binding ErbB receptors (2). Subsequent homology modeling of 
various phage display selectants provided an explanation why some residues 
act as a positive and other as negative constraint in binding to the various 
ErbB receptors. 
 Based on a combination of these various approaches, we have been 
able to divide the residues in EGF-like growth factors into four categories. First 
of all, the conserved residues that are essential for the tertiary structure:  the 
six cysteines, as well as G18 and G39. Secondly, the less conserved  amino 
acids that are not directly involved in receptor binding, but play a role in the 
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secondary structure formation. These include Y22 and Y29 that are essential 
for proper beta-sheet formation of the B-loop (8). Thirdly, the residues that 
are directly involved in ErbB1 binding (positive constraints), some of which 
are the highly conserved (Y13, L15, R41, L47) , while others (E40, Y44, R45 
and K48) are less strict (9). The fourth group of residues are those that are 
not essential for high affi nity binding but are conserved because they are 
involved in ErbB specifi city by preventing the unintended binding to other 
ErbB molecules (negative constraints): S2D3 in EGF, E26 in TGFA and R45 in 
EGF. We could not identify residues that can be mutated at will and are only 
essential for the proper amino acid spacing, and therefore the conformation, 
of the looped regions. P7, V19, E24, D27 and V34 are examples of residues 
that are not in direct contact with the receptor and appear not essential for 
high affi nity binding (9). Still, these residues are well conserved among 
vertebrate EGF orthologues. Therefore we must conclude that in a small 
molecule like EGF every amino acid plays a functional role. 
The recent availability of the crystal structure of liganded and 
unliganded ErbB receptors has made it possible to understand the molecular 
action of negative constraints by homology modeling. Our experimental data 
show that R45 of EGF is a negative constraint for binding to ErbB3 and ErbB4, 
and homology modeling shows that this may be due to charge repulsion 
with K415 and K418, respectively. Since R45 is not essential for high affi nity 
binding of EGF to ErbB1, it appears that the conserved presence of a positive 
residues at this position in EGF is important for obtaining the proper receptor 
specifi city. AREG is an ErbB1 specifi c ligand, while its evolutionary homologue 
HB-EGF binds both ErbB1 and ErbB4. Interestingly, AREG has an Arg on a 
similar position as R45 in EGF, while HB-EGF has not. This indicates that 
during evolution the introduction or release of negative constraints may have 
resulted in ligands with the requested receptor specifi city. 
Our observation that R45 of EGF causes a charge repulsion with 
K415 and K418 in ErbB3 and ErbB4, respectively, made us curious for the 
mechanism by with R45 of EGF prevents binding to the chicken EGF receptor 
(CER). Therefore we looked for positively charged amino acids in CER that 
would come in close contact with R45 in EGF. A putative candidate is K415 
in CER which might cause charge repulsion with R45 in human EGF. Figure 1 
shows EGF in complex with ErbB1 and panerbin in complex with ErbB3. K415 
in CER, the corresponding residue for G441 in ErbB1 and A439 in ErbB3, is 
orientated close to the position of K415 in ErbB3. Thus R45 in human EGF 
probably prevents CER binding by causing charge repulsion with K415 in CER. 
This hypothesis can be substantiated by measuring the distance between 
K415 of CER and A45 of the EGF/R45A mutant, in a homology model of CER 
in complex with the EGF/R45A. Eventually, the hypotheses can be tested 
experimentally by mutating K415 in CER. 
The observation that EGF in which the N-terminal linear region has 
been replaced by  TGFA  sequences (T1E) is able to bind ErbB3 and ErbB4, 
indicates that the linear N-terminus of EGF contains a negative constraint 
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for binding to ErbB3 and ErbB4. Our studies have indicated that the S2/D3 
sequence in EGF impairs binding to ErbB3, most likely because these two 
residues do not provide the proper ligand conformation for receptor binding. 
It has been hypothesized that triple beta-sheet formation between the N-
terminal linear region and the B-loop of the ligand is essential for binding to 
ErbB3, but not to ErbB1 (12, 13). These requirements are much better met 
by the H2/F3 sequence in TGFA  than with S2/D3 in EGF, in agreement with 
protein conformation predictions by the Chou-Fasman algorithm. Again, since 
S2/D3 in EGF is not essential for ErbB1 binding, the role of the N-terminal 
linear region in EGF appears primarily to prevent the unintended binding to 
other receptors. Further research will have to indicate to what extent the N-
terminal linear region plays a role in binding selectivity between ErbB3 and 
ErbB4.
Mutation studies have indicated that E26 in the B-loop of TGFA forms 
the primary negative constraint for binding to ErbB3. Homology modeling 
shows that E26 would induce steric hindrance with M97 of this receptor, 
whereas it can act as a positive constraint for binding to ErbB1 by formation of 
Figure 1. Involvement of K415 in CER in a charge repulsion with R45 in 
hEGF. A. Homology model of EGF in complex with ErbB1. R45 in EGF is indicated 
as well as the ErbB1 residues S418 and G441, the corresponding residues of K415 
in ErbB3 and K415 in CER. B. Homology model of panerbin (T1E/YYDLL) in complex 
with ErbB3.  K415 in ErbB3 is indicated as well as A439, the corresponding residue 
of K415 in CER, and Y45, the corresponding residue of R45 in human EGF. K415 in 
CER, the corresponding residue for G441 in ErbB1 and A439 in ErbB3, is orientated 
close to the position of K415 in ErbB3.
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a salt bridge with R124 of this receptor. In comparison, ErbB4 contains a bulky 
Phe at position 97, but this residue is able to form another rotamer than M97 
of ErbB3 and will thereby not cause steric hindrance. Preliminary data show 
that E26 does not act as a receptor-selective negative constraint, since it also 
reduces ligand affi nity for ErbB4. Using a series of protein A-tagged EGF/TGFA 
chimeric ligands, it is shown in Figure 2 that T1E displays the highest binding 
affi nity for ErbB4 (IC50 = 40 ng/ml), followed by T3E (IC50 = 300 ng/ml) and 
T4E, qualitatively very similar to our previous observations on ErbB3 (11). 
T3E and T4E differ only in their B-loop, which contains EGF sequences in T3E 
and  TGFA  sequences in T4E. In order to study to what extent the difference 
in affi nity between T3E and T4E results from E26, we mutated this residue in 
T4E for the corresponding Leu from EGF. Figure 2 shows that T4E/E26L has 
much higher binding affi nity for ErbB4 than T4E itself, indicating that E26 not 
only acts as a negative constraint for ErbB3, but also for ErbB4.  In contrast 
to ErbB3, however, E26 appears unable to fully prevent ErbB4 binding. This 
is indicated by our observation that TGFA/YYDLL, which contains E26 as the 
only known negative constraint, has detectable affi nity for ErbB4, but not for 
ErbB3. Interestingly, E26 is evolutionary conserved in the ErbB4 binding ligand 
BTC (Figure 9), which indicates that the effect of this negative constraint can 
be overcome by a suffi ciently large number of positive constraints for this 
receptor. Thus our data show that ErbB3 and ErbB4 largely recognize similar 
negative constraints (E26; R45), but ErbB3 appears much more sensitive for 
the inhibitory effects of these residues than ErbB4. 
While positive constraints form the major basis for binding affi nity, 
negative constraints appear to control binding selectivity. Figure 3A illustrates 
schematically how mutation of a positive constraint can lead to a decrease 
in receptor binding affi nity, because important interactions with the receptor 
Figure 2. Ligand binding 
displacement assay of [125I-]-
NRG1β on T47-14 cells. Cells 
were treated with increasing 
concentrations of NRG1β (──), 
protein A-T1E (─p─),protein A-
T3E (─¿─), protein A-T4E (─¢─) 
and protein A-T3E/E26L (   £   ). 
The concentration of the protein 
A-tagged TGFA-EGF chimeras 
are indicated in mEGF binding 
equivalents for binding to ErbB1 
overexpressing HER14 cells. 
Values of bound radiolabeled 
ligand without competition of 
unlabeled ligand was set on 100%. 
Results are the mean of at least 
two independent experiments 
performed in duplicate. 
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are lost. For instance mutation of L47 in EGF to Ala results to a dramatic 
decrease of ErbB1 affi nity (14), because of depletion of an important positive 
constraint. Depletion of a single negative constraint in a ligand, however, can 
enhance the affi nity for its receptor many fold without affecting the number 
of putative interactions between ligand and receptor. The E26L mutation 
in T4E and R45Y mutation in T1E strongly enhanced affi nity for ErbB3 and 
ErbB4. One could argue that both mutations exchange a negative constraint 
for a positive constraint and that therefore the enhanced affi nity does not 
only result from a release of a negative constraint. For future research it will 
be interestingly to mutate these negative constraints to Ala, since this will in 
general not result in introduction of a positive constraint. Furthermore it will be 
interestingly to study the effect of artifi cially introduced negative constraints 
in ErbB specifi city, e.g. by local introduction of bulky Trp residues.
 Van de Poll et al. (15) have studied the minimal requirements for high 
affi nity ligand binding to ErbB1. In their study they showed that an EGF-like 
repeat from the Drosophila Notch protein, linked to the N- and C-terminal 
linear sequences of human EGF, did  not show measurable binding affi nity for 
Figure 3. Relation between 
ErbB-ligand binding affi nity and 
the number of interaction sites. 
A. Dashed arrow indicates the 
effect of introduction of a negative 
constraint.  The solid arrow indicates 
the effect of mutation of a positive 
constraint. Deletion of a positive 
constraint results in a decrease in 
binding affi nity due to a decrease in 
the number of interactions between 
ligand and receptor, whereas a 
negative constraint decreases 
affi nity without affecting the 
number of interaction sites. B. EGF 
has the maximum affi nity for ErbB1. 
No mutations in EGF have resulted 
in signifi cant increase of ErbB1 
affi nity. C. NRG1β does not have 
maximal affi nity for ErbB3, since 
introduction of additional positive 
constraints by replacement of the 
NRG1β linear C-terminal region by 
the YYDLL sequence of panerbin 
results in a strong increase of ErbB3 
affi nity.
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ErbB1. However, introduction of only six amino acids from human EGF, which 
are known to be important for ErbB1 binding, was suffi cient to make Notch a 
high affi nity ligand for ErbB1. The introduced residues from EGF included Y13 
in the A2-loop, M21, Y22 and A29 in the B-loop, N31 in the hinge and E40 in 
the C-loop. Out of these six residues only Y13 is present in Spitz. However, in 
the chimera S3E5S, which does not bind ErbB1, all these residues are present 
with the exception of E40. Unlike the Notch mutants studied, however, S3E5S 
lacks residues in the C-terminal linear region, including L47, that are essential 
for high affi nity binding. It therefore appears that Spitz cannot bind ErbB1, 
because important positive constraints are lacking. 
 NRG1β lacks all the six residues mentioned above, but has a Phe as 
a functional substitution for Y13, and an Asp for E40. However, the NRG1β-
panerbin chimera N3P4N6P has in addition the three residues from the B-loop 
of EGF, while its Lys in the hinge region is also present in the ErbB1-specifi c 
ligand  AREG. Since N3P4N6P has an optimal C-terminal linear region for 
binding to ErbB1, it therefore appears that its complete lack of affi nity for 
ErbB1 does not result from the absence of positive constraints. We must 
therefore conclude that NRG1β most likely lacks binding affi nity for ErbB1, 
because of the presence of so-far unidentifi ed negative constraints. From an 
evolutionary point of view it makes sense that Drosophila Spitz and EGF do 
not bind to each other’s receptor, since they are present in highly diverted 
species.
9.3 The molecular basis of mitogenic activity
Binding affi nity and mitogenic activity are not necessarily correlated, 
as has been studied in particular detail for ErbB1 binding ligands. Low affi nity 
EGF mutants may have similar mitogenic activity as wild-type EGF, particularly 
on ErbB1 overexpressing cells (16-18). Other mutants have similar binding 
affi nity as EGF but show enhanced mitogenic activity, thus acting as so-called 
superagonists. We have shown that the EGF/TGFA chimeras E3T and E4T 
induce mitogenic activity at a ten-fold lower concentration than wild-type EGF 
or TGFA, in spite of the fact that they have similar receptor binding affi nity for 
ErbB1 and induce the same extent of receptor tyrosine kinase activity (19). 
BIAcore experiments have shown that these superagonists have enhanced 
on/off rates (3) suggesting that the frequency whereby the ligand binds its 
receptor determines the mitogenic activity of a ligand, more than the mean 
time it occupies the receptor. Upon activation of ErbB1 by EGF the EGF-ErbB1 
complex is internalized via clathrin-coated vesicles and continues to signal in 
the endosomes until both ligand and receptor are degraded in the lysosomes. 
TGFA, on the other hand, also induces ErbB1 internalization but rapidly 
dissociates from the receptor due to the low pH in the endosomes, resulting 
in receptor recycling to the cell surface where it can be reactivated. So EGF 
signals from the endosomes for a relatively long period of time after which 
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the receptor is degraded, whereas TGFA signals for a relatively short period 
of time but the receptor molecules can signal more frequently because of 
receptor recycling. Still, both the binding affi nity and mitogenic activity of EGF 
and TGFA are similar. The superagonist E4T shows enhanced ErbB1 recycling 
which correlates with decreased receptor ubiquitination and degradation (20). 
E4T has a pH sensitivity of binding which is intermediate between EGF and 
TGFA, and therefore it has been proposed that the superagonistic behavior 
can be explained by the relatively long signaling duration along the endocytic 
routing, similar to EGF, in combination with recycling of the receptor to the 
cell surface, similar to TGFA (5).  
It has been shown that growth factor-induced cell cycle progression 
of quiescent cells occurs in two distinct phases of signaling. The fi rst phase 
stimulates the cells to leave the G0 phase and requires activation of MAPK and 
c-Myc. The second phase occurs 8 hours later and drives cells through the 
restriction point of late G1-S phase, a process which requires activation of the 
PI3K-Akt pathway (21, 22). As a result of receptor-mediated internalization 
high-affi nity ligands such as EGF are depleted much more rapidly from 
the extracellular medium than low affi nity ligands (4). As a consequence, 
the mitogenic activity of EGF on ErbB1 overexpressing cells is limited by 
substantial degradation of internalized ligand in the period before cells pass 
the restriction point in the late G1-S phase. This has been evidenced by 
the observation that the concentration required for half-maximum growth 
stimulation by EGF decreases upon increasing the volume in which the 
assay is carried out. The observation that superagonists have higher on/off 
rates than wild-type ligands, could result in reduced ligand internalisation 
and degradation rates, but experimental evidence for this hypothesis is still 
lacking so far (3).         
Since ErbB3 and ErbB4 are not internalized upon ligand binding, pH 
sensitivity of binding and ligand depletion from the medium do not appear to 
control the mitogenic activity of their ligands. Since ErbB3 is dependent on 
ErbB2 for forming a mitogenic complex, the effi cacy by which a ligand can 
form ErbB2-ErbB3 heterodimers will largely determine the mitogenic potential 
of a ligand. For the relationship between ErbB3 affi nity and mitogenic activity 
on ErbB2 and ErbB3 overexpressing cells we propose two alternative models. 
The fi rst model is a dynamic model (Figure 4), according to which the ligand 
binds an ErbB3 receptor after which the complex  recruits either an ErbB2 
or another ligand-bound ErbB3 receptor. Crucial for this model is that the 
liganded ErbB3 receptor is able to form biologically inactive homodimers or is 
stable as a monomer. We have observed that NRG/YYDLL has a higher binding 
affi nity for ErbB3 than wild-type NRG1β, while the latter has higher mitogenic 
activity on cells containing both ErbB2 and ErbB3. This observation could be 
explained in the dynamic model if NRG/YYDLL with its high affi nity for ErbB3 
forms more ErbB3 homodimers, while NRG1β with its lower affi nity for ErB3 
gives rise to more ErbB2-ErbB3 heterodimers. However, besides the fact that 
ErbB3 homodimers have not been identifi ed experimentally, this model can 
204
Chapter 9
not readily explain why NRG/YYDLL binds on D3 cells with higher affi nity than 
on D23 cells. Alternatively, the data can be explained in terms of a preformed 
dimer model. Junttila et al. (23) have shown that ligand-independent 
preformed ErbB2-ErbB3 heterodimers exist on the surface of SKBR3 cells. If 
the majority of receptors on D23 cells would be present as such preformed 
ErbB2-ErbB3 heterodimers, with only few free ErbB3 monomers remaining, 
this could explain why both   NRG/YYDLL and NRG1β have similar binding 
affi nity on these cells. However, this model appears unable to explain why, in 
Figure 4. Relation between ErbB3 binding affi nity and the mitogenic 
potential on cells expressing ErbB3 and ErbB2 according to the dynamic 
model. Low affi nity ErbB3 ligands depend on the presence of ErbB2 to form a 
stable dimer. High affi nity ErbB3 ligands do not depend on ErbB2 to form a stable 
complex with ErbB3, whereas low and intermediate ErbB3 binders preferentially 
form signaling ErbB2-ErbB3. It is assumed that high affi nity ErbB3 binders are also 
able to form inactive ErbB3 monomers or homodimers. The mitogenic activity of 
a ligand on ErbB2 and ErbB3 overexpressing cells depends on the ability to form 
ErbB2-ErbB3 heterodimers. T1E is a low affi nity ligand for ErbB3 and therefore 
depends on ErbB2 to form a stable ErbB2-ErbB3 complex, which is mitogenically 
active. Still the affi nity of T1E for ErbB2-ErbB3 heterodimer is not high enough the 
form the maximal number of ErbB2-ErbB3 heterodimers. NRG/YYDLL has a high 
affi nity for ErbB3 and does not depend on ErbB2 to form a stable ligand ErbB3 
complex. In fact the affi nity of NRG/YYDLL for the ErbB2-ErbB3 heterodimer is for 
unknown reasons lower than for ErbB3 alone. Therefore NRG/YYDLL will form ligand-
ErbB3 complexes in addition to ErbB2-ErbB3 heterodimers. ErbB3 homodimers or 
monomeric ligand ErbB3 complexes do not give a mitogenic response, since ErbB3 
has an inactive kinase. Wild-type NRG1β has the optimal mitogenic capacity, since 
it has the optimal binding affi nity for the ErbB2-ErbB3 heterodimer. It is able to 
form a lot a ErbB2-ErbB3 heterodimers while formation of ErbB3 homodimers or 
ligand-ErbB3 monomeric complexes is not at the expense of the number of ErbB2-
ErbB3 heterodimers being formed. 
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spite of this similar binding affi nity,  NRG1β has higher mitogenic activity than 
NRG/YYDLL on these cells. In conclusion, these two models can only partly 
explain the observed discrepancy between binding affi nity and mitogenic 
activity of NRG1β and NRG/YYDLL for cells containing only ErbB3 and cells 
containing both ErbB2 and ErbB3 receptors.   
 In contrast to ErbB3, ErbB4 can form signaling homodimers 
and the mitogenic potential, measured by [3H]-thymidine incorporation on 
ErbB2-negative ErbB4 overexpressing T47-14 cells, largely correlates with 
the binding affi nity. In the presence of ErbB2 cell survival, measured in an 
MTT assay on ErbB2 and ErbB4 expressing D24 cells, correlates with binding 
affi nity to ErbB4, probably because ErbB4 does not depend on ErbB2 in order 
to form a signaling dimer. T1E/YYDLL binds with higher affi nity to ErbB4 
homodimers than to ErbB2-ErbB4 heterodimers, but it is unclear whether 
at the low concentrations used in mitogenic assays this ligand preferentially 
signals through ErbB4 homodimers or through ErbB2-ErbB4 heterodimers. 
From an evolutionary point of view our models, for the relationship between 
ErbB affi nity and mitogenic activity, might explain the occurrence of the alpha 
and beta isoforms of NRG1 and NRG2, which differ in their affi nity for ErbB3 and 
ErbB4 but not in receptor specifi city. The alpha isoforms have low affi nities for 
ErbB3 and ErbB4 alone and show higher binding affi nities in presence of ErbB2 
(25), suggesting that the alpha isoforms preferentially signal through ErbB2-
ErbB3 or ErbB2-ErbB4 heterodimers rather than through ErbB4 homodimers. 
On cells with a surplus of ErbB2 over ErbB3 receptors, high affi nity ligand will 
give an optimal mitogenic response, but on cells with a surplus of ErbB3 over 
ErbB2 receptors low affi nity ligands are preferred, since these will not give 
rise to biologically inactive ErbB3 monomers of homodimers.
Mitogenic stimulation through ErbB4 is further complicated by the 
presence of different isoforms of this receptor, which can either signal through 
tyrosine phosphorylation or by cleavage of a soluble intracellular domain, which 
can act as a transcriptional cofactor (26). Overexpression studies in 32D cells 
have demonstrated that the JM-a CYT-2 and the JM-b CYT-1 isoforms of ErbB4 
have the highest potential in NRG1β-induced cell survival assays (27). The 
JM-a CYT-2 isoform, however, also promotes ligand-independent signaling by 
a mechanism involving both ligand-independent tyrosine phosphorylation and 
proteolytic generation of the intracellular domain (27). The cleavable JM-a 
isoform is more abundantly expressed in breast cancers than the uncleavable 
JM-b isoform. Expression of the ErbB4 intracellular domain correlates with 
poor prognosis for breast cancer patients in comparison with cell surface 
ErbB4 expression (28). Finally it has been shown that BTC and NRG1β induce 
different phosphorylation patterns of ErbB4 and might therefore induce a 
different level of mitogenic activity (29). In conclusion, the mitogenic activity 
mediated by ErbB4 depends on ligand affi nity, the presence of ErbB2,  the 
induced receptor phosphorylation pattern and the ErbB4 isoform. 
 It is intriguing that during evolution low affi nity ligands have been 
maintained for for all ligand binding ErbB receptors. For ErbB1 EREG acts 
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as a low affi nity ligand, while NRG1α and NRG2α are low affi nity ligands for 
ErbB3 and ErbB4. As mentioned it has been speculated that for ErbB2-ErbB3 
heterodimers low affi nity ligands are preferred, in order to avoid the formation 
of biologically inactive ErbB3 homodimers. In the case of ErbB4, it can be 
imagined that low affi nity ligands will preferentially activate ErbB2-ErbB4 
heterodimers, with its higher diversity of intracellular second messengers. 
In the case of ErbB1, low affi nity ligands may be preferred on cell types 
with a high receptor density, in order to avoid ligand depletion in a small 
compartment. It remains to be investigated if these ligands show reduced 
affi nity due to loss of positive constaints or due to introduction of negative 
constaints.      
9.4 Coevolution of ErbB receptors and their ligands
 During evolution of vertebrae two whole genome duplications have 
occurred. Evolution of ErbB receptors started with a single ErbB-precursor 
receptor and one or a few activating ligands, similarly as still present in 
Drosophila melanogaster. Our hypothesis of how ErbB receptors and their 
ligands may have coevolved is illustrated in Figure 5A. It is proposed that 
during the fi rst whole genome duplication a single parental ErbB precursor 
receptor has given rise to a proto-ErbB1 receptor and a proto-ErbB4 receptor. 
The proto-ErbB1 receptor would probably be bound and activated by proto-
TGFA, proto-AREG and proto-EPGN type of ligands, similar to the current 
situation in Ciona intestinalis (Van Leeuwen, unpublished). The proto-ErbB4 
receptor would most likely be bound and activated by a proto-NRG type of 
ligand, also similar to the current situation in Ciona intestinalis (Van Leeuwen, 
unpublished). Following the second whole genome duplication, the duplicated 
proto-ErbB1 receptor evolved into a ligand-activated ErbB1 and an orphan 
ErbB2 receptor, with a conformation ready to dimerize with other liganded 
ErbB receptors. Simultaneously, the proto-ErbB4 receptor gave rise to ErbB4 
and the kinase dead ErbB3 receptors. 
Along with the ErbB receptors the proto-TGFA, proto-AREG and proto-
NRG ligands duplicated into TGFA and BTC, AREG and HB-EGF, and NRG1 
and NRG2, respectively. The duplication of proto-EPGN into EPGN and EREG 
happened most likely by micro-chromosomal gene duplication rather than 
during the whole genome duplication (30). Remarkably, duplication of the 
ligands for the ErbB1-like receptors resulted in ErbB1 specifi c ligands, e.g. 
TGFA, AREG and EPGN, and ligands with ErbB1-ErbB4 dual specifi city, e.g. 
BTC, HB-EGF and EREG, in a pair-wise manner. Multiplication of proto-NRG 
resulted in NRG1 and NRG2, which show similar ErbB receptor specifi city. 
Similarly, the alpha and beta isoforms of NRG1 and NRG2 bind and activate 
both ErbB3 and ErbB4, although with different affi nities. Since the ErbB 
specifi city of the evolutionary related NRG3 and NRG4 has not been well 
characterized, it is not possible to speculate on the mechanism that has put 
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Figure 5. A. Hypothetical model for the coevolution of ErbB receptors and 
their ligands. Evolutionary pressure on the receptor specifi city  of ErbB ligands 
has resulted in the introduction of negative constraints in the ligands. It is assumed 
that after the fi rst whole genome duplication two ErbB receptors have evolved, 
an ErbB1-like and an ErbB4 like precursor. The ErbB1-like receptor was probably 
activated by a TGFA-like, an AREG-like and a EPGN-like ligand, while the ErbB4-like 
receptor was activated by a NRG-like precursor. Following a second whole genome 
duplication, the ErbB1-like precursor evolved into the ErbB1 and the orphan ErbB2 
receptor, while the ErbB4-like receptor gave rise to ErbB4 and the kinase death 
ErbB3. The TGFA-like, AREG-like and EPGN-like ligands each developed into an 
ErbB1-specifi c and an ErbB1/ErbB4 bispecifi c ligand, whereby bispecifi city resulted 
from a release of negative constraints for ErbB4. EGF is not included since this 
protein belongs to the LDL receptor family and has most likely followed a different 
route during evolution. NRG3 and NRG4 are also not included, since there is little 
known about their affi nities and ErbB specifi cities. B. Evolution of PDGF receptors 
and c-KIT/c-FMS. C. Chromosomal localizations of human ErbB receptors, their 
ligands and PDGF receptor-related genes. Note that EPGN, EREG, AREG and BTC 
are located next to each other on chromosome 14q13. Similarly PDGFRA and c-KIT, 
as well as PDGFRB and c-FMS are neighboring genes on chromosome 4q11-q13 and 
5q31-q32, respectively.
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evolutionary pressure on the maintenance of these two ligands. 
 Since during evolution the proto-ErbB1 specifi c ligands all three 
diverted into an ErbB1 specifi c ligand and a ligand that is bispecifi c for ErbB1 
and ErbB4, it is tempting to speculate that one of the duplicate ligands lost its 
negative constraints for binding to ErbB4, while maintaining those for ErbB3. 
It would be very interesting to identify the ErbB4-specifi c negative constraints 
that are still present in TGFA, AREG and EPGN, but lost in BTC, HB-EGF and 
EREG. Domain-exchange studies of the intercysteine domains of the EGF-like 
domains between the evolutionary related pairs TGFA and BTC, AREG and 
HB-EGF, and EPGN and EREG will show if the ErbB1-specifi c ligands share the 
same negative constraints for binding to ErbB4. 
 In order to substantiate the hypothesis of the duplication of ErbB 
genes and their ligands, we made a comparison with the evolution of platelet-
derived growth factor receptor (PDGFR)-related genes (Figure 5B). Evolution 
of the mammalian PDGF alpha-receptor and PDGF beta-receptor genes and 
their evolutionary related genes c-KIT and c-FMS probably started with a 
micro-chromosomal gene duplication generating a PDGFR-like precursor and 
a c-KIT/c-FMS-like receptor (31). Following the whole genome duplication the 
PDGFR-like and the c-KIT/c-FMS-like receptor gave rise to the PDGFRA and 
PDGFRB on the one hand, and c-KIT and c-FMS on the other hand which are 
still present in the  mammalian genome (32). In addition to primary amino 
acid sequence homology, the duplication of neighboring genes is another clue 
for the suggestion that two genes have been derived from duplication of a 
common ancestor. Unlike the PDGFR-related genes, however, the evolutionary 
related ErbB receptors (ErbB1 and ErbB2; ErbB3 and ErbB4) and EGF-like 
growth factors (TGFA and BTC; AREG and HB-EGF; EPGN and EREG) do 
not show chromosomal co-localization. Figure 5C shows the chromosomal 
locations of human ErbB receptors and their ligands in relation to PDGFR-
related genes.  
9.5 Why does NRG1β not bind ErbB1?
 The negative constraints we have identifi ed so far, are residues in 
ErbB1 ligands that prevent the interactions with the NRG receptors ErbB3 
and ErbB4. These negative constraints explain why EGF and TGFA do not bind 
ErbB3 and ErbB4, but it remains unclear why NRG1β does not interact with 
ErbB1. Based on the crystal structure TGFA in complex with ErbB1, we made 
homology models of NRG1β in complex with ErbB3 and ErbB4. These models 
showed that NRG1β can form similar positive constraints with these receptors 
as TGFA with ErbB1, while in addition no evidence was found for steric clashes 
or charge repulsion that would prevent receptor binding. Thus based on these 
homology models no argument was found why NRG1β does not interact with 
ErbB1. 
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Domain exchange studies by Barbacci et al. (33) showed that 
introduction of each intercysteine sequence of NRG1β into EGF resulted in a 
dramatic loss of ErbB1 affi nity. This suggests that all intercysteine domains 
of NRG1β either lack an important positive constraint or have a negative 
constraint which prevents ErbB1 interaction. In Chapter 3 we discussed 
panerbin, an EGF-TGFA chimera that has lost all negative constraints and 
therefore interacts with ErbB1, ErbB3 and ErbB4. Subsequent domain 
exchange studies between NRG1β and panerbin (Chapter 7) demonstrated 
that the A1-loop  (sequence between the fi rst and the second cysteine) 
and C-loop (sequence between the fi fth and the sixth cysteine) of NRG1β 
are involved in preventing interaction with ErbB1. It is currently unknown, 
however, whether this results from negative constraints for ErbB1 in the A1-
loop of NRG1β, or that the identifi ed residue D11 in the A1-loop of EGF is 
an essential positive constraint for ErbB1 interaction. Interestingly, in our 
homology models most of the residues present in the A1-loop and C-loop 
are oriented away from the receptor molecule and are therefore not directly 
involved in receptor-ligand binding. It can be speculated that the A1-loop 
and C-loop play a, so far not recognized, subtle role in the conformation of 
the ligand and thereby directly affect receptor-binding affi nity. Furthermore it 
cannot be excluded that upon introduction of the A1-loop or C-loop of NRG1β, 
panerbin loses the proper conformation for binding to ErbB1, although high 
affi nity for ErbB4 is maintained.
9.6 Design of ErbB3 and ErbB4 specifi c ligands
Based on their specifi city, naturally occurring ErbB ligands can be 
divided into three groups; ligands that bind exclusively ErbB1, the neuregulins 
that interact with ErbB3 and ErbB4 and ligands that bind to ErbB1 and ErbB4 
but not to ErbB3. It has been claimed that NRG3 and NRG4 are specifi c for 
ErbB4, but these ligands have not been characterized in detail. Some reports 
show activation of ErbB2-ErbB3 heterodimers by these two ligands as well 
(34). Furthermore it appears that these two ligands bind ErbB4 with only very 
low affi nity (25). This implies that ligands which specifi cally bind ErbB3 or 
ErbB4 do not occur in nature. Still, designed ErbB3 and ErbB4 specifi c ligands 
hold great promise as therapeutic drugs (see below). 
ErbB3 and ErbB4 specifi c ligands can theoretically be developed by 
introduction of ErbB4 and ErbB3-specifi c negative constraints in NRG1β, 
respectively. However, homology modeling studies have not given any 
indication for the presence of such receptor-specifi c constraints in NRG (35). 
Alternatively, EGF-based ligands are available that discriminate between ErbB3 
and ErbB4, and these could be used as a basis for development of ErbB3 or 
ErbB4 specifi c ligands, provided that the affi nity for ErbB1 can be eliminated. 
Emphasis in our studies have so far been on the identifi cation of negative 
constraints for ErbB3 and ErbB4, and therefore putative ErbB1-specifi c 
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negative constraints have not been identifi ed yet. Such negative constraints 
for ErbB1 could be identifi ed e.g. by investigating which intercysteine domain 
of NRG has to be introduced into BTC to prevent ErbB1 binding. Since both 
NRG1β and BTC bind ErbB4, the NRG1β-BTC chimeras will most likely retain 
their high binding affi nity for ErbB4, which will be helpful for purifi cation and 
quantifi cation of biologically active fractions of these chimeras. Subsequent 
introduction of ErbB1-specifi c negative constraints into BTC will result in the 
generation of an ErbB4 specifi c ligand. 
Our previous studies have indicated that not only the ligand’s C-
terminal, but also the N-terminal linear region plays an important role in 
ErbB selectivity. By introducing the optimal sequence requirements for ErbB3 
binding in both the N- and C-terminal linear regions we designed an EGF 
mutant, designated WVR/EGF/IADIQ, which shows  high affi nity for ErbB3 
and ErbB1, but only very low affi nity for ErbB4 (Figure 6). This ligand could be 
used as a starting point for designing ErbB3 selective ligands, by introducing 
negative constraints for ErbB1 and further reducing the affi nity for ErbB4. 
Design of ligands that specifi cally interact with either ErbB3 or ErbB4 
will attribute greatly to our understanding or ErbB specifi city but can also 
Figure 6. Binding affi nity of 
mutant EGF-like growth factors 
for ErbB3 and ErbB4. (A) Ligand 
binding displacement analysis on 
ErbB3 overexpressing D3 cells treated 
with 1 ng/ml [125I]-NRG1β. (B) Ligand 
binding displacement analysis on 
ErbB4 overexpressing T47-14 cells 
treated with 1 ng/ml [125I]-NRG1β. 
Cells were incubated with increasing 
amounts of the unlabeled NRG1β 
(─¢─), EGF/YYDLL (─¯─), T1E/IADIQ 
(──) and VWR/IADIQ (─r─). Values 
of bound radiolabeled ligand without 
competition of unlabeled ligand were 
set on 100%. Results are the mean of 
at least two independent experiments 
performed in duplicate.
211
General Discussion
be of great therapeutic value. In vivo treatment with recombinant NRG1 
has been shown to improve cardiac function and survival in animals with 
ischemic, dilated and viral cardiomyopathy (35), while reduced ischemic-
induced brain damage has been observed in rats (36). ErbB3 and ErbB4 have 
different functions in cardiac and brain development, as known from receptor-
specifi c knock-out mice. Therefore, in vivo treatment with NRG may result in 
unintended side effects because it activates both ErbB3 and ErbB4. It would 
therefore be of great interest if receptor-specifi c agonistic ligands can be 
designed for treatment of patients with the above diseases. 
From a scientifi c point of view administration of ErbB3 and ErbB4-
selective ligands can be used in order to study the individual roles of ErbB3 
and ErbB4 in developmental processes or in in vitro differentiation assays 
of for instance neuronal progenitor cells. Because of the role of NRG in the 
neuro-muscular junction and in oligodendrocyte development, ErbB3 and 
ErbB4-specifi c ligands will also be of great importance for the determination 
of the individual roles of ErbB3 and ErbB4 in multiple sclerosis (37) and 
schizophrenia (38). Several genetic studies have identifi ed NRG1β as a 
susceptibility gene for schizophrenia (39). Mice heterozygous for mutations in 
the NRG1β gene or with a null mutation in the ErbB4 gene display phenotypic 
characteristics similar to schizophrenia. Furthermore, signifi cant reduction 
of ErbB3 expression has been observed in schizophrenia patients. NRG1 
plays a key role in neuronal developmental processes in the central nervous 
system, including neuronal migration and specifi cation, hormonal control of 
puberty, regulation of acetylcholine, GABA and glutamate receptor expression 
and oligodendrocyte development. (reviewed in (40)). However the exact 
role of the individual NRG receptors, ErbB3 and ErbB4, in these processes 
is not fully understood since NRG activates both receptors. Many NRG1-
mediated processes have been found to be deregulated in schizophrenia 
patients, resulting in heterotopias, enlarged ventricles, alterations in 
neurotransmitter receptor expression, reduced myelination, reduced number 
of oligodendrocytes and disordered sexual maturation of the hypothlamus 
in the puberty. By administration of ErbB3 or ErbB4-specifi c ligands to NRG 
knockout mice, the contribution of the individual NRG receptors in the above-
mentioned processes could be studied in more detail. ErbB specifi c ligands 
may therefore be of therapeutic value since they can activate one of the two 
neuregulin receptors without affecting the other.
9.7 Design of ErbB antagonists
 The resolution of the crystal structure of unliganded and ligand-bound 
ErbB receptors has been a breakthrough in our understanding of ligand-
mediated receptor dimerization. The crystal structures provide important 
information about possibilities to interfere with receptor dimerization, which 
could be of great therapeutic value. Here we will focus on the possible 
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development of receptor  antagonists and reverse agonists. An antagonist 
competes effectively with ErbB agonists for binding to ErbB receptors but fails 
to induce domain rearrangement of the receptors which is required for ErbB 
signaling. Reverse agonists do not compete with agonistic ligands for receptor 
binding but prevent the receptor from adopting the conformation required 
for dimerisation. Additional crystal structures have identifi ed the epitopes 
on ErbB receptors which are recognized by therapeutic antibodies, and have 
thereby attributed to our understanding of the working mechanism of these 
antibodies (41, 42). Several strategies have been used to interfere with 
ErbB signaling, of which the use of anti-receptor antibodies has so far been 
most successful.  Cetuximab, a monoclonal antibody directed against ErbB1, 
interacts exclusively with domain III of ErbB1, thereby blocking the ligand 
binding region of this domain and preventing the ligand-induced domain 
rearrangement of the receptor (41) (Figure 7C). Blocking the dimerization 
interface is another option for preventing receptor activation. This has been 
shown for pertuzumab, a monoclonal antibody directed against ErbB2, that 
sterically blocks ErbB2-mediated dimerization (42) (Figure 7G). The most 
successful anti-ErbB therapy is treatment with Herceptin, an antibody directed 
against the S2 domain of ErbB2, which blocks a protease cleavage site in the 
receptor and thereby prevents the formation of a constitutively active p95 
fragment, which is frequently found in breast tumors (Figure 7I).
 Alternatively mutant forms of EGF-like growth factors with antagonist 
activity can potentially be designed, e.g. by mutating one of the receptor 
Figure 7. Strategies for 
the development of ErbB 
antagonists. (A) ErbB receptor 
in its extended conformation. 
(B) Ligand-bound ErbB dimer. 
(C) Cetuximab blocks one of the 
ligand binding domains. (D) ErbB 
antagonist interacting with one 
of the ligand binding domains 
whereby mutations prevent the 
interaction with the other ligand 
binding domain. (E) Two ErbB 
ligands with fl exible linker. One of 
the ligands can only bind the L1 
domain while the other can only 
bind the L2 domain. (F) Antibody 
that locks the ErbB receptor in 
its autoinhibited conformation. 
(G) Pertuzumab blocking the 
dimerisation interface. (H) 
S1 mimetic peptide blocking 
the dimerisation interface. (I) 
Herceptin preventing ectodomain 
cleavage of ErbB2.
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binding domains in the ligand molecules, while leaving the other intact. This 
will initially result in a ligand with very low affi nity, since half of the positive 
constraints for receptor binding will be lacking.  It will be a challenge to improve 
the affi nity of the remaining receptor binding domain by ligand extension and 
phage display approaches to design an antagonist with wild-type affi nity. 
Alternatively, ligand-based reverse agonists can be designed by linking two 
ligand molecules with a spacer, such that after binding the L domains of the 
receptor are kept far apart from each other in order to prevent the receptor 
from adopting the conformation required for dimerisation (Figure 7B). This 
elongated ligand may exist of two EGF molecules that are separated by a 
fl exible linker. The C-terminal EGF domain of this elongated ligand requires 
mutations in the C-loop and C-terminal linear region involved in L2 domain 
binding, whereas the L1 binding capacity of the N-terminal EGF domain has 
to be impaired by mutations in the B-loop (Figure 7E). As an alternative, 
mimetic peptides of the S2 domain have been made which were able to block 
receptor dimerization (43) (Figure 7H). 
In the case of ErbB4, anti-receptor antibodies that prevent exodomain 
cleavage might be of therapeutic value. ErbB4 can be cleaved by TACE and γ-
secretase at the extracellular juxtamembrane region and intramembraneous 
region, respectively. The intracellular domain (ICD) of ErbB4 translocates to 
the nucleus where it acts as a transcriptional cofactor. The cleaveable JM–a 
isoform is more abundantly expressed in breast cancers than the uncleavable 
JM-b isoform. Breast cancer patients with localization of an ErbB4 ICD epitope 
in the cancer cell nuclei have poor prognosis, compared with patients with cell 
surface ErbB4 expression (28). So by blocking ectodomain cleavage of ErbB4 
receptors the formation of oncogenic or highly mitogenic receptor fragments 
can be prevented, similarly as is achieved by Herceptin for ErbB2.
 An attractive alternative for the classical antibodies are camelid 
antibodies which consist only of a single heavy chain. The extended 
complementarity-determining region (CDR3) of camelid antibodies makes 
them very suitable for the recognition of epitopes that are normally not 
recognized by conventional antibodies. Because of their relatively small size, 
camelid antibodies have been selected for epitope recognition in enzymes 
based on the ability of CDR3 to penetrate into the substrate-binding pocket 
(44). The variable domains of these camelid antibodies, called nanobodies, 
have the advantage over the classical antibodies that they are very stable 
and easy to produce as recombinant protein. Because of their small size, 
they are easy to clone and expresses on fi lamentous phage which allows 
selection of specifi c high affi nity binders to e.g. ErbB receptors. Using 
such phage display strategies antagonistic nanobodies have been selected 
with high affi nity for ErbB1, which are able to prevent EGF-induced ErbB1 
activation (45). Nanobodies lack an Fc-domain, and therefore they do not 
induce antibody-dependent cellular cytotoxicity (ADCC). For treatment of 
solid tumors with overexpression of ErbBs this does not have to be a problem 
since also pertuzumab is expected to give poor ADCC when blocking ligand 
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binding to ErbB1 (46). Due to their small size there is a rapid renal clearance 
of nanobodies. This has advantages for in vivo diagnosis studies or when 
targeting tumors with nanobody-coupled toxins. When treating tumors 
by blocking a biological process, e.g. ligand-receptor interaction, receptor 
dimerisation, or ectodomain shedding, however, such a short life span is 
a disadvantage. This can be overcome by the use of bispecifi c antibodies 
in which one nanobody recognizes albumin and the other the epitope of 
interest, which increases the lifetime of the nanobody. The potential of anti-
ErbB directed nanobodies for treatment of cancer patients has to be further 
explored.
9.8 Possibilities for Argos-based design of antagonists for human 
ErbB receptors
 Ever since the identifi cation of Argos as an inhibitor of the Drosophila 
EGF receptor (DER) it has been proposed that Argos binds to DER without 
activating this receptor, thereby acting as a receptor antagonist (47). This 
hypothesis was based on the observation that Argos itself contains a single 
EGF-like domain (albeit a-typical). BIAcore measurements showed that Argos 
indeed binds with high affi nity (17-41 nM) to DER (48). Several studies 
have shown that the EGF-like domain of Argos is essential and suffi cient for 
its antagonistic activity (49). In particular, studies by Howes et al. (50) on 
Spitz-Argos chimeras showed that the B-loop and the C-terminal linear region 
are essential for the antagonistic activity of Argos. Other studies aimed to 
adapt Argos in such a way that it will inhibit human ErbB receptors, have 
been without success (18). However, in 2004 it has been reported that Argos 
inhibits DER signaling by sequestration of agonist ligands such as Spitz (51) 
and recently the crystal structure of Argos in complex with Spitz has been 
published (52). Although both mechanisms of antagonism (competitive 
binding to DER and ligand sequestration) are not mutually exclusive, there 
is currently more structural evidence for ligand sequestration, making this 
mechanism more plausible. Furthermore, crystal structure analysis has 
demonstrated that Argos does not have a similar folding as EGF, which makes 
it even more unlikely that Argos as a receptor antagonist by direct binding to 
DER. 
The crystal structure of Argos revealed a striking similarity with the 
ligand binding regions of receptors for the TGFβ family of growth factors. Even 
more interestingly is the structural similarity with the cell surface receptor 
of urokinase-type plasminogen activator receptor (uPAR) which is known to 
interact with the EGF domain of uPAR. Since there are many proteins with a 
uPAR-like domain of unknown function, this group of proteins may contain a 
human orthologue of Argos. Even if no human uPAR orthologue with a three-
fi nger toxin fold domains exists, Argos can potentially be used as a structural 
scaffold to design human scavengers of ErbB ligands. 
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 Argos has been shown to interact with human EGF, although only with 
very low affi nity (Kd ± 5 μM). This raises the question whether it is possible 
to optimize this interaction by mutating Argos. Among the 17 amino acids 
of Spitz that are directly involved in Argos binding, only 7 are conserved in 
human EGF (see Figure 8). Most interactions are formed by residues on the 
tip of the B-loop, which in the case of Spitz is two amino acids shorter than 
in human EGF. Furthermore the A-loop of Spitz is one amino acid longer than 
in EGF as a result of an additional tryptophan, which is clearly involved in 
a hydrophobic interaction. These differences in length of the A1-loop and 
the B-loop will make it very diffi cult to mutate Argos in such a way that the 
affi nity for human EGF will be increased towards Kd values in the nanomolar 
level. Within the EGF-like domain there is relatively high amino acid sequence 
homology between Spitz and Keren. Based on this sequence homology we 
estimate that Keren would make 16 interactions with Argos compared to 20 
interactions between Spitz and Argos (Figure 8). So in addition to Spitz, Keren 
might also be a candidate binding partner for Argos. Figure 8 also shows 
that the amino acids of Spitz which are involved in Argos binding are poorly 
conserved in Vein and Gurken, which makes it unlikely that DER activation by 
these ligands will be inhibited by Argos.
Figure 8. Interaction sites for binding of Spitz to DER and Argos. Presented 
sequences are of Drosophila melanogaster ligands Spitz, Keren, Gurken and Vein, 
in addition to  human EGF, TGFA and NRG1β. The fi rst amino acid and the conserved 
cysteines are numbered and are depicted in bold. The Spitz-Argos interactions 
are according Klein et al. (52). The Spitz-DER interactions are according to our 
homology modeling. The putative interactions of Keren, Gurken, Vein, EGF, TGFA 
and NRG1β are predicted on the basis of primary sequence homology and the 
chemical nature of the amino acid. Residues in red are involved in hydrogen bond 
formation, residues in green are involved in hydrophobic interactions, residues in 
blue are involved in salt bridge formation with the indicated ErbB receptors, while 
residues in pink are involved in both, hydrogen bound formation and hydrophobic 
interaction. Spitz is depicted twice, since some amino acids can be involved in both 
hydrogen bound formation and hydrophobic interactions. 
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 Important lessons can be learned from the antagonistic mechanism 
of Argos, whereby it acts a scavenger for agonistic DER ligands. There are 
many examples in nature whereby soluble extracellular proteins act as 
growth factors scavengers. In comparison, there are only few examples of 
natural ligands that act as receptor antagonists, by binding a receptor without 
subsequent activation. Examples of ligands that act as receptor antagonists 
are inhibin (53) and LEFTY (54) for serine/threonine kinase receptors. Soluble 
extracellular regions of receptor molecules, either formed by alternative 
splicing or by protein shedding, can act as soluble ligand scavengers. Moreover, 
during evolution many unrelated proteins have developed that act as ligand 
scavengers (for instance WIF, Noggin and Gremlin). These scavengers play an 
important role in the formation of morphogen gradients which are essential 
for axis formation during development (55-57). Apparently during evolution 
the development of scavengers has appeared more effective than that of 
receptor-binding ligands with antagonist activity. 
Argos is not the fi rst protein with ErbB ligand scavenging activity. 
Recombinant extracellular domain fragments of ErbB1 have been shown to 
act as competitive inhibitors of EGF-stimulated mitogenesis (58). The full 
length extracellular domain,  sEGFR621, has a relatively low affi nity for 
EGF (Kd 180-300 nM) and TGFA (Kd 840-1320 nM), whereas the shorter 
sEGFR501 fragment has a much higher affi nity for EGF (Kd 13-21 nM) and 
TGFA (Kd 35-40 nM). The sEGFR501 lacks the extracellular C2 domain and is 
therefore unable to adopt the auto-inhibited conformation and therefore has 
a higher affi nity for EGF and TGFA  (58).  The full length soluble extracellular 
domain fragment of ErbB1 has been identifi ed in the conditioned culture 
media of the A431 adenocarcinoma cell line and MDA-MB-468 breast cancer 
cells as a result of proteolytic shedding (59). It is unclear, however, whether 
this naturally occurring full length soluble extracellular domain fragment of 
ErbB1 indeed interacts in vivo with ErbB1 ligands in order to prevent them 
from activating membrane-bound ErbB1 receptors. Another natural ErbB 
antagonist is Herstatin, which is encoded by an alternative splice variant of 
the ErbB2 gene, and consists of the extracellular domain of ErbB2 followed by 
a proline rich region. Herstatin is not a scavenger of ErbB ligands but probably 
functions by blocking the major dimerisation interface (S1 or CR2 domain) 
of ErbB receptors and thereby prevents functional dimerisation. Furthermore 
Herstatin induces the downregulation of ErbB2 and inhibits NRG-induced 
proliferation of MCF7 and BT474 breast cancer cells (60). 
A soluble p85 splice variant (61) of ErbB3 binds NRG1β with high 
affi nity (Kd 3.0 nM) and thereby inhibits NRG-mediated activation of ErbB2, 
ErbB3 and ErbB4 (62). JM-a isoforms of ErbB4 can be cleaved by TACE and 
γ-secretase thereby releasing not only a transcriptionally active intracellular 
domain, but also the ligand binding extracellular domain of ErbB4. This 
extracellular domain of ErbB4 can function as a ligand to activate backward 
signaling via membrane-bound NRG1β isoforms (63). A functional role of the 
extracellular domain of ErbB4 in scavenging ligand has not been reported 
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so far. These naturally occurring ErbB ligand scavengers have similarly high 
affi nity for their ligands as Argos for Spitz. Potentially such antagonists are 
interesting drugs for the treatment of carcinomas with show ErbB-mediated 
autocrine growth stimulation. The identifi cation of uPAR or Argos-like three-
fi nger toxin fold domains in human proteins which are able to antagonize ErbB 
signaling would therefore not only be interesting from a scientifi c point of 
view, but also opens possibilities for their use in anti-cancer therapies. 
Remarkably all ErbB-directed strategies currently used in the clinic 
target the receptor. No strategies are aimed at scavenging the ErbB ligands 
with antibodies or nanobodies, while nature generally uses ligand scavengers 
to antagonize receptor signaling. Most probably therapies aimed at scavenging 
ErbB ligand are not an option for tumors which overexpress multiple ErbB 
ligands (64). Still, in the case of acquired tumor resistance to ErbB1 and 
ErbB2 directing drugs, scavenging NRG1β by a neutralizing antibody may be 
a promising approach, since siRNA targeting of NRG1β expression has been 
demonstrated to restore tumor sensitivity to ErbB1 and ErbB2 directing drugs 
(65). 
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Figure 9. Sequence homology between tetrapod ErbB receptors (see next 
pages). Sequences of the extracellular domain of the ErbB receptors and the EGF-
like domains of the ErbB ligands, were derived from Genbank fi les available as of 
2009-03-01. Alignments were generated using ClustalW software, imported into the 
Chroma software package, and annotated using default black and white settings. 
ErbB1, ErbB3 and ErbB4 sequences were grouped into distinct sets and within each 
set, identity thresholds were set at 100% and consensus sequences were defi ned. 
Finally, the resulting alignment was exported into MS Word program. Sequences 
from C. jacchus (marmoset) were constructed from blast searches without the help 
of the underlying nucleotide sequence. The conservation of negative constraints 
in ligand and receptor are indicated with an arrow. Characteristics of the amino 
acids: Negative charge (-) DE; Positive charge (+) HKR; Aliphatic (l) ILV; Tiny (t) 
AGS; Aromatic (a) FHWY; Charged (c) DEHKR; Small (s) ACDGNPSTV; Polar (p) 
CDEHKNQRST; Hydrophobic (h) ACFGHILMTVWY and Big (b) EFHIKLMQRWY.
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SUMMARY
 The ErbB family of receptor tyrosine kinases consists of ErbB1, 
ErbB2, ErbB3 and ErbB4, which all play a crucial role in the growth control of 
mammalian cells and the development of multicellular organisms. Depending 
on their ErbB binding specifi city, EGF-like growth factors can be divided into 
three subfamilies: EGF, transforming growth factor-α (TGFα), amphiregulin 
(AREG) and epigen (EPGN) form a subfamily that binds exclusively to ErbB1, 
while the subfamily consisting of betacellulin (BTC), epiregulin (EREG) and 
heparin-binding EGF (HBEGF) binds not only ErbB1, but also ErbB4. Finally 
the neuregulins form a subfamily of which NRG1 and NRG2 bind both ErbB3 
and ErbB4, while NRG3 and NRG4 appear specifi c for ErbB4. ErbB2 does not 
bind ligand by itself, but is the preferred heterodimerization partner for all 
liganded ErbBs and is particularly important for ErbB3 signaling which has a 
defective tyrosine kinase domain. The aim of this thesis is to understand the 
mechanisms of receptor specifi city of the ErbB ligands. 
 In their mature form EGF-like growth factors contain approximately 
55 amino acids and are characterized by three disulphide bridges which 
give rise to three looped structures and two terminal linear regions. The 
ligands bind to the L1 and L2 domain of the receptor, which causes these 
receptors to dimerize. Subsequently, the kinase domains of both receptors 
transphosphorylate the tyrosine residues in their intracellular tail. These 
phosphorylated tyrosine residues subsequently form docking sites for 
signaling molecules. Depending on the ErbB combination in the dimer and the 
cellular context, these intracellular signals can induce proliferation, migration 
or differentiation. 
 From crystal structure analysis of EGF or TGFα in complex with ErbB1, 
it is known that EGF-like growth factors contain approximately 20 residues that 
directly interact with their receptor. These residues, which we have referred to 
as positive constraints, form the basis for the observed high affi nity receptor 
interaction. However, we have provided evidence that EGF-like growth factors 
contain in addition a limited number of residues that are not essential for high 
affi nity binding to their cognate receptor, but are involved in ErbB selectivity. 
Using domain-exchange strategies, we have shown that mutation of Ser2/
Asp3 within the N-terminal linear region of EGF into the corresponding 
residues His2/Phe3 from TGFα is suffi cient to give EGF considerable affi nity 
for ErbB3 and ErbB4. Similarly the point mutation E26L in the B-loop of TGFα 
has been shown to broaden its affi nity to at least ErbB3. 
 Based on these changes in receptor selectivity by one or two amino 
acid mutations, we have postulated that EGF-like growth factors do not only 
contain residues that are directly involved in ErbB binding (positive constraints) 
but also residues that are not essential for binding to their cognate receptor 
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but prevent their unintended interaction with other ErbB receptors (negative 
constraints). The main aim in this thesis was to provide evidence that such 
negative constraints in ligand molecules and receptors form the primary basis 
for ErbB specifi city. 
 In this thesis we have used a phage display approach to determine the 
requirements within the C-terminal linear region of ErbB ligands for optimal 
binding to different ErbB receptors. We have found that the ligand-binding 
receptors ErbB1, ErbB3 and ErbB4 have unique requirements for ligand 
binding, but that a consensus sequence can be derived that permits high 
affi nity binding to all three receptors. From the data obtained, we concluded 
that the EGF/TGFα chimera T1E is a low affi nity ligand for ErbB3 and ErbB4, 
because Arg45 forms a negative constraint for binding to ErbB3 and ErbB4 
but not to ErbB1. Removal of this arginine from T1E resulted in the generation 
of a ligand, designated panerbin, that binds all three receptors with similarly 
high affi nity as their wild-type ligands. Homology modeling of panerbin in 
complex with ErbB1, ErbB3 or ErbB4 showed that panerbin binds all three 
receptors in an almost identical manner, indicating that ErbB receptors 
recognize similar positive constraints in their ligand molecules. However, 
introduction of the identifi ed negative constraints into panerbin resulted in 
local charge repulsion, conformational impairment, or steric hindrance for 
binding to ErbB3 and ErbB4 but not for ErbB1, thereby providing a molecular 
basis for their role in receptor specifi city.
 Introduction of the YYDLL sequence in naturally occurring ErbB ligands 
altered the receptor specifi city of some EGF-like growth factors. The ErbB1-
specifi c ligands EGF and TGFα broadened their receptor specifi city towards 
ErbB4, without affecting their ErbB1 binding affi nity. EREG, which by itself 
binds ErbB1 and ErbB4, but lacks affi nity for ErbB3, broadened its binding 
specifi city towards ErbB3. In case of NRG1β, introduction of the YYDLL 
sequence did not alter its receptor specifi city but enhanced its ErbB3 binding 
affi nity ten-fold. Although NRG/YYDLL showed a very high binding affi nity to 
ErbB3, for unknown reasons its mitogenic potential towards ErbB2 and ErbB3 
overexpressing cells was lower that that of wild-type NRG1β. 
 We have subsequently studied why NRG1β is unable to bind ErbB1. 
Comparison of the amino acid interactions of EGF and TGFα with ErbB1, 
and the possible interactions of NRG1β with ErbB3 and ErbB4 showed that 
the NRG1β-ErbB3/ErbB4 interaction is largely similar to EGF/TGFα-ErbB1 
interaction. Domain-exchange studies between panerbin and NRG1β showed 
that the A1-loop and C-loop of NRG1β contain sequences that prevent ErbB1 
interaction. It remains unclear, however, whether this implies that the A1 
loop and C-loop of NRG1β lack ErbB1-specifi c positive constraints or that they 
contain negative constraints that prevent ErbB1 interaction. Remarkably, 
the A1-loop and the C-loop are oriented away from the receptor, making it 
unlikely that there are positive constraints for ErbB1 missing in the NRG1β 
A1-loop and C-loop or, alternatively, that these sequences contain negative 
constraints for ErbB1 interaction. How these NRG sequences are involved 
in the prevention of ErbB1 remains unclear, but we hypothesize that subtle 
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conformational changes in the loop structures that are not directly involved in 
receptor interaction, might alter receptor specifi city.
 The EGF receptor signaling network in Drosophila melanogaster consists 
of a single receptor (DER), which can be activated by four distinct ligands, 
designated Spitz, Keren Gurken and Vein. The Drosophila EGFR signaling 
network is unique in that it contains a soluble antagonist, Argos. Because 
in human epithelial tumors ErbB receptors are frequently overexpressed in 
combination with a continuous secretion of ligand, a humanized version of 
Argos would be very interesting to block the autocrine growth stimulation 
in these tumors. Therefore, we have investigated the compatibility between 
the human ErbB system and the DER system. DER overexpressing S2DER 
cells did not give a mitogenic response to human ErbB ligands and cells 
overexpressing human ErbB receptors did not respond to Spitz, Keren, 
Vein and Gurken. Although their overall structure is very similar, human 
and Drosophila EGF-like growth factors are unable to bind to each other’s 
receptors. To determine why human EGF does not bind and activate DER and 
why Drosophila Spitz does not bind and activate human ErbB1, several hEGF-
Spitz chimeras were designed. EGF in which the region between the third 
and the fi fth cysteine had been replaced by Spitz sequences, bound with low 
affi nity to both ErbB1 and DER, and was able to induce MAPK activation in 
both DER overexpressing S2DER cells and ErbB1 overexpressing HER14 cells. 
This indicates that the receptor specifi city of Spitz and EGF does not result 
from structural differences between these ligands and their receptors. The 
lack of cross-reactivity between the EGF receptor signaling network of both 
species may refl ect their evolutionary difference, whereby positive constraints 
and protein conformation have evolved differently in such a way that it does 
not permit binding to each other’s receptor. 
 The artifi cial ErbB ligands we designed have been shown to be very 
useful in the determination of the ErbB number on breast cancer cells. Using 
panerbin as a radiolabeled ligand, we have been able to determine the ErbB 
expression profi le of a number of ErbB overexpressing human breast tumor 
cell lines by a single radioreceptor assay. Using concentrations of [125I]-
panerbin that nearly saturate all ErbB receptors, we were able to determine 
by competition analysis with unlabeled BTC, NRG and TGFα the ratio of the 
number of ErbB1 + ErbB4, ErbB3 + ErbB4 and ErbB1 levels, respectively. The 
combination of the total number of panerbin binding sites with the ratio of the 
ErbB receptors allowed the determination of the number of all three ligand 
binding ErbB numbers on the cell surface, separately. 
 Determination of ErbB3 numbers on the cell surface of living cells 
using NRG1β is problematic. In our hands iodinated NRG1β is unstable and 
tends to underestimate the number of ErbB3 receptors in a radio-receptor 
assay. NRG/YYDLL is much more stable and using [125I]-NRG/YYDLL as a label 
we observed 5-10 fold higher levels of ErbB3 receptors/cell  than with [125I]-
NRG1β. Using near saturating concentrations of [125I]-NRG/YYDLL a separate 
estimate of the total number of ErbB3 and ErbB4 receptors was made by 
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studying differential competition with unlabeled NRG/YYDLL and BTC.
 All ErbB ligands show similar patterns of positive constraints that 
from a basis for binding to their receptor. Fine-tuning of these positive 
constraints can enhance the affi nity by which these ligand bind their receptor. 
Receptor selectivity is regulated by negative constraints. In this thesis we 
used homology modeling to characterize three of those negative constraints. 
Ser2/Asp3 in the N-terminal linear region of EGF impaired ErbB3 and ErbB4 
binding by causing an unstructured N-terminal linear region. Glu26 in TGFα 
caused a steric clash with Met97 in ErbB3 and Arg45 in EGF caused a charge 
repulsion with K415 in ErbB3 and K418 in ErbB4. Furthermore we observed 
that these negative constraints in receptor and ligand are highly conserved 
in vertebrate. So far we did not identify ErbB1-specifi c negative constraints 
in NRG1β, but it is reasonable to assume that they exist. Finally, we suggest 
that a combination of positive and negative constrains has put evolutionary 
pressure on the maintenance of multiple ErbB receptors and ligands.
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 De ErbB familie van tyrosine kinases bestaat uit ErbB1, ErbB2, 
ErbB3 en ErbB4, die alle een belangrijke rol spelen bij de proliferatie van 
zoogdiercellen en de ontwikkeling van multicellulaire organismen. Afhankelijk 
van hun ErbB specifi citeit zijn de EGF-achtige groeifactoren te verdelen in drie 
subfamilies: EGF, transforming growth factor-α (TGFα), amphiregulin (AREG) 
en epigen (EPGN) behoren tot een subfamilie die uitsluitend aan ErbB1 
binden, terwijl de subfamilie bestaande uit betacellulin (BTC), epiregulin 
(EREG) en heparin-binding EGF (HBEGF) niet alleen aan ErbB1 bindt, maar 
ook aan ErbB4. Tenslotte vormen de neuregulins een subfamilie waarvan 
NRG1 en NRG2 zowel ErbB3 als ErbB4 binden, terwijl de bindingsspecifi citeit 
van NRG3 en NRG4 nog beter gekarakteriseerd moet worden. ErbB2 bindt zelf 
geen ligand, maar is de preferentiële heterodimerisatiepartner voor de ligand-
gebonden ErbBs. ErbB2 is vooral belangrijk voor ErbB3 signalering, omdat 
ErbB3 een defect tyrosine kinase domein heeft. Het doel van dit proefschrift 
is om de mechanismen die ten grondslag liggen aan receptorspecifi citeit van 
ErbB liganden, te begrijpen.    
 In hun mature vorm bestaan EGF-achtige groeifactoren uit ongeveer 
55 aminozuren en worden zij gekarakteriseerd door drie disulfi debruggen, 
die zorgen voor drie loop-structuren en twee terminale lineaire regio’s. De 
liganden binden aan de zogenoemde L1 en L2 domeinen van de receptor, 
hetgeen resulteert in dimerisatie van de receptoren. Vervolgens fosforyleren 
de kinase domeinen van deze receptoren tyrosine-residuen in de intracellulaire 
staart van hun partner receptor. Deze gefosforyleerde tyrosine-residuen 
vormen vervolgens bindingsplaatsen voor signaleringsmoleculen. Afhankelijk 
van de ErbB combinatie in de dimeer en de cellulaire context, induceren deze 
intracellulaire signalen proliferatie, migratie en differentiatie van de betrokken 
cellen. 
 Via kristalstructuuranalyse van EGF of TGFα in complex met ErbB1 
is bekend, dat EGF-achtige groeifactoren ongeveer 20 aminozuren bevatten 
die een directe interactie aangaan met de receptor. Deze residuen, die 
wij positive constraints zijn gaan noemen, vormen de basis voor de hoge 
affi niteitsbinding met de receptor. Daarnaast hebben wij bewijs gevonden 
voor het bestaan van een beperkt aantal aminozuren die niet essentieel zijn 
voor hoge affi niteitsbinding aan de receptor, maar juist betrokken zijn bij 
ErbB selectiviteit. Door gebruik te maken van domeinuitwisselingsstrategieën 
hebben wij laten zien dat mutatie van Ser2/Asp3 in de N-terminale lineaire 
regio van EGF naar de corresponderende aminozuren van TGFα, His2/Phe3, 
voldoende is om EGF aanzienlijke affi niteit voor ErbB3 en ErbB4 te geven.  Op 
een vergelijkbare wijze heeft de puntmutatie E26L in TGFα als effect dat de 
receptorspecifi citeit wordt verbreed naar tenminste ErbB3.  
 Op basis van deze veranderingen in receptorspecifi citeit door slechts 
een enkele aminozuurmutatie hebben wij de hypothese opgesteld dat EGF-
achtige groeifactoren niet alleen amonozuren bevatten die direct betrokken 
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zijn bij receptorbinding (positive constraints), maar ook aminozuren die 
niet essentieel zijn voor hoge affi niteitsbinding en juist essentieel zijn om 
onbedoelde interacties met andere ErbB receptoren te voorkomen (negative 
constraints). Het doel van dit proefschrift is om bewijs aan te dragen dat zulke 
negative constraints de basis vormen voor aanwezige ErbB specifi citeit. 
 In dit proefschrift hebben wij gebruik gemaakt van de phage display 
techniek om te onderzoeken welke aminozuursequenties in de C-terminale 
lineaire regio nodig zijn, om het ligand optimaal aan de verschillende ErbB 
receptoren te laten binden. Wij hebben gevonden dat de ligand-bindende 
ErbB receptoren unieke aminozuursequenties nodig hebben voor binding aan 
hun receptoren, maar dat een consensus-sequentie bestaat die toestaat dat 
een ligand aan alle drie de receptoren met hoge affi niteit kan binden. Op basis 
van de verkregen gegevens concluderen wij dat de EGF/TGFα chimera T1E 
een lage-affi niteitsligand is voor ErbB3 en ErbB4, omdat Arg45 een negative 
constraint vormt voor ErbB3 en ErbB4, maar niet voor ErbB1. Verwijdering 
van deze arginine uit T1E resulteerde in de vorming van een ligand, panerbin 
genoemd, die met hoge affi niteit aan alle drie de receptoren bindt. Homology 
modeling van panerbin in complex met ErbB1, ErbB3 en ErbB4 liet zien dat 
panerbin alle drie de receptoren op een vergelijkbare manier bindt, hetgeen 
aantoont dat ErbB receptoren vergelijkbare positive constraints herkennen 
in hun ligand moleculen. Introductie van de geïdentifi ceerde negative 
constraints in panerbin resulteerde in een locale ladingsafstoting, verandering 
van de conformatie of sterische hindering met ErbB3 en ErbB4, maar niet met 
ErbB1, hetgeen een bewijs is voor hun rol in de moleculaire basis van ErbB 
specifi citeit. 
 Introductie van de YYDLL sequentie in natuurlijk voorkomende ErbB 
liganden bleek de receptor-specifi citeit van enkele EGF-achtige groeifactoren. 
De ErbB1 specifi eke liganden EGF en TGFα verbreedden hun selectiviteit 
naar ErbB4, zonder verandering in hun affi niteit voor ErbB1. EREG, dat zelf 
ErbB1 en ErbB4 bindt, maar geen affi niteit heeft voor ErbB3, verbreedde 
zijn affi niteit naar ErbB3. In het geval van NRG1β gaf introductie van de 
YYDLL sequentie geen verandering in receptor-specifi citeit, maar wel een 
tienvoudige verhoging van de affi niteit voor ErbB3. Alhoewel NRG/YYDLL een 
zeer hoge affi niteit heeft voor ErbB3 is, om onbekende reden, de mitogene 
activiteit op cellen die ErbB3 en ErbB2 tot overexpressie brengen, lager dan 
die van NRG1β. 
 Vervolgens hebben wij bestudeerd waarom NRG1β niet aan ErbB1 kan 
binden. De aminozuur interacties van EGF en TGFα met ErbB1 bleken erg 
vergelijkbaar te zijn met die tussen NRG1β en ErbB3/ErbB4. Domeinuitwisse
lingsstudies tussen panerbin en NRG1β lieten zien dat de A1-loop en C-loop 
van NRG1β sequenties bevatten die de interactie met ErbB1 voorkomen. Het is 
echter nog onduidelijk of de A1-loop en C-loop van NRG1β belangrijke positive 
constraints missen of juist negative constraints bevatten die de interactie met 
ErbB1 voorkomen. Merkwaardig is dat de A1-loop en C-loop van NRG1β beide 
van de receptor afgekeerd liggen, hetgeen het onlogisch maakt dat deze 
domeinen ofwel positive constraints missen ofwel ErbB1 specifi eke negative 
constraints bevatten. Hoe deze NRG1β sequenties de interactie met ErbB1 
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voorkomen blijft onduidelijk, maar mogelijk kunnen subtiele conformationele 
veranderingen in de loop structuren die niet direct betrokken zijn bij receptor 
binding, veranderingen in receptor specifi citeit teweeg brengen.
  Het EGF receptor signaleringsnetwerk in Drosophila melanogaster 
bestaat uit slechts een enkele receptor (DER), die geactiveerd kan worden 
door vier verschillende liganden, te weten Spitz, Keren, Gurken en Vein. Het 
EGF receptor netwerk in Drosophila is uniek omdat het een extracellulaire, 
niet-membraangebonden antagonist bevat, genaamd Argos. Omdat in 
humane epitheliale tumoren ErbB receptoren vaak tot overexpressie 
komen, in combinatie met continue secretie van activerend ligand, zou een 
gehumaniseerde versie van Argos erg interessant zijn om de autocriene 
groeistimulatie in deze tumoren te blokkeren. Daarom hebben wij onderzocht 
of er wederzijdse interactie bestaat tussen het humane en het Drosophila EGF 
receptor netwerk. DER-overexpresserende S2DER cellen vertoonden geen 
mitogene respons na stimulatie met humane ErbB liganden, terwijl cellen 
die humane ErbB receptoren tot overexpressie brengen, niet reageerden 
op Spitz, Keren, Gurken en Vein. Ook al is de overall structuur van de 
humane en de Drosophila EGF-achtige groeifactoren sterk vergelijkbaar, 
zij zijn kennelijk niet in staat om aan elkaars receptoren te binden. Om te 
onderzoeken waarom humaan EGF niet aan DER bindt en waarom Spitz niet 
aan ErbB1 bindt, hebben wij verschillende EGF-Spitz chimeren gemaakt. 
EGF waarin de regio tussen het derde en vijfde cysteine is vervangen door 
de overeenkomstige sequenties uit Spitz, bleek wel in staat om met lage 
affi niteit aan beide receptoren te binden en om MAPK te activeren in zowel 
DER overexpresserende S2DER cellen als ErbB1 overexpressererde HER14 
cellen. Dit geeft aan dat de receptor-specifi citeit van EGF en Spitz niet het 
resultaat is van structurele verschillen. Het feit dat er geen cross-reactiviteit 
is waargenomen tussen de EGF receptor netwerken van beide species komt 
waarschijnlijk omdat zij evolutionair zeer verschillend zijn, waarbij positive 
constraints en eiwit-conformatie op een andere manier geëvolueerd zijn, 
waardoor de liganden niet meer compatibel zijn met elkaars receptoren.  
 De artifi ciële ErbB liganden die wij hebben gemaakt, bleken 
zeer waardevol in het bepalen van de aantallen ErbB receptoren op 
borsttumorcellen. Door gebruik te maken van radioactief gelabeld panerbin 
waren wij in staat om het ErbB expressie-profi el van een aantal ErbB 
overexpresserende borsttumorcellen in weefselkweek te bepalen met behulp 
van een enkele radio-receptorassay. Door gebruik te maken van [125I]panerbin 
bij een concentratie dat nagenoeg alle ErbB receptoren bezet zijn, hebben wij 
aan de hand van competitiecurves met BTC, NRG en TGFα, respectievelijk de 
ratio ErbB1 + ErbB4, ErbB3 + ErbB4 en ErbB1 bepaald. De combinatie van 
het totaal aantal panerbin bindingsplaatsen samen met de ratio van de ErbB 
receptoren maakte het mogelijk de aantallen van alle drie de ligand-bindende 
ErbB receptoren op het celoppervlak te bepalen. 
 Het bepalen van het aantal ErbB3 receptoren op het celoppervlak is 
problematisch. In onze handen is het gejodeerde NRG1β instabiel, waardoor 
het aantal bindingsplaatsen in een radio-receptor assay wordt onderschat. 
[125I]NRG/YYDLL blijkt veel stabieler en gebruik makend van [125I]NRG/YYDLL 
239
Samenvatting
als label vinden wij 5 tot 10 keer meer ErbB3 receptoren per cel dan met 
[125I]NRG1β. Door gebruik te maken van bijna verzadigende [125I]NRG/YYDLL 
concentraties hebben wij aldus het totaal aantal ErbB3 en ErbB4 receptoren 
kunnen bepalen. Vervolgens kon de ratio tussen ErbB3 en ErbB4 receptoren 
worden bepaald door competitiestudies met ongelabeld NRG/YYDLL en BTC. 
 Alle ErbB liganden laten een vergelijkbaar patroon van positive 
constraints zien, hetgeen de basis vormt voor receptor binding. Fine tuning 
van deze positive constraints kan de affi niteit verder verhogen, terwijl 
receptor specifi citeit met name door negative constraints wordt gereguleerd. 
In dit proefschrift hebben wij homology modeling gebruikt om drie van 
dergelijke negative constraints te karakteriseren. Ser2/Asp3 in EGF voorkomt 
ErbB3 en ErbB4 binding vanwege een ongestructureerde N-terminale lineaire 
regio. Glu26 in TGFα veroorzaakt een sterische ontoegankelijkheid met Met97 
in ErbB3, terwijl Arg45 in EGF een ladingsafstoting met K415 in ErbB3 in 
K418 in ErbB4 veroorzaakt. Verder hebben wij aangetoond dat de negative 
constraints in de ErbB liganden sterk geconserveerd zijn in vertebraten. Tot 
nu toe zijn er nog geen ErbB1-specifi eke negative constraints geïdentifi ceerd 
in NRG1β, maar onze studies geven aanwijzingen dat deze bestaan. 
Uiteindelijk suggereren onze gegevens dat een combinatie van positive en 
negative constraints gedurende de evolutie druk heeft uitgeoefend heeft op 
het behouden van meerdere ErbB liganden en receptoren 
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